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General introduction
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Cannabinoids in late-onset Alzheimer’s disease. 
Ahmed AI, van der Marck MA, van den Elsen GA, Olde Rikkert 
MG.
Clinical Pharmacology & Therapeutics 2015;97(6):597-606.
and
Medicinal use of cannabis and cannabinoids in older adults: 
where is the evidence?
Ahmed AI, van den Elsen GA, van der Marck MA, Olde Rikkert 
MG. 
Journal of the American Geriatrics Society 2014;62(2):410-
411.
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Background
Demographic changes and the rapid aging of the population 
worldwide will lead to an increase in the prevalence of older 
people with dementia (≥ 65 years), many of whom suffer from 
multimorbidity.1,2 Given the substantial burden of dementia and 
its related neuropsychiatric symptoms on patients, their caregivers, 
and healthcare systems, finding an effective therapy is one of the 
highest medical priorities of scientists, clinicians, and governments. 
The past few years have seen a growing interest in the medicinal 
uses of cannabinoids, the bioactive 
components of the cannabis plant 
(Cannabis sativa L.), such as in the 
treatment of dementia, dementia-
related neuropsychiatric symptoms, 
and other physical conditions that 
are common in older people.3–5 
Tetrahydrocannabinol (also known 
as delta-9-tetrahydrocannabinol, 
THC; figure 1) is the main psychoactive cannabinoid and appears to 
be responsible for most of the physiological effects of the cannabis 
plant.6 Therefore, it has been one of the most studied cannabinoids 
in the past years.6
This thesis focuses on the clinical pharmacology of oral THC in 
older people with dementia (≥ 65 years), and specifically on its 
pharmacokinetic and pharmacodynamic effects, including safety 
and efficacy. The choice to focus on older people with dementia was 
made for several reasons,7 as discussed below.
Dementia
Prevalence, pathophysiology, and treatment
Dementia is a syndrome characterized by a progressive, 
irreversible decline in cognitive functions, such as memory, learning 
capacity, orientation, executive function, language, and perceptual-
motor skills, a decline that interferes with activities of daily living.1 
Figure 1  Delta-9-tetrahydrocannabinol (THC)
13
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The clinical picture is, however, more complex and frequently 
involves behavioral and psychological changes.
Alzheimer’s disease is the most common type of dementia, 
contributing to 60-80% of all cases, followed by vascular dementia 
(10–15%), frontotemporal lobe dementia (about 5–10%), and 
dementia with Lewy bodies (< 5%).1 However, postmortem studies 
have shown that many people with dementia have mixed Alzheimer’s 
disease and vascular dementia pathology, which suggests that mixed-
type dementia is often underdiagnosed.8-10 According to the recent 
report of Alzheimer’s Disease International (World Alzheimer Report 
2015),1 the number of people suffering from dementia worldwide is 
estimated at 47 million people.1 This number is expected to more 
than triple by 2050, causing a major public health problem with an 
immense impact on individual patients, their families, healthcare 
systems, and economies.1 
In general, clinicians distinguish between late-onset Alzheimer’s 
disease and early-onset Alzheimer’s disease. The term “late-onset 
Alzheimer’s disease” refers to Alzheimer’s disease diagnosed at or 
after 60 years of age (about 95% of Alzheimer cases), whereas the 
term “early-onset Alzheimer’s disease” refers to Alzheimer’s disease 
with an onset between 30 and 64 years (about 5% of all Alzheimer 
cases). Early-onset Alzheimer’s disease is often linked to familial 
Alzheimer’s disease, which has a different pathophysiological 
mechanism from late-onset Alzheimer’s disease, involving gene 
mutations on chromosomes 21, 14, and 1. Although its incidence 
and prevalence increase with advancing age, late-onset Alzheimer’s 
disease is not a normal part of aging.11 It is probably a complex, 
multicausal syndrome in which component causes, such as genetic, 
epigenetic, and environmental factors, increase the likelihood of an 
individual developing the disease.12
The brains of patients with Alzheimer’s disease are characterized 
by the accumulation of amyloid-β protein (Aβ; mainly Aβ1–42 and Aβ1–40) 
in extracellular senile plaques in various brain regions, but especially 
in the hippocampus, cerebral prefrontal cortex, and amygdala.13 Aβ 
protein is generated by the aberrant processing of amyloid precursor 
protein, a single-pass transmembrane glycoprotein. The second 
14
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pathological hallmark of Alzheimer’s disease is the presence of 
intracellular neurofibrillary tangles, formed by hyperphosphorylated 
tau.13 
It may take decades for Alzheimer’s disease to progress from 
its asymptomatic or minimally symptomatic early stages to its full-
blown symptomatic stage with dementia. Therefore, successfully 
targeting the neuropathology of Alzheimer’s disease in an early 
stage would help diminish the burden of dementia and its associated 
neuropsychiatric symptoms. However, currently approved 
pharmacological treatments for Alzheimer’s disease, which include 
cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and 
the N-methyl-D-aspartate receptor antagonist memantine, act only 
on symptoms and do not have profound disease-modifying effects.
Neuropsychiatric symptoms
Almost all patients with dementia, including Alzheimer’s disease, 
develop neuropsychiatric symptoms at some time during the course 
of the disease.14 These symptoms, which include depression, 
anxiety, agitation, aggression, wandering, pacing, sleep disorders, 
psychosis, and appetite/eating disorders, are often distressing to 
patients and their caregivers.14, 15 Furthermore, they are associated 
with a more rapid progression of dementia, higher healthcare costs, 
and early nursing home placement.15-17 An earlier study showed 
that approximately a third of the total annual cost of Alzheimer’s 
disease treatment is directly attributable to the management of 
neuropsychiatric symptoms.17 Therefore, effective treatment of the 
neuropsychiatric symptoms of dementia may have the potential to 
modify the disease course, improve the quality of life of affected 
individuals and their caregivers, and lower healthcare costs. 
Yet no drugs have been approved by either the US Food and 
Drug Administration (FDA) or the European Medicines Agency (EMA) 
for the treatment of the neuropsychiatric symptoms of dementia. 
Studies of the cholinesterase inhibitors donepezil, rivastigmine, and 
galantamine reported modest or no improvement in neuropsychiatric 
symptoms.18 In addition, the N-methyl-D-aspartate receptor 
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antagonist memantine did not improve agitation compared with 
placebo in patients with moderate-to-severe Alzheimer’s disease 
(n=149).19 Recently, a phase 2 randomized, double-blind, placebo-
controlled trial demonstrated the efficacy of combination therapy 
with dextromethorphan/quinidine in treating agitation in patients 
with Alzheimer’s disease (n=194).20 This combination therapy was 
approved by the  FDA and EMA for the treatment of pseudobulbar 
affect (uncontrollable episodes of crying) in adults with underlying 
amyotrophic lateral sclerosis or multiple sclerosis. Although the 
findings of the trial are interesting and seem promising, they have 
generated considerable discussion, in particular about limitations in 
the study methodology (last-observation carried forward is not a 
recommended method for imputing missing data in dementia trials, 
and bias introduced by the choice of rescue medication, lorazepam) 
and the funding of the trial by the pharmaceutical industry.21-23 
Moreover, other recently published trials suggest that treatment 
approaches with already available drugs, such as citalopram, and 
the management of pain with analgesics may also be effective 
in reducing agitation in patients with dementia.24, 25 Currently, 
psychotropic medications, such as antipsychotics, benzodiazepines, 
antidepressants, and antiepileptic drugs, are frequently used 
off-label for the treatment of the neuropsychiatric symptoms of 
dementia, but they are ineffective in most cases or only have a 
short-term effect.26 In addition, they are associated with serious 
adverse events in older individuals, including falls,27 cardiovascular 
and cerebrovascular events,28 and even death.29 
Taken together, there is an urgent need for new, effective, 
and safe pharmacological interventions to diminish the burden of 
neuropsychiatric symptoms of dementia.
Cannabinoid-based drugs as potential drug candidates 
for dementia and physical conditions
The cannabis plant (Cannabis sativa L.) has been used for 
centuries to treat a wide range of conditions that are common 
16
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in older people (e.g., pain, depression, sleep disturbance, and 
loss of appetite).30 These broad therapeutic applications are due 
to the pharmacological effects of its bioactive components, the 
“cannabinoids”.6 Currently, more than 60 different cannabinoids 
have been identified and isolated from the cannabis plant, with THC 
and cannabidiol (CBD) being the most studied.6 Although the exact 
mechanism of action and the physiological effects of cannabinoids 
are still not fully understood, THC seems to be responsible for most 
of the physical and psychoactive effects of cannabis.6 
In previous studies, the endocannabinoid system has been 
proposed as target for the treatment of Alzheimer’s disease and 
dementia-related symptoms.31-34 Numerous in vitro and in vivo 
studies have demonstrated the protective effects of cannabinoids 
against Aβ peptide and tau phosphorylation, the neuropathological 
hallmarks of the disease.31-34 Moreover, fixed dose, cannabinoid-
based drugs have recently become available for medical use. For 
example, dronabinol (Marinol®; Solvay Pharmaceuticals, Belgium) 
and nabilone (Cesamet®; Valeant Pharmaceuticals International 
North America, Canada) are both synthetic THC in capsule form. 
They have been approved in North America and some European 
countries for appetite stimulation in AIDS-related anorexia and 
chemotherapy-induced nausea and vomiting. Nabiximols (Sativex®, 
GW Pharmaceuticals, UK) is an oromucosal mouth spray that contains 
both THC and CBD (ratio=1:1). It is used for the symptomatic relief 
of neuropathic pain and muscle spasticity in patients with multiple 
sclerosis and is available in 15 countries, including the United 
Kingdom and seven other European countries, New Zealand, and 
Canada, but not in the United States.
Although the above-mentioned conditions, such as pain, nausea, 
and loss of appetite, are very common in older people, preapproval 
clinical trials of cannabinoid-based drugs excluded old people, 
especially those with cognitive impairments, from participation or did 
not include them in sufficient numbers to determine whether they 
respond differently from younger participants.35-37 Therefore, it is not 
possible to directly extrapolate data on the clinical pharmacology of 
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cannabinoid-based drugs obtained in studies involving young adults 
to older people. 
Why is it important to understand the clinical pharma-
cology of cannabinoid-based drugs in older people with 
dementia?
The main goal of clinical pharmacology, as a science, is to 
understand drug dose-effect relationships in humans. This knowledge 
is needed to individualize the dose, maximize the therapeutic 
benefits, and minimize the toxic effects of drugs.38 However, there is 
a lack of information in the literature about the clinical pharmacology 
of cannabinoid-based drugs in older people. 
In general, older people with dementia (≥ 65 years) are more 
vulnerable to adverse drug reactions than healthy older and younger 
people.7 This is because they often have multimorbidity1, 2 and use 
multiple medications,1, 2 which increases the risk of drug-drug and 
drug-disease interactions. Moreover, age-related physiological 
changes in lean body mass, liver enzyme activities, serum albumin, 
renal clearance, and dementia-related brain changes (e.g., 
degeneration of neurons, decreased brain volume and receptors, 
and dysregulation of neurotransmitters) can lead to altered drug 
pharmacokinetics and pharmacodynamics. These alterations may 
increase the sensitivity to the effects of drugs, especially those 
drugs that act on the central nervous system,7 such as THC-based 
drugs. Older people with dementia and multiple comorbidities might 
benefit greatly from the therapeutic use of THC as a multi-target 
drug candidate, one drug for several conditions.3-5 Therefore, there 
is an urgent need to understand the clinical pharmacology of THC-
based drugs in older people before these drugs can be prescribed 
to frail elderly individuals with dementia and multiple comorbidities.
Main aims of this thesis
The broad mechanisms of action and multiple physiological effects 
of THC make it a promising drug candidate for older people with 
dementia and multiple comorbidities. However, the lack of information 
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in the literature on the pharmacodynamic and pharmacokinetic 
effects raises questions about the safety and efficacy of oral THC in 
frail older people with dementia. Therefore, the main aim of the this 
thesis was to evaluate the pharmacokinetic and pharmacodynamic 
effects of oral THC in frail older people with dementia.
In the past five years, I worked with Dr. Geke van den Elsen 
(resident in Geriatric Medicine / researcher) on this project. Dr. 
van der Elsen mainly focused on the effects of oral THC in the 
management of dementia-related behavioral disturbances, resulting 
in her PhD thesis, entitled “Tetrahydrocannabinol in the treatment 
of neuropsychiatric symptoms in dementia”, which she successfully 
defended in March 2016. As a geriatrician and clinical pharmacologist, 
I focused mainly on the pharmacokinetic and pharmacodynamic 
effects of oral THC in frail older people with dementia. 
The studies presented in this thesis were performed at the 
Department of Geriatric Medicine / Alzheimer Center and the Clinical 
Research Centre Nijmegen of the Radboud University Medical Center, 
Nijmegen, the Netherlands, and the Department of Psychogeriatric 
Medicine of the Vincent van Gogh Institute, Venray, the Netherlands. 
In the clinical trials described in this thesis, Namisol® was used as study 
medication. Namisol® is a novel THC-based drug formulation (THC 
≥ 98%) in tablet form. It was developed using a novel drug delivery 
technology, Alitra™, to improve the absorption and bioavailability 
of poorly soluble lipophilic compounds. Both Namisol® and Alitra™ 
were developed by the Dutch company Echo Pharmaceuticals B.V. 
(Weesp, the Netherlands). Namisol® has not yet gained marketing 
approval.
Funding
Our project was supported by a grant from the European Union, 
the European Fund for Regional Development, and the Dutch 
province Gelderland (Grant number: 2009-019329), awarded to the 
consortium of Echo Pharmaceuticals B.V. (Weesp, the Netherlands), 
the developer of Namisol®, and the Radboud University Medical 
Center (Nijmegen, the Netherlands). Echo Pharmaceuticals B.V. 
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had no role in the design of the study, in data collection, analysis, 
or interpretation, or in the writing of manuscripts and this thesis. 
None of the research team members or the authors of the articles 
reported in this thesis have any conflict of interest in relation to the 
Namisol® project.
Outline of the thesis
PART I General introduction
PART II Cannabinoids in old age and dementia
Little is known about the safety and effectiveness of medicinal 
cannabis and cannabinoids in older people (≥ 65 years) with 
dementia. In Chapter 1, we summarize and discuss evidence on the 
effectiveness and safety of medicinal cannabinoids in older people. 
Chapter 2 presents an overview of the potential of cannabinoids 
in the treatment of late-onset Alzheimer’s disease and related 
neuropsychiatric symptoms. We also discuss the efficacy, safety, 
and pharmacokinetics of cannabinoid-based drugs in older people 
with dementia.
PART III  Efficacy of tetrahydrocannabinol in the treatment 
of neuro-psychiatric symptoms of dementia
The pharmacological treatment of the neuropsychiatric symptoms 
of dementia is challenging, because currently available drugs have 
important drawbacks concerning the benefit-to-risk ratio. In this 
part of the thesis (Chapters 3 and 4), we report the results of 
two randomized, double-blind, placebo-controlled trials of the 
effectiveness of oral THC in the treatment of neuropsychiatric 
symptoms of dementia. We also discuss our findings on the 
effectiveness of THC for the treatment pain and pain-related 
behaviors in this frail population.
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PART IV  Safety, pharmacodynamics, and pharmacokinetics 
of oral tetrahydrocannabinol
There is a lack of information in the literature on the pharmaco-
dynamic and pharmacokinetic effects of THC-based drugs in older 
populations. Older people, especially those with cognitive impairment, 
have often been excluded from or are under-represented in clinical 
trials. In Chapters 5 and 6, we present the results of two clinical 
studies of the safety, pharmacodynamics, and pharmacokinetics of 
a novel THC in tablet form, Namisol®. The first study (Chapter 5) 
was a phase 1, randomized, double-blind, double-dummy, placebo-
controlled, cross-over trial, in which the safety and pharmacokinetics 
of three oral doses of THC were evaluated in healthy older people 
without dementia. In the second study (Chapter 6), we evaluated 
the safety, pharmacodynamics, and pharmacokinetics of multiple 
oral doses of THC in older people with dementia. We hypothesized 
that plasma levels of THC would be higher in older people with 
dementia than in young adults or healthy older individuals without 
dementia (data from published studies), potentially increasing the 
pharmacodynamic effects of THC, including its adverse effects.
PART V Pain and pain-related symptoms in dementia
Whereas the majority of patients with dementia still live at home, 
most studies of pain and pain-related behavioral problems have 
involved residents of long-term care facilities. Early recognition 
and adequate treatment of pain in patients with dementia living at 
home may prevent or reduce pain-related behavioral changes and 
associated caregiver distress, and subsequently may delay nursing 
home placement. In this part of the thesis (Chapters 7 and 8), 
we report the prevalence and impact of pain in community-dwelling 
patients with dementia and the relationship between pain and 
behavioral and psychological symptoms. We discuss the potential 
of cannabinoid-based drugs, including THC, as multi-target drug 
candidates for the treatment of pain and pain-related behavioral 
and psychological symptoms in patients with dementia.
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PART VI Summary
The main findings of the studies are summarized.
PART VII General discussion
Lastly, the main findings are discussed with respect to the literature 
and recommendations for future research are given.
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Efficacy and safety of 
medical cannabinoids 
in older subjects: A 
systematic review
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Ageing Research Reviews 2014;14:56-64.
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Abstract
This systematic review aims to integrate the evidence on 
indications, efficacy, safety and pharmacokinetics of medical 
cannabinoids in older subjects. 
The literature search was conducted using PubMed, EMBASE, 
CINAHL and Cochrane Library. We selected controlled trials including 
solely older subjects (≥65 years) or reporting data on older 
subgroups. 105 (74%) papers, on controlled intervention trials, 
reported the inclusion of older subjects. Five studies reported data 
on older persons separately. These were randomized controlled 
trials, including in total 267 participants (mean age 47-78 years). 
Interventions were oral tetrahydro-cannabinol (THC) (n=3) and 
oral THC combined with cannabidiol (n=2). The studies showed no 
efficacy on dyskinesia, breathlessness and chemotherapy induced 
nausea and vomiting. Two studies showed that THC might be useful 
in treatment of anorexia and behavioral symptoms in dementia. 
Adverse events were more common during cannabinoid treatment 
compared to the control treatment, and were most frequently 
sedation like symptoms. 
Although trials studying medical cannabinoids included older 
subjects, there is a lack of evidence of its use specifically in older 
patients. Adequately powered trials are needed to assess the 
efficacy and safety of cannabinoids in older subjects, as the potential 
symptomatic benefit is especially attractive in this age group.
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Introduction
For many centuries the cannabis plant (Cannabis sativa L.) has 
been used worldwide for medical as well as recreational purposes. 
Possible indications of cannabis, such as cancer pain, cachexia and 
neuropathic pain, are found in a quickly growing population of older 
patients. Unfortunately, there are only limited data on the extent 
of the use of medicinal cannabinoids in older persons. Although 
international web-based surveys show only a low percentage of 
older users, in the Dutch setting, more than one third of patients 
using medicinal cannabis on prescription are over 60 years.1, 2 On 
the one hand, this group may highly benefit from medical application 
of cannabis, because of a greater emphasis on symptomatic and 
palliative effects of medication, which is directly related to their 
limited life expectancy. On the other hand, an increased vulnerability 
of the brain, due to a reduction in cognitive functioning and brain 
atrophy,3, 4 and age related changes in pharmacokinetic factors,5 
may result in more severe adverse effects.
Cannabis preparations contain numerous cannabinoids, including 
delta-9-tetrahydrocannabinol (THC), with psychoactive effects, and 
cannabidiol  (CBD),  with  neuroprotective,  anticonvulsive, antiemetic 
and  anti-inflammatory  effects,  as  the  major  constituents. These 
cannabinoids act upon an endogenous cannabinoid system of which 
two receptors (CB1 and CB2) have been identified.6, 7 These receptors 
are mainly located in the central nervous system (CB1 and CB2) and 
the immune system (CB2).8, 9
Several trials studying the efficacy of medical cannabinoids 
have been conducted, covering a wide range of diseases and 
conditions, including neuropathic pain, chemotherapy-induced 
nausea and vomiting and loss of appetite.10-13 Unfortunately, data 
on efficacy and safety established in studies with adults cannot 
simply be extrapolated to the older patient group, due to changes 
in pharmacokinetic and pharmacodynamic factors associated with 
increasing age, leading to differences in efficacy and a high risk of 
developing adverse drug reaction. This can result in drug-related 
morbidity, hospital admission and mortality.14, 15 Examples of changes 
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in pharmacokinetic factors associated with increasing age are a 
decreased lean body mass, reduction of renal and hepatic clearance 
and loss of ability to maintain homeostasis.16, 17 The high prevalence 
of co-morbidity and related polypharmacy further complicates drug 
treatment in this population. It is therefore highly relevant to study 
the effects of medical cannabinoids in older patients separately, 
before advocating wide spread use.
To date, no review on the efficacy and safety of cannabinoids 
in older patients has been conducted. Although, the Cochrane 
Collaboration published a systematic review on cannabinoids in 
dementia patients,18 including one small randomized controlled trial 
(RCT) studying the efficacy of nabilone on anorexia and behavioral 
disturbances in subjects with severe dementia.19 In the current 
systematic review we aimed to provide broader evidence on the 
safety and efficacy of medical cannabinoids in older subjects, 
independent of the reasons for prescription or the patients’ cognitive 
status.
Methods
Search strategy
We performed a search of PubMed, EMBASE, CINAHL and Cochrane 
Library databases up to October 7th 2013 for articles published 
in English. For PubMed, a comprehensive search was developed, 
which was adapted to the other databases (see appendices). The 
search strategy and eligibility criteria were specified in advance and 
documented in a study protocol. Relevant search term synonyms 
were determined using Thesaurus and discussion with experts. 
We used the following terms to determine the subject group: 
‘aged’, ‘frail’, ‘elderly’, ‘older’, ‘aging’, ‘ageing’ and ‘geriatric’. To 
determine the intervention we used the terms: ‘cannabinoids’, 
‘cannabinoid’, ‘cannabinol’, ‘cannabidiol’, ‘tetrahydrocannabinol’, 
‘marinol’, ‘cesamet’, ‘THC’, ‘CBD’, ‘sativex’, ‘nabilone’, ‘dronabinol’, 
‘delta-9-tetrahydrocannabinol’, ’delta-THC’, ‘cannabis’, ‘marihuana’, 
‘marijuana’ and ‘hashish’. The existing clinical query ‘Therapy/
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Broad’ was used in PubMed to select therapeutic studies. Duplicate 
publications were selected and removed. The final results were 
ranked alphabetically and received an article specific number.
Eligibility criteria
Two reviewers (GE and ML) conducted the search by independently 
examining the title and available abstract of each article, in an 
unblinded manner. Studies were considered for inclusion when they: 
(1) included exclusively older subjects (defined as ≥ 65 years) or a 
distinct subgroup of older subjects and provided separate results on 
this subgroup; (2) studied the efficacy, safety or pharmacokinetics 
of medical cannabinoids administered by any route, at any dose and 
for any duration; (3) were prospective, controlled intervention trials 
and; (4) provided data on efficacy, safety, or pharmacokinetics. 
Studies were excluded when they (1) included exclusively younger 
subjects (< 65 years); (2) studied cannabinoids for recreational 
purposes; (3) studied endocannabinoids or cannabinoid antagonists. 
Articles that seemed to meet the eligibility criteria based on title or 
abstract were screened in full text by the same reviewers (GE and 
ML). In case of disagreement or uncertainty two other researchers 
(MM and MOR) were consulted to reach consensus. The snowball 
method was used to manually identify relevant references from the 
reference lists of included articles.
Data extraction and assessment of methodological quality
A modified Cochrane data extraction sheet was used to extract 
data from the included articles. Data collection included study design, 
participant characteristics (including age, gender and number 
of participants), intervention indication, intervention, outcome 
measures, results, data on adverse events and pharmacokinetics. 
The corresponding authors of the included studies were contacted 
to request details on subject characteristics, study conduct, primary 
efficacy and safety data, if not sufficiently described in the original 
articles. When feasible, study analyses were repeated for subjects 
aged 65 years and older. Additional information was provided by 
three out of four corresponding authors that were contacted. One 
34
Chapter 1  |  Efficacy and safety of medical cannabinoids in older subjects: a systematic reviewPart II  |  Cannabinoids in old age and dementia
author could not be contacted, as that study was conducted more 
than 30 years ago.20 Two corresponding authors provided additional 
information on study methods, efficacy and safety.21, 22 One author 
provided information on study methods, in order to complete the risk 
of bias table.19 No primary data from this study could be provided, 
as these had been discarded years ago.
Quality assessment of all included articles was carried out using 
a modified Effective Practice and Organization of Care form (EPOC, 
2009). This form includes seven criteria for the assessment of risk of 
bias in individual studies: adequate sequence generation, allocation 
concealment, introduction of a washout period, incomplete outcome 
data, blinding, protection against contamination, intention to treat 
analysis and selective reporting. A consensus-based risk of bias 
table was constructed.
Data synthesis and analysis
It was not feasible to conduct a meta-analysis, due to the 
high clinical and methodological diversity. Results of the included 
studies were therefore analyzed by making qualitative, descriptive 
summaries.
Results
Selection procedure
The selection procedure is shown in Figure 1. The search strategy 
identified 1676 citations. Adjustment for duplicates left 1296 
citations. Of these, 1124 articles were excluded based on screening 
of title and abstract. 172 full text articles were retrieved and assessed 
on eligibility. 105 (74%) out of 142 reports of controlled intervention 
trials studying cannabinoids, included one or more subjects aged  ≥ 
65 years. Nonetheless, most of these articles did not report data on 
the older subject group separately. Five studies could be included for 
analysis as these reported separate data on older subjects.19-23 The 
snowball method yielded no further studies.
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Figure1    Flow diagram of the selection of studies included in this systematic 
review
Search results
(Pubmed, Embase, Cinahl and 
Cochrane
Library)
N = 1676
Excluded dublicate articles
N = 380
Number of srticles screened based 
on
title/abstract
N = 1296
Excluded articles based on title/
abstract
N = 1124
Number of full text articles 
assessed for
eligibility
N = 172
Excluded articles based on full text
N = 167
Reasons:
- No data on elderly subgroup: 100
- Only adult subjects included: 28
- Inappropriate study design: 16
- Age (range or SD) unknown: 8
- Study results not described: 5
- Only adult subjects in 
intervention groep: 4
- Language: 3
- No separate data on 
cannabinoids: 2
- Recreational use: 1
Studies included for analysis
N = 5
Snow ball method
N = 0
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Study characteristics
There was a substantial variation in study characteristics among 
the five included studies, which is outlined in table 1. All studies 
were RCTs with a crossover design, of which one was preceded by 
an open label dose escalation study.21 In general, the study sample 
sizes were small (range 2 to 214 subjects). In total, 267 participants 
were included of which 262 participants were included in studies’ 
analyses. The mean age of the populations varied from 47 to 78 
years. Only two studies assessed the efficacy of medical cannabinoids 
in an exclusively older (≥ 65 years) population.19, 22 The three other 
studies were included in this systematic review as these included 
older subjects in an open label sub study,21 reported safety data on 
an older subgroup,23 or reported results on efficacy per age group.20 
The interventions existed of THC administered as tablet,19, 20, 22 and 
THC in combination with cannabidiol (CBD) administered as tablet,21 
or as sublingual spray.23 The treatment dosage varied extensively 
among the included studies, ranging from 2.5 mg,22 to maximally 
62.5 mg of THC daily.20
All studies used different outcome measures, linked to the 
different indications for prescription. Studied indications were 
anorexia and behavioral disturbances in dementia, dyskinesia in 
Parkinson’s disease, chemotherapy induced nausea and vomiting, 
and breathlessness in Chronic Obstructive Pulmonary Disease 
(COPD). The duration of intervention varied from 1 to 42 days per 
period.
The study from Volicer et al. was the only RCT with more than 
10 participants that exclusively included older subjects. Therefore, 
we report on this study most extensively. This study involved fifteen 
hospitalized patients with severe Alzheimer’s disease, who exhibited 
food refusal. After baseline measurements, subjects were randomly 
assigned to dronabinol (THC) 2.5 mg twice daily first or placebo 
twice daily first. Treatment duration was six weeks, followed directly 
by the crossover treatment of another six weeks. There was no 
washout period. Nutritional status was measured by body weight and 
triceps skin fold thickness (assessed weekly) and plasma albumin 
and lymphocyte count (assessed at the beginning and end of each
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treatment period). Furthermore, behavioral disturbances were 
measured weekly by Cohen-Mansfield Agitation Inventory (CMAI) 
and Lawton Observed Affect Scale–Past. In total, eleven subjects 
completed both treatment periods and were analyzed. One participant 
died two weeks before completing the study, but was also included 
in the analysis. The average age was 72.7 years (range 65 to 82 
years).
Risk of bias assessment
The risk of bias is reported in table 2. This table was finalized after 
receiving additional information by the corresponding authors.19, 
20, 22 Four out of five included studies showed a moderate to high 
risk of bias in several relevant domains. The study of Volicer et al. was 
judged to have a high risk of bias. Although the researchers used a 
random number table for sequence generation, the only person who 
had access to this table, was also involved in outcome assessment, 
leading to a bias in allocation concealment and blind assessment of 
outcomes. Furthermore, no washout period was introduced between 
the treatment periods, causing a significant risk of carry over effect.
Efficacy
It was not feasible to report summary outcome measures as most 
studies did not report means and standard deviations per treatment 
group or study samples were too small to provide a reliable effect 
size. 
THC did not improve chemotherapy related nausea and vomiting,20 
compared to prochlorperazine. In this study, different age groups 
were compared, but the efficacy on nausea reduction did not 
differ significantly between groups (χ2 = 2.13, NS). Furthermore, 
treatment with THC combined with CBD did not result in a statistical 
significant improvement of breathlessness in COPD (Pickering et al., 
2011) or dyskinesia in Parkinson’s disease,21 compared to placebo. 
We reanalyzed the primary data on UPDRS total score from Carroll 
et al., including only subjects aged 65 years and older (n=12). This 
did not result in a significant difference between the treatment arms 
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Table 2    Risk of bias in the five studies reporting on medical 
application of cannabinoids in older subjects.
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+, yes; -, no; ?, unclear/not reported
* Data not reported in the article, but provided by author on request.
(p=0.27 for total UPDRS before levodopa challenge and p=0.86 for 
total UPDRS after levodopa challenge).
One study on the efficacy of THC in two patients with Alzheimer’s 
disease showed a decline in nighttime motor activity, measured 
by wrist actigraphy in one male subject until the third week of 
treatment.22 This subject received dronabinol for two weeks, followed 
by placebo. There was no washout period. Behavioral disturbances 
declined during the entire 4 week study period, as measured with 
the Neuropsychiatric Inventory. In the other subject, who received 
placebo first, nighttime motor activity reduced only during the first 
week of dronabinol treatment and increased again in the second 
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week. Behavioral disturbances declined during placebo treatment, 
but increased again on the first week of dronabinol. The provided 
primary efficacy data did not allow for statistical analysis, due to the 
very small sample size. 
The publication from Volicer and colleagues reported an increase 
in body weight during the study period of 12 weeks, regardless of 
the order of treatment. Weight gain was greater for subjects who 
received dronabinol first. In the first 6-week treatment period subjects 
receiving dronabinol gained 7.0±1.5 lb compared to 4.6±1.3 lb in 
subjects receiving placebo. Caloric intake was not changed. Triceps 
skin fold thickness seemed to increase during the total study period, 
but was not affected by treatment or order of treatment. Disturbed 
behavior, as measured with CMAI, decreased during both dronabinol 
periods and this decrease persisted during the placebo period 
following dronabinol. Positive affect remained similar during both 
treatments, while negative affect decreased over the 12 week study 
period, and more while subjects received dronabinol, compared to 
placebo. The authors of this study concluded that dronabinol might 
be useful in the treatment of anorexia and disturbed behavior in 
patients with dementia. P-values or confidence intervals were not 
reported, nor were means and standard deviations of the results 
from secondary outcome measures.
Safety
The results on adverse effects are reported in table 3. Two RCTs 
reported data on adverse events for the total group of participants, 
including those younger than 65 years. On request, Carroll provided 
safety data per subject in the open label phase, which are added to 
table 3. Overall, adverse events were inconsistently assessed and 
it was not clear whether these events represent a clinically relevant 
change. Therefore, we only report the most frequently reported 
adverse events.
Overall, cannabinoid treatment resulted in more adverse 
effects than placebo or prochlorperazine (266 vs. 133).19-21, 23 
Symptoms of sedation/drowsiness were most frequently reported 
in the cannabinoid group. One study only assessed the occurrence 
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of severe adverse events, due to the lack of reliable reporting of 
adverse events by subjects with severe cognitive disorder.22 In the 
study with five COPD patients and six healthy controls, two older 
COPD subjects developed cardiac arrhythmias (Wenckebach block 
phenomenon and ventricular tachycardia) after receiving 2.7 mg/2.5 
mg and 8.1 mg/7.5 mg THC/CBD, respectively.23 Another older 
subject with COPD developed symptoms of mild intoxication after 5.4 
mg/5 mg THC/CBD, which was not further clarified. This subject was 
unable to continue the measurements. None of the studies reported 
cannabinoid related severe adverse effects, although one subject 
developed a grand mal seizure after first administration of 2.5 mg 
dronabinol and was withdrawn.19 The authors stated that it was not 
clear whether this event was related to dronabinol or progression of 
Alzheimer’s disease. Despite the lack of anticonvulsant treatment, 
the seizure did not recur. This subject died two months after the 
event of causes unrelated to study participation.
Pharmacokinetics
One study, with subjects between 51 and 78 years of age 
receiving oral THC:CBD (0.034–0.25 mg THC/kg), collected blood 
samples for pharmacokinetic data.21 The maximum concentration 
(Cmax) of THC was reached within 2 h after ingestion of cannabis 
extract in most patients. Cmax varied from 0.25 to 5.4 ng/mL THC. 
There was no clear dose response. In subjects taking the same dose 
of THC:CBD, a wide variability in blood concentration was seen. No 
pharmacokinetic data was presented separately for subjects ≥ 65 
years.
Discussion
Principal findings and previous literature
This systematic review aimed to evaluate study participation, 
intervention indications, efficacy and safety of medical cannabinoids 
in older subjects. The age ranges of subjects described in the papers 
suggest that elderly are indeed included in research studying medical 
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cannabinoids for several indications. However, separate data on the 
older subgroup are very rare. The five studies that did report on older 
subjects showed no efficacy on dyskinesia, breathlessness (versus 
placebo) and chemotherapy induced nausea and vomiting (versus 
prochlorperazine). Studies on oral THC in symptomatic treatment of 
behavioral problems in dementia did not prove efficacy, because of 
the small sizes and overall low to moderate methodological quality.
Overall, despite the relatively low doses used in the included studies, 
adverse events were more frequently reported during cannabinoid 
treatment than during treatment with the control product, especially 
concerning sedation-like symptoms, as drowsiness, tiredness and 
somnolence. This is in line with the results of a systematic review 
on 31 studies on medical cannabinoids in adult subjects, reporting 
nervous system disorders as the most frequently occurring adverse 
events (36.7% in RCTs, 39.7% in observational studies), including 
dizziness, somnolence and sedation.24 This finding could be of major 
clinical importance in older patients, as these adverse events may 
lead to an increased risk of falls, especially when administering 
higher doses cannabinoids, as THC is known to cause a dose 
dependent increase in adverse events.25 In the previous systematic 
review from Wang et al., the rate of serious adverse events did 
not differ significantly between cannabinoid group and controls (RR 
1.04, 95%CI 0.78–1.39). In our own review, we only found one 
serious adverse event; the development of a grand mal seizure in 
an older subject with Alzheimer’s disease, directly after receiving 
2.5 mg dronabinol.19
From previous literature, it is not clear whether cannabinoids induce 
seizures. Animal studies even suggest that cannabinoid agonists 
may actually have an anti-epileptic effect,26-28 while CB1 receptor 
antagonists lower the seizure threshold.29 Unfortunately, a possible 
anti-epileptic effect of cannabinoids could not be demonstrated in 
human studies.30 In the light of the current preliminary literature 
status, caution is needed when prescribing cannabinoids to patients 
with a history of seizures or to patients with structural brain lesions.
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Our search also included one study that reported the occurrence 
of cardiac arrhythmias in two older subjects with COPD after 
administration of sublingual THC and CBD combined.23 Cannabinoids 
may influence the cardiovascular system, mainly by increasing heart 
rate.25, 31, 32 This effect is probably caused by direct CB1 receptor 
agonism in cardiac tissue, independent of catecholaminergic 
activity.33 To our knowledge, no systematically collected data are 
available on oral cannabinoids and cardiac arrhythmias, except for 
some case reports describing the occurrence of ventricular fibrillation 
and paroxysmal atrial fibrillation after smoking marijuana.34, 
35 Taken together, physicians should be reluctant to prescribe 
medical cannabinoids to (older) patients with a history of severe 
cardiovascular disease or significant arrhythmia.
Only one  study  included in  our  review  evaluated the 
pharmacokinetics of THC in a relatively older subject group.21 This 
study showed a high inter-individual variability in various parameters, 
consistent with data from young adult subjects, which also  showed 
a  high variation  in tmax and Cmax.
25, 36-38 One must keep in mind that 
the pharmacokinetic profile of THC is highly dependent on the route 
of administration. As compared to inhalation, oral and sublingual 
administration of THC is characterized by a slower absorption, a 
more extensive first pass effect and a lower rate of drug delivery 
to the brain, probably resulting in fewer and delayed adverse 
effects.31, 37 Remarkably, oral administration results in relatively high 
plasma concentrations of the metabolite 11-OH-THC, which in turn 
contributes to psycho-active symptoms.25 Ageing also affects several 
relevant pharmacokinetic parameters, such as reduced hepatic 
clearance, because of an decrease in liver mass and hepatic blood 
flow,5 which might increase the bioavailability of THC. On the other 
hand, ageing might also lead to a higher volume of distribution, a 
prolongation in half life and lower Cmax, due to a relative increase in 
body fat. Exploratory findings from the current systematic review 
provide too little information to confirm these expected changes 
in pharmacokinetics of THC in older persons. Direct comparative 
studies in young versus old subjects are therefore most necessary.
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Strengths and weaknesses of the review
This study is the first systematic review on medical cannabinoids 
in older subjects. It was developed and executed according the 
Cochrane Collaboration guidelines,39 using a selection procedure 
based on strict eligibility criteria and resulting in five controlled 
clinical trials.
Our search strategy yielded also three open label studies on the 
efficacy of cannabinoids in older persons.40-42 All showed positive 
effects of cannabinoids on behavioral disturbances in dementia, 
anorexia in long term care residents and psychotic symptoms in 
Parkinson’s disease, respectively. None reported cannabinoid 
related adverse effects. The absence of a control product and blind 
assessments, however, might have led to an overestimation of 
the efficacy of the intervention, which was the main reason not to 
include these studies in our analysis.
Although only prospective and controlled intervention trials were 
included for analysis in this review, four out of five included trials 
still had a moderate to high risk of bias. This raises the question 
whether these studies are methodologically deficient and could just 
have been performed better, or whether research on these frail 
subjects is too difficult and complex in practice to meet the high 
quality methodological criteria. This is an important and general 
paradox in the quest for high quality evidence in frail older subjects: 
the methods needed for high quality evidence are often themselves 
interventions these subjects can no longer stand or comply to. It 
is therefore highly relevant to carefully adapt the study methods 
(including design, inclusion criteria and outcome measures) to the 
frailty of the target population.
This review addresses the upcoming interest in the use of medical 
cannabinoids in the older patient. There is a growing number of 
countries permitting the use of medicinal cannabinoids, including 
18 states in the USA.2, 43 Furthermore, a recent poll among readers 
from New England Journal of Medicine, showed that a vast majority 
(76%) of clinicians from a wide variety of countries worldwide 
would recommend the use of marijuana in a 68-year old woman 
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with metastatic breast cancer, suffering from pain and nausea. Many 
responders called for more research on this topic to create a stronger 
basis of evidence.44 As such, this review points at an important 
problem, namely the under-representation of older subjects in 
clinical studies and study reports on the medical use of cannabinoids. 
This under-representation of elder participants is however not per se 
linked to cannabinoids as a treatment intervention, but is also seen 
in other medical fields, like oncology and cardiovascular medicine.45, 
46 Therefore, it is out most important to include a significant number 
of older subjects in trials on medical cannabinoids, to be able to 
draw firmer conclusions to support clinical decisions.
The present study was not without shortcomings. First, we 
aimed to subtract data on medical cannabinoids exclusively in older 
subjects. As a consequence, we were not able to answer the question 
whether there is an effect of age on the efficacy and safety of medical 
cannabinoids. Hence, this would be an important objective for future 
research in medical cannabinoids. Second, it was not possible to 
provide reliable summary measures (e.g. effect sizes) based on 
the data reported in the original studies. This was caused by three 
major factors; a high heterogeneity among the included studies, the 
absence of reported means and standard deviations per treatment 
group, and the generally very small sample sizes. Therefore, only 
qualitative and descriptive summaries could be provided.
Conclusions and implications
With the growing number of older patients, there is an urgent 
need for evidence based therapeutic interventions in this group. 
Many studies have been conducted on the efficacy and safety of 
medical cannabinoids in a variety of conditions in adult patients, and 
in a substantial number of studies, older subjects were included. 
Nevertheless, our review shows that there is a lack of evidence 
concerning the use of cannabinoids specifically in older patients, 
resulting in scarcity of data to guide treatment decisions. Adequately 
powered trials are needed to assess the efficacy and safety of 
cannabinoids in older subjects, including a critical evaluation of the 
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risk-benefit ratio, as the potential symptomatic benefits might be 
attractive for elderly with specific complaints and limited lifespan 
expectancy. It is highly worthwhile to conduct well designed studies 
on the efficacy of cannabinoids in symptom management in dementia, 
given the initial positive results on weight loss and agitation in this 
patient population, and the great lack of other effective and safe 
strategies in this field.
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SUPPLEMENTARY MATERIAL 
Appendix 1 – PubMed search strategy 
01. Cannabinoids [MeSH Terms]  
02. Cannabinoids [tiab]  
03. Cannabinoid [tiab]  
04. Cannabinol [tiab]  
05. Cannabidiol [tiab]  
06. Tetrahydrocannabinol [tiab]  
07. THC [tiab]  
08. CBD [tiab]  
09. Marinol [tiab]  
10. Cesamet [tiab]  
11. Sativex [tiab]  
12. Nabilone [tiab]  
13. Dronabinol [tiab]  
14. Delta-9-tetrahydrocannabinol [tiab]  
15. Delta-9-THC [tiab]  
16. Cannabis [tiab]  
17. Marihuana [tiab]  
18. Marijuana [tiab]  
19. Hashish [tiab] 
20.  1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 or 15 or 16 or 17 or 18 or 19 
21. Aged [MeSH]  
22. Frail [tiab]  
23. Elderly [tiab]  
24. Elder [tiab] 
25. Older [tiab]  
26. Aging [tiab]  
27. Ageing [tiab]  
28. Geriatric* [tiab]  
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
30.  Clinical Query: Therapy/broad = ((clinical[Title/Abstract] 
AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR 
clinical trial [Publication Type] OR random *[Title/Abstract] 
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OR random allocation [MeSH Terms] OR therapeutic use 
[MeSH Subheading]) 
31. 20 and 29 and 30 
32. Limit 31 to English languag
Appendix 2 – EMBASE search strategy 
01.  (cannabinoids or cannabinoid or cannabinol or cannabidiol 
or tetrahydrocannabinol or THC or CBD or marinol or 
cesamet or sativex or nabilone or dronabinol or delta-9 
tetrahydrocannabinol or delta-THC or cannabinol or marihuana 
or marijuana or hashish or cannabis).ti,ab. 
02. exp cannabinoid/ 
03. (frail or elder or older or elderly or aging or geriatric*).ti,ab. 
04. aged/ 
05. 3 or 4 
06. 1 or 2 
07. 5 and 6 
08. exp “clinical trial (topic)”/ 
09. exp randomization/ 
10. exp clinical trial/ 
11. ((clinical and trial) or random*).ti,ab. 
12. 8 or 9 or 10 or 11 
13. exp drug therapy/ 
14. 12 or 13 
15. 7 and 14 
16. limit 15 to English language  
Appendix 3 – CINAHL search strategy 
01.  TI (cannabinoids OR cannabinoid OR cannabinol OR 
tetrahydrocannabinol OR THC OR CBD OR marinol OR 
cesamet OR sativex OR nabilone OR dronabinol OR delta-9 
tetrahydrocannabinol OR delta-THC OR cannabinol OR 
cannabidiol OR marihuana OR marijuana OR hashish OR 
cannabis)
02.  AB (cannabinoids OR cannabinoids OR cannabinol OR 
tetrahydrocannabinol OR THC OR CBD OR marinol OR 
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cesamet OR sativex OR nabilone OR dronabinol OR delta-9 
tetrahydrocannabinol OR delta-THC OR cannabinol OR 
cannabidiol OR marihuana OR marijuana OR hashish OR 
cannabis) 
03. 01 or 02 
04. (MH “Cannabis”) 
05. 03 or 04 
06. TI (frail OR elderly OR elder OR older OR aging OR geriatric*) 
07. AB (frail OR elderly OR elder OR older OR aging OR geriatric*) 
08. 06 or 07 
09. (MH “Aged+”) 
10. 08 or 09 
11. 05 and 10 
12. (MH “Drug Therapy+”) 
13. (MH “Clinical Trials+”) 
14. TI (clinical and trial) 
15. TI (random*) 
16. 14 or 15 
17. AB (clinical and trial) 
18. AB (random*) 
19. 17 or 18 
20. 16 or 19 
21. (MH “Random Assignment”) 
22. 12 or 13 or 20 or 21 
23. 11 and 22   
Appendix 4 - Cochrane Library search strategy 
01. Cannabis 
02. Cannabinoid* 
03. 01 or 02 
04. Elderly 
05. 03 and 04
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Abstract
Given the lack of effective treatments for late-onset Alzheimer’s 
disease (LOAD) and the substantial burden on patients, families, 
health care systems, and economies, finding an effective therapy is 
one of the highest medical priorities. 
The past few years have seen a growing interest in the medicinal 
uses of cannabinoids, the bioactive components of the cannabis 
plant, including the treatment of LOAD and other physical conditions 
that are common in older people. Several in vitro and in vivo studies 
have demonstrated that cannabinoids can reduce oxidative stress, 
neuroinflammation, and the formation of amyloid plaques and 
neurofibrillary tangles, the key hallmarks of LOAD. In addition, in 
population- based studies, cannabinoids reduced dementia-related 
symptoms (e.g., behavioral disturbances). 
The current article provides an overview of the potential of 
cannabinoids in the treatment of LOAD and related neuropsychiatric 
symptoms in older people. We also discuss the efficacy, safety, and 
pharmacokinetics of cannabinoid-based drugs in older people with 
dementia.
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INTRODUCTION 
Demographic changes and the rapid aging of the population 
worldwide will lead to an increase in the prevalence of older people 
with late-onset Alzheimer’s disease (LOAD), many of whom suffer 
from multimorbidity.1,2 The term “LOAD” refers to Alzheimer’s 
disease diagnosed at or after 60 years of age.1 Given the substantial 
burden of LOAD on patients, their caregivers, and the economy, 
finding an effective therapy is one of the highest medical priorities 
of scientists, clinicians, and governments. The past few years have 
seen a growing interest in the medicinal uses of cannabinoids, the 
bioactive components of the cannabis plant (Cannabis sativa L.), 
including the treatment of LOAD and other physical conditions that 
are common in older people.3–5 
The current review provides an overview of the potential of 
cannabinoids as treatment for LOAD and its related symptoms, 
focusing on older individuals (≥ 65 years). The focus on older 
individuals was done for a number of reasons. (1) The prevalence 
of dementia caused by LOAD is high in older age groups (about 
95% of all cases), whereas early onset Alzheimer’s disease with 
an onset between 30 and 64 years is rare (< 5%) and often linked 
to familial Alzheimer’s disease, which is associated with a different 
pathophysiological mechanism and is caused by gene mutations on 
chromosomes 21, 14, and 1. (2) Older individuals, and especially 
those with cognitive impairment, have often been excluded or 
underrepresented in clinical trials,3,5 and it is not possible to 
directly extrapolate safety and efficacy data for cannabinoid-based 
drugs obtained in studies involving young adults to older people. 
(3) Older people with LOAD are more vulnerable to adverse drug 
reactions, and especially to drugs that act on the central nervous 
system, such as cannabinoids, than healthy older or younger 
people.6 This is because of age-related physiological changes (e.g., 
decrease in liver enzyme activity, lean body mass, renal clearance, 
and brain volume/receptors) that often alter the pharmacokinetics 
and pharmacodynamics of drugs.6 (4) Comorbidity is also more 
common in older people with dementia than in their non-demented 
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counterparts,2 leading to the use of multiple medications and to 
an increased risk of drug-drug and drug-disease interactions. As it 
is possible that older people with Alzheimer’s disease and multiple 
comorbidities might benefit from the use of cannabinoids as a multi-
target drug candidate (one drug for several conditions), we reviewed 
the literature on the potential of cannabinoids in the treatment of 
dementia and dementia-related symptoms in older people.
LATE-ONSET ALZHEIMER’S DISEASE 
Prevalence and pathophysiology 
It is estimated that 36 million people suffer from dementia 
worldwide. This number is expected to reach 115 million people 
by 2050, causing a major public health problem with an immense 
impact on individual patients, their families, health care systems, 
and economies.1 
Alzheimer’s disease is the most common type of dementia, 
accounting for 60 – 80% of cases, followed by vascular dementia 
(10-15%).7 In the United States alone, the prevalence of LOAD has 
been estimated at 5 million individuals aged 65 years and older, 
with at least 200,000 (4%) individuals younger than 65 years being 
affected by young-onset Alzheimer’s disease.7 Alzheimer’s disease, 
in general, is a progressive, neurodegenerative disease that is 
characterized by a decline in cognitive and intellectual functions 
(e.g., memory, executive function, language, and perceptual-motor 
skills) that significantly interferes with activities of daily living.8 The 
clinical picture is, however, more complex and frequently involves 
behavioral and psychological changes. Although its incidence and 
prevalence increase with advancing age, LOAD is not a normal part 
of aging.7 LOAD is probably a complex, multi-causal syndrome in 
which component causes, such as genetic, epigenetic, and late-
onset environmental factors, increase the likelihood of an individual 
developing LOAD.8 
In general, the brains of patients with Alzheimer’s disease 
are characterized by the accumulation of amyloid-β protein 
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(Aβ; mainly Aβ1–42 and Aβ1–40) in extracellular senile plaques in 
various brain regions, but especially in the hippocampus, cerebral 
prefrontal cortex, and amygdala.9 Aβ protein is generated by the 
aberrant processing of amyloid precursor protein, a single-pass 
transmembrane glycoprotein. The second pathological hallmark of 
Alzheimer’s disease is the presence of intracellular neurofibrillary 
tangles, formed by hyperphosphorylated tau.9 
It has been suggested that neuro-inflammation and oxidative 
stress play an important role in the pathogenesis of LOAD,10 
although there are still important missing links in our understanding 
of Alzheimer’s disease, especially LOAD. The accumulation and 
aggregation of senile plaques into toxic oligomers in the brain leads 
to the chronic activation of microglial cells and astrocytes, which 
surround the plaques, thereby initiating a pro-inflammatory cascade 
and oxidative stress that result in the release of potentially neurotoxic 
substances, such as cytokines, chemokines, reactive oxygen/
nitrogen species, complement proteins, and various proteolytic 
enzymes. This process leads to local inflammation and neuronal 
death, which subsequently leads to cognitive decline and behavioral 
changes.10 In addition, mitochondrial dysfunction has been shown 
to play a key role in LOAD.11 Aβ accumulation inhibits integrated 
mitochondrial respiration and the activity of key enzymes.11 This 
may result in increased oxidative stress, the production of reactive 
oxygen species, and damage to different molecules, including 
nucleic acids, proteins, and lipids, and endoplasmic reticulum-
related protein defolding.11 Moreover, intracellular Aβ accumulation 
contributes to the dysregulation of intracellular calcium homeostasis 
and excessive activation of the N-methyl-D-aspartate subtype of 
glutamate receptor, inducing excitotoxicity and neuronal death.12
Treatment of late-onset Alzheimer’s disease 
In general, the progression and treatment of LOAD do not differ 
from young-onset Alzheimer’s disease. The progression of Alzheimer’s 
disease from early stages of the disease (asymptomatic or minimally 
symptomatic) to dementia stages (symptomatic) may take decades. 
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Therefore, successfully targeting the neuropathology of Alzheimer’s 
disease in an early stage would help diminish the burden of dementia 
and its associated neuropsychiatric symptoms. However, currently 
approved pharmacological treatments for Alzheimer’s disease, 
which include cholinesterase inhibitors (donepezil, rivastigmine, 
galantamine) and the N-methyl-Daspartate receptor antagonist 
memantine, act on symptoms and do not have profound disease-
modifying effects. 
A Cochrane meta-analysis of 13 randomized, double-blind, 
placebo-controlled trials with donepezil, rivastigmine, and 
galantamine demonstrated that the three cholinesterase inhibitors 
are efficacious for mild-to-moderate Alzheimer’s disease, but it is 
not possible to identify patients who will respond to treatment in 
advance.13 Although the three cholinesterase inhibitors seem to be 
equally effective, donepezil seems to give rise to fewer side effects 
than rivastigmine.13 However, the tolerability of galantamine and 
rivastigmine (oral form) can be improved to match that of donepezil 
if the drugs are administered according to a gradual titration routine 
over more than three months. Donepezil dose titration is more 
straightforward and lower doses may be effective.13 
Rivastigmine is currently also available as a transdermal patch 
(Exelon patch, Rivastach patch, Prometax patch), which is associated 
with better patient satisfaction, tolerability, and compliance 
compared to the oral formulation.14 
In the past decades, several attempts have been made to 
develop disease-modifying drugs for Alzheimer’s disease. One of the 
most innovative is the development of immunotherapy, based on 
the stimulation of amyloid plaque clearance from Alzheimer brains 
via the administration of Aβ antigens (active vaccination) or anti-
Aβ antibodies (passive vaccination). The first in vivo immunization 
study was reported in 1999 by Schenk et al.15 They demonstrated 
that immunization of transgenic mice with Aβ1–42 prevented the 
development of beta-amyloid-plaque formation, neuritic dystrophy, 
and astrogliosis in young mice (with young-onset Alzheimer’s 
disease) and significantly reduced the extent and progression of 
Alzheimer’s disease-like pathology in older mice (with LOAD).15 On 
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the basis of these results and those of a phase 1 safety study, a 
follow-up multicenter, randomized, placebo-controlled, phase 2 
double-blind clinical trial was carried out involving patients with 
mild-to-moderate Alzheimer’s disease.16,17 Patients were randomly 
assigned to receive intramuscular injections of AN1792 (aggregated 
Aβ1–42 and an immune adjuvant, QS-21) or placebo. Unfortunately, 
the trial had to be abandoned as 18 of the 298 included patients 
(6%) developed meningoencephalitis.16,17 Sixteen of the 18 had 
received two doses, one had received one dose, and one had received 
three doses of the study drug before symptoms occurred.16 This 
severe side effect was caused by an inflammatory T cell response. 
Postmortem analysis of the brains of participants with Alzheimer’s 
disease showed that the AN1792 vaccine had significantly reduced 
the number of amyloid plaques compared to placebo.18 However, 
the progression of cognitive decline was unchanged and did not 
correlate with clearance of amyloid plaques, which suggests that 
plaque clearance is not enough to counter the progression of 
Alzheimer’s disease.18 Since then, several attempts have been made 
to develop safe and effective drugs, but none have proven effective 
in phase 3 clinical trials involving patients with mild-to-moderate 
disease.19 Causes and factors associated with this failure include 
the use of inadequate biological and neuropsychological markers 
for the diagnosis of LOAD, inability to reach a therapeutic dosage 
(e.g., because of severe adverse events), short treatment duration, 
poor penetration to the brain, and advanced disease stage.19 The 
data of phase 3 studies suggest that mild-to-moderate Alzheimer’s 
disease has already progressed too far for treatment to be effective 
in improving neuronal and synaptic damage.19,20 
It is important to note that because the neuropathology of 
LOAD involves multiple hallmarks, it is reasonable to assume that 
a treatment strategy focusing on multiple targets may be more 
beneficial than a strategy focusing on one target only.
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Treatment of neuropsychiatric symptoms of late-onset 
Alzheimer’s disease
Almost all patients with LOAD (98%) develop neuropsychiatric 
symptoms at some point.21 These symptoms include depression, 
anxiety, agitation, aggression, wandering, pacing, sleep disorders, 
psychosis, and appetite/eating disorders, and are often distressing 
to patients and their caregivers, leading to early nursing home 
placement.22 Moreover, they are associated with more rapid dementia 
progression and higher health care costs.23,24 
An earlier study showed that approximately 30% of the total 
annual cost of Alzheimer’s disease treatment is directly attributable 
to the management of neuropsychiatric symptoms.24 Therefore, 
effective treatment of the neuropsychiatric symptoms of LOAD may 
have the potential to modify the disease course, lower costs, and 
improve the quality of life of affected individuals and their caregivers. 
Yet no drugs have been approved by either the US Food and 
Drug Administration or the European Medicines Agency for the 
treatment of the neuropsychiatric symptoms of Alzheimer’s disease. 
Studies of the cholinesterase inhibitors donepezil, rivastigmine, and 
galantamine reported modest or no improvement in neuropsychiatric 
symptoms.25 In addition, the N-methyl-D-aspartate receptor 
antagonist memantine did not improve agitation compared with 
placebo in patients with moderate-to-severe Alzheimer’s disease 
(n=149).26 
Psychotropic medications, such as antipsychotics, benzodiazepines, 
antidepressants, and antiepileptic drugs, are also frequently used 
off-label for the treatment of the neuropsychiatric symptoms of 
Alzheimer’s disease, but they are ineffective in most cases or only 
have a short-term effect.27 Moreover, they are associated with serious 
adverse events in older individuals, including falls,28 cardiovascular 
and cerebrovascular events,29 and even death.30 
Taken together, there is an urgent need for new effective and safe 
pharmacological interventions to retard LOAD progression toward 
dementia (symptomatic) and diminish the burden of neuropsychiatric 
symptoms.
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THE ENDOCANNABINOID SYSTEM AS MULTITARGET 
DRUG CANDIDATE 
In the past decade, the medicinal use of cannabis has moved 
to the forefront of public and scientific debate, and the past few 
years have seen a growing interest in its medical applications in 
older people, including those with Alzheimer’s disease and multiple 
comorbidities.3–5 This is not surprising because the cannabis plant 
(Cannabis sativa L.) has been used for centuries to treat a wide 
range of conditions that are common in older people (e.g., pain, 
depression, sleep disturbance, and loss of appetite).31 These broad 
therapeutic applications are due to the pharmacological effects of 
its bioactive components, the “cannabinoids.”32 Currently, more than 
60 different cannabinoids have been identified and isolated from 
the cannabis plant, with delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) being the most studied.32 
Although the exact mechanism of action and the physiological 
effects of cannabinoids are still not fully understood, THC seems 
to be responsible for most of the physical and psychoactive 
effects of cannabis.32 Cannabinoids exert some of their multiple 
effects through an interaction with the endocannabinoid system. 
This system consists of cannabinoid receptors, endogenous lipid 
ligands (endocannabinoids), including Narachidonoylethanolamine 
(anandamide) and 2arachidonoylglycerol, and enzymes (e.g., 
fatty acid amide hydrolase and monoglyceride lipase) involved 
in the synthesis and degradation of these endocannabinoids.33 
Cannabinoids bind to the cannabinoid receptors CB1 and CB2, both 
of which are G protein-coupled receptors.34–36 CB1 receptors are 
mainly expressed in the nervous system (basal ganglia, cerebellum, 
hippocampus, hypothalamus, and dorsal horn), whereas CB2 
receptors are primarily found in cells and organs of the immune 
system.34–36 However, cannabinoids also exert effects by interacting 
with other cannabinoid receptors in the brain, such as GPR55 receptors 
and noncannabinoid receptors, such as peroxisome proliferator-
activated receptors alpha and gamma, transient receptor potential 
vannilloid-1 channels, acetylcholine, dopamine, serotonin, gamma-
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aminobutyric acid, glutamate, norepinephrine, prostaglandins, and 
opioid peptides.37 This broad interaction reflects the potential of 
cannabinoids and the endocannabinoid system as multitarget drug 
candidates for LOAD.4
THE ENDOCANNABINOID SYSTEM IN AGING AND 
ALZHEIMER BRAINS 
The endocannabinoid system has been associated with several 
pathological conditions and processes in aging, including synaptic 
plasticity (learning and memory), neuroinflammation and 
neurodegeneration, behavior and mood disorders, regulation of 
the wake-sleep cycle, immune function, inflammatory diseases, 
physiological homeostasis, cardiovascular function, bone 
development and density, pain, motor alterations, and regulation of 
food intake and energy balance.38 In this respect, it is important to 
distinguish between age-related and LOAD-related changes in the 
endocannabinoid system before it can be considered as a therapeutic 
target for LOAD. Unfortunately, there have been only a few studies 
investigating possible age-related and Alzheimer’s disease-related 
changes in the endocannabinoid system. 
One of the few such studies reported a significant decrease in 
cannabinoid receptor binding in various brain regions (cerebellum, 
cerebral cortex, limbic and hypothalamic structures, and 
hippocampus) in aged rats compared with young rats.39 
In another study, receptor binding was decreased in most regions 
of the basal ganglia in aged rats, except for the globus pallidus, in 
which binding levels were similar in both aged and young rats.40 The 
greatest decrease was found in the entopeduncular nucleus (50%), 
substantia nigra pars reticulata (45%), and lateral caudate putamen 
(29%). With aging, brain cannabinoid CB1 receptor density in the 
hippocampus also decreases (30%).41 
Although the endocannabinoid system may be influenced by 
Alzheimer-type neurodegeneration, it is not clear whether these 
changes are a cause or a consequence of LOAD, and whether these 
changes are dependent or independent of normal age-related 
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changes. Postmortem studies of Alzheimer brains have reported 
contradictory results regarding the expression and density of 
cannabinoid receptors.42–49 Whereas the majority of studies found 
no changes in the expression and availability of CB1 receptors in 
Alzheimer brains compared with control brains,42–45 some studies 
reported a decreased expression of CB1 receptors in Alzheimer 
brains, mainly in neurons distant from senile plaques.46,47 One study 
failed to distinguish between age-related and Alzheimer’s disease-
related changes in CB1 receptor expression.48 A decreased level of 
CB1 receptors in the brain may alter the pharmacodynamic effects 
of exogenous cannabinoids in people with LOAD because the effects 
of cannabinoids are mainly mediated by CB1 receptors.
CANNABINOIDS IN LATE-ONSET ALZHEIMER’S 
DISEASE 
In vitro and in vivo studies
Targeting the endocannabinoid system has been proposed as 
a potential approach to the treatment of Alzheimer’s disease.46, 
49–51 Numerous in vitro and in vivo studies have demonstrated 
the protective effects of cannabinoids against Aβ peptide and tau 
phosphorylation, the neuropathological hallmarks of the disease.46, 
49–51 The endogenous cannabinoids N-arachidonoylethanolamine and 
2-arachidonoylglycerol have been found to cause a concentration 
dependent inhibition of Aβ neurotoxicity, through the activation of 
the CB1 receptor and mitogen-activated protein kinase pathways, 
that regulate cell function (e.g., cell growth, mitosis, survival, and 
apoptosis).52 
Another study demonstrated that the administration of 
N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine, a potent 
cannabinoid reuptake inhibitor, to rats improved Aβ-induced neuronal 
damage and memory impairment. These positive effects were 
dependent on early administration of Narachidonoyl-(2-methyl-4-
hydroxyphenyl) amine, which suggests that early pharmacological 
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enhancement of brain cannabinoid levels may protect against Aβ 
neurotoxicity.53 
Ramírez et al.46 reported that intracerebroventricular 
administration of the synthetic cannabinoid WIN55,212-2 to rats 
prevented Aβ-induced microglial activation, cognitive impairment, 
and loss of neuronal markers. The synthetic cannabinoids HU210, 
WIN55,212-2, and JWH-133 may block Aβ-induced activation of 
cultured microglial cells, as judged by mitochondrial activity, cell 
morphology, and tumor necrosis factor-α release. These effects 
seem to be independent of the antioxidant action of cannabinoid 
compounds and are also exerted by a CB2 selective agonist. Moreover, 
cannabinoids prevent microglia mediated neurotoxicity after the 
addition of Aβ to rat cortical cultures.46 The authors concluded that 
cannabinoid receptors are important in the pathology of Alzheimer’s 
disease and that cannabinoids can prevent the neurodegenerative 
process occurring in the disease.46 
Other positive results were obtained with exogenous 
cannabinoids, such as cannabidiol, a nonpsychoactive cannabinoid. 
CBD has been proposed as an antioxidant neuroprotective agent in 
neurodegenerative diseases because it inhibits in vivo Aβ plaque 
formation and decreases reactive oxygen species production and 
lipid peroxidation.49 Moreover, CBD has been shown to rescue PC12 
cells, a rat pheochromocytoma cell line that is used as a model 
system for studying neuronal cell death, from the toxicity induced 
by Aβ peptide.54 
It has also been reported that CBD inhibits the hyperphosphory-
lation of tau protein in Aβ-stimulated PC12 neuronal cells by 
reducing the phosphorylation of glycogen synthase kinase-3beta, 
which is responsible for the tau hyperphosphorylation in Alzheimer’s 
disease.55 
In addition, glycogen synthase kinase-3beta can block the 
production of Aβ peptides by interfering with amyloid precursor 
protein cleavage at the gamma-secretase step.56 Thus, CBD is an 
attractive drug candidate for the management of LOAD because it 
reduces the hallmarks of the disease, namely the formation of both 
amyloid plaques and neurofibrillary tangles. 
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In a recent study, Martín-Moreno et al.57 compared the effects 
of cannabinoids on microglial cell function in vitro and on learning 
behavior and cytokine expression after the intraventricular 
administration of Aβ to mice. They reported that two cannabinoids, 
CBD and WIN55,212-2 (synthetic cannabinoid), were able to 
modulate microglial cell functions and cytokine expression, improving 
the learning behavior of mice injected with Aβ.57 
In addition, Scuderi et al.58, in their study of whether CBD could 
modulate amyloid precursor protein processing in transfected 
human neuroblastoma SHSY5Y(APP1) neurons, found that CBD 
induced the ubiquitination of amyloid precursor protein, which led to 
a substantial decrease in levels of the full-length protein in neurons 
and to a decrease in Aβ production.58 Moreover, CBD promoted the 
survival of SHSY5Y(APP1) neurons by reducing the rate of apoptosis. 
All the effects of CBD were dependent on the selective activation of 
peroxisome proliferator-activated receptors gamma.58 
Eubanks et al.59 also pointed out the potential of another 
exogenous cannabinoid, THC, as a new drug candidate for the 
treatment of Alzheimer’s disease. They found THC to competitively 
inhibit the enzyme acetylcholinesterase and to prevent 
acetylcholinesterase-induced Aβ aggregation even more effectively 
than acetylcholinesterase inhibitors, the drugs currently registered 
for Alzheimer’s disease. 
In a more recent study, Aso et al.60 evaluated the therapeutic 
properties of Sativex (combination of THC/CBD) in an animal model 
of LOAD (AβPP/PS1 mice). These mice exhibit the most relevant 
features of LOAD, such as cognitive impairment and several 
pathological alterations, such as Aβ accumulation, dystrophic 
neurites, synaptic failure, mitochondrial dysfunction, and oxidative 
stress damage.60 Intraperitoneal administration of THC/CBD (0.75 
mg/kg each for 5 weeks) significantly reduced cognitive impairment. 
Moreover, it reduced levels of soluble Aβ1–42, but not those of Aβ1–40, 
thereby changing the composition of amyloid plaques in these mice. 
This suggests that combination treatment with THC/CBD may be 
more beneficial than treatment with either agent alone.
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Population-based studies 
Unfortunately, there have been no population-based studies of 
cannabinoids as a potential cure for LOAD. Comparing the preclinical 
and clinical data of therapeutic properties of cannabinoids with 
the evidence supporting more investigated approaches for the 
treatment of LOAD (e.g., cholinesterase inhibitors and the N-methyl-
D-aspartate receptor antagonist), the majority of the evidence of 
cannabinoids has been based on cellular and animal models that 
mimic a variety of Alzheimer’s disease-related changes. Moreover, 
little is known about the safety of cannabinoids in people with LOAD. 
Previous epidemiological studies have shown that prolonged exposure 
to cannabinoids could increase the risk of developing psychiatric 
disorders (e.g., cognitive abnormalities, psychotic illness, and mood 
disorders), especially in people who already have a vulnerability to 
develop a psychiatric syndrome.61 
Given the interesting results of cannabinoids reported in in vitro 
and in vivo studies, population-based studies are urgently warranted, 
especially sufficiently powered randomized clinical trials that are 
designed to differentiate between symptomatic improvement and 
disease modification.
TREATMENT OF NEUROPSYCHIATRIC SYMPTOMS 
Our literature search in PubMed (February 2015), using the terms 
“Alzheimer’s disease,” “dementia,” and “cannabinoids,” identified one 
systematic review, one case report, and four small clinical studies 
(out of 160 articles) on the effectiveness and safety of cannabinoids 
in the treatment of people with dementia. The systematic review62 
included only one double-blind placebo-controlled crossover trial. 
According to the authors, the trial data were presented in such a 
way that they could not be used for further analysis and there was 
insufficient quantitative data to validate the results. Therefore, 
they concluded that there is no evidence that cannabinoids are 
effective in the treatment of disturbed behavior or other symptoms 
of dementia.62 In the case report, the synthetic THC nabilone was 
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used in a 72-year-old man with LOAD who had developed behavioral 
symptoms, including wandering, pacing, disinhibition, agitation, and 
aggression.63 The patient had previously been treated with donepezil, 
memantine, gabapentin, trazodone, quetiapine, olanzapine, 
lorazepam, and citalopram without significant improvement. 
Nabilone 0.5 mg/day was started and was later increased to 0.5 mg 
twice daily, which led to a significant improvement in the patient’s 
behavioral symptoms without emergent side effects during the 
three-month follow-up. 
The four clinical studies of the effectiveness of cannabinoids in the 
treatment of dementia symptoms included in total 60 subjects, all 
of whom were treated with the synthetic THC dronabinol.64–67 Table 
1 summarizes these studies. In a double-blind placebo-controlled 
crossover trial, Volicer et al.64 included 15 institutionalized patients 
with Alzheimer’s disease who refused food. During the 12-week 
trial, the patients were randomly assigned to placebo first (6 weeks) 
or dronabinol (2.5 mg twice daily) first (6 weeks). Twelve patients 
(mean age 72.7±4.9; 11 men) were included in the final analysis. 
Trial medication was terminated in three participants because one 
developed a grand mal seizure after the first dronabinol dose and two 
developed serious intercurrent infections.64 Patients gained weight 
and agitation decreased during dronabinol treatment. Compared to 
placebo, dronabinol was associated with tiredness, somnolence, and 
euphoria.64 
In an open-label pilot study, Walther et al.65 evaluated the effect 
of dronabinol on sleep and behavioral disturbances in six patients 
(mean age = 81.5±6.1; 4 women) with severe dementia (five with 
Alzheimer’s disease). Participants received 2.5 mg dronabinol daily 
for 2 weeks. Actigraphy and the Neuropsychiatric Inventory were 
used to measure the effect of dronabinol on nocturnal motor activity 
and behavior, respectively. Compared to baseline, dronabinol 
significantly improved nocturnal motor activity and behavior. No 
side effects were observed during the study period.65 Subsequently, 
Walther et al.66 started a randomized, double-blind, placebo-
controlled, crossover trial to further evaluate the effects of dronabinol 
on behavioral disturbances in Alzheimer’s disease. After the inclusion 
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of two patients, the trial was prematurely discontinuedbecause of 
recruitment failure. The two included patients were 75 and 81-year-
old men with LOAD who had been treated with 2.5 mg dronabinol for 
four weeks for nighttime agitation. In both cases, the administration 
of dronabinol reduced nighttime activity and strengthened circadian 
rhythms without any adverse events. 
More recently, in a retrospective systematic chart review, 
Woodward et al.67 evaluated the data of 40 patients with dementia 
(13 with Alzheimer’s disease; 28 women) who had been treated 
with dronabinol for behavioral or appetite disturbances. The medical 
records of included patients were reviewed by geriatric psychiatrists 
to rate the patients’ behavior before and after seven days of 
dronabinol treatment, using the Pittsburgh Agitation Scale, Clinical 
Global Impression, and Global Assessment of Functioning.67 In 
addition, data were collected on the percentage of food consumed at 
each meal, sleep duration, and adverse events. The mean duration 
of dronabinol treatment was 17 days (range= 4–50 days) and the 
mean dose was 7 mg/day. Administration of dronabinol significantly 
improved scores on the Pittsburgh Agitation Scale and the Clinical 
Global Impression, but not on the Global Assessment of Functioning. 
There were also significant improvements in sleep duration and 
percentage of food consumed during active treatment. Twenty-six 
adverse events were reported during dronabinol treatment, with 
sedation (n=9), delirium (n=4), urinary tract infection (n=3), and 
confusion (n=2) being the most frequently reported. However, while 
it was not possible to assess whether the reported adverse events 
were associated with dronabinol, none of the adverse events led to 
medication discontinuation.67 
Although the findings from the above-mentioned clinical studies 
and case report suggest that THC is effective and safe to use in 
the treatment of dementia-related symptoms in older people, the 
studies had several limitations that need to be addressed. For 
example, the studies were either not randomized or included a very 
limited number of participants (range= 10–40 participants), so that 
the studies had insufficient power to draw firm conclusions about 
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the safe and effective use of cannabinoids for older people with 
dementia. Moreover, the THC treatment period was too short (2–7 
weeks). Last, all the studies focused on dementia-related symptoms 
and did not include the assessment of memory and cognitive 
function as outcome measures. It is of great importance to establish 
whether cannabinoids, particularly when used long term, affect 
memory and cognitive functions in frail older people with LOAD. In 
previous general population studies, prolonged use of cannabis was 
associated with memory deficits and cognitive impairments.61 
More adequately powered randomized clinical trials are needed 
to confirm the findings of the above-mentioned studies. Until then, 
individual evaluation of the risk-benefit ratio is needed before 
cannabinoid-based drugs can be prescribed to frail older individuals 
with LOAD.
CANNABINOIDS IN THE TREATMENT OF OTHER 
CONDITIONS IN OLDER PEOPLE 
Current prescriptions 
Because of the significant therapeutic potential of cannabis and 
cannabinoids, people aged 65 years and older probably constitute a 
growing population of potential users.3 Although there are numerous 
studies of the medicinal use of cannabis (marijuana, cannabinoids 
based-drugs, and cannabis extracts) in the general population, little 
is known about its effect in older people.5 
In the United Kingdom, between 1998 and 2002, 947 people 
reported ever having used cannabis for medicinal purposes68; 14% 
of these individuals were older than 60 years. Medicinal cannabis is 
mostly used for multiple sclerosis (12% of participants), neuropathy 
(11%), chronic pain (11%), depression (8%), and arthritis (7%). 
In the Netherlands, where herbal cannabis (marijuana) is available 
at community pharmacies, more than 5,500 patients (57% were 
women) were prescribed herbal cannabis between 2003 and 2010.69 
Of these, 31% were aged between 61 and 80 years and 6% were 
older than 80 years, with an average duration of use of six months 
and three months, respectively. 
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Hazekamp et al.70 recently reported the results of an international 
survey on the medicinal use of cannabis and cannabinoids in 31 
countries (e.g., United States, Germany, Canada, France, the 
Netherlands, and Spain). Of the 953 users of medicinal cannabis 
(mean age= 40.7 years; 64% men) who completed the survey, 
24% were aged between 51 and 60 years, 6% between 61 and 70 
years, and 1% older than 70 years. The five most reported medical 
conditions for medicinal cannabis use were back pain (11.9%), 
sleeping disorder (6.9%), depression (6.7%), pain resulting from 
an injury or accident (6.2%), and multiple sclerosis (4.1%).70
Efficacy and safety of cannabinoid-based drugs 
There are currently three cannabinoid-based drugs available 
for medical use, dronabinol, nabilone, and nabiximols. Dronabinol 
(Marinol; Solvay Pharmaceuticals, Belgium) and nabilone (Cesamet; 
Valeant Pharmaceuticals International North America, Canada) are 
both synthetic THC in capsule form. They have been approved 
in North America and some European countries for appetite 
stimulation in AIDS-related anorexia and chemotherapy-induced 
nausea and vomiting. Nabiximols (Sativex, GW Pharmaceuticals, 
UK) is an oromucosal mouth spray that contains both THC and CBD 
(ratio= 1:1). It is used for the symptomatic relief of neuropathic 
pain and muscle spasticity in patients with multiple sclerosis and is 
available in 15 countries including the United Kingdom and seven 
other European countries, New Zealand, and Canada, but not in 
the United States. Cannabinoid-based drugs that have not yet 
gained marketing approval are: (1) Namisol (Echo Pharmaceutical, 
The Netherlands), a THC-based formulation in tablet form.71 This 
drug is under investigation for the treatment of pain (multiple 
sclerosis, chronic pancreatitis) and neuropsychiatric symptoms of 
Alzheimer’s disease (agitation/aggression); and (2) Epidiolex (GW 
Pharmaceuticals, UK) which is a CBD-based formulation that has 
recently been tested in children and young adults with treatment-
resistant epilepsy.72 
Several studies have demonstrated the efficacy and safety of 
cannabinoid-based drugs in the treatment of different conditions 
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that are highly prevalent in the older population, such as pain, 
anorexia, and nausea and vomiting.3,5 Although all these conditions 
are common in older people, and in those with dementia, few 
studies reported data on older people separately.3,5 Moreover, most 
preapproval clinical trials of cannabinoid-based drugs excluded 
older individuals (≥ 65 years) from participation or did not include 
sufficient numbers of older participants to compare them with young 
participants.3,5 
Recently, we performed a systematic literature review to identify 
studies investigating the efficacy and safety of medical cannabinoids 
in older subjects.5 We found 105 randomized clinical trials that 
reported the inclusion of older individuals (≥ 65 years). Of these, 
only five trials reported data for older individuals separately. These 
trials included a total of 267 participants (mean age= 47–78 years). 
Three trials used oral THC and two trials used an oral combination 
of THC/CBD. The studies found neither THC nor THC/CBD to be 
effective against dyskinesia, breathlessness, and chemotherapy-
induced nausea and vomiting. Two studies showed that THC might 
be useful for the treatment of anorexia and behavioral symptoms 
of dementia. Adverse events were more frequently associated 
with cannabinoid treatment than with the control condition, with 
sedation/drowsiness being the most reported adverse events. None 
of the studies reported severe adverse effects related to cannabinoid 
use. Thus, for the moment, no firm conclusion can be drawn about 
the safety and efficacy of cannabinoid-based drugs in older people. 
In general, older people seem to be more susceptible than 
younger people to the effects of drugs acting on the central nervous 
system. This can be explained by four important factors.73 (1) 
Age-related changes in brain volume and number of neurons, as 
well as alterations in neurotransmitter sensitivity, may increase 
the pharmacological effect of a drug. (2) Certain neurotransmitter 
receptors may be selectively affected by age-related changes at 
presynaptic and postsynaptic levels. (3) Age-related changes in 
receptors, whether they are located at the actual neurotransmitter 
binding site or within the second messenger or effector system, may 
change sensitivity to the available neurotransmitter. Altered binding 
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of the neurotransmitter to its receptor site may affect its sensitivity 
to be blockaded by some drugs that act in the central nervous 
system. (4) Altered drug disposition in older individuals generally 
results in a higher concentration of psychotropic drugs at central 
nervous system receptor sites.73 Moreover, synthetic cannabinoids 
are lipophilic compounds, and age-related physiological changes, 
such as an increase in adipose tissue and a decrease in lean body 
mass and total body water, increase the volume of distribution of 
lipophilic drugs. In addition, age-related changes in hepatic function 
(decrease in hepatic blood flow and slow hepatic metabolism) can 
slow the elimination of lipophilic drugs, which can subsequently lead 
to side effects.
PHARMACOKINETICS OF CANNABINOIDS 
Relatively little is known about the pharmacokinetics of cannabis 
and cannabinoids in older individuals, especially in people with LOAD. 
None of the preapproval clinical trials of cannabinoidbased drugs 
currently available for clinical use (Marinol, Cesamet, and Sativex) 
reported pharmacokinetic data for older individuals or people 
with dementia. Moreover, the most recent studies of cannabinoid-
based drugs that included older participants without dementia 
did not perform separate pharmacokinetic analyses for the older 
subgroup.5,71 Carroll et al.74 were the first to report pharmacokinetic 
data for cannabinoids in older people without dementia. They 
included 19 participants (12 men; mean age= 67 years; range= 51–
78 years) with Parkinson disease who received Cannador (THC 2.5 
mg and CBD 1.25 mg per capsule). In most patients, the maximum 
concentration (Cmax) of THC was reached within two hours of drug 
administration, with levels ranging from 0.25–5.4 ng/mL. There was 
no clear dose response. The authors did not report pharmacokinetic 
data for subjects older than 65 years.74 
In our recent phase 1 study,71 we evaluated the pharmacokinetics 
of three oral doses of THC (3 mg, 5 mg, and 6.5 mg) in 12 healthy 
older subjects (6 men; mean age = 72±5 years; range= 65–80 
years). One subject was not medication compliant and so the data 
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for 11 subjects (5 men and 6 women) were analyzed. Blood samples 
were collected before and at 40, 55, and 120 minutes after dosing. 
There was a wide interindividual variation in plasma concentrations 
of THC and its active metabolites, 11-hydroxy-delta 9-THC and 
11-nor-9-carboxy-delta 9-tetrahydrocannabinol. In one subject, the 
THC concentration had not reached a maximum by 120 minutes 
after dosing with 3 mg THC, and in four and five subjects after 
dosing with 5 mg and 6.5 mg THC, respectively. For subjects for 
whom Cmax was reached within 120 minutes, the geometric mean 
THC Cmax was 1.42 ng/mL (range= 0.53–3.48) for 3 mg (n=10), 
3.15 ng/ mL (range= 1.54–6.95) for 5 mg (n=7), and 4.57 ng/mL 
(range= 2.11–8.65) for 6.5 mg (n=6).71 However, as the study was 
initially designed to assess the safety, not pharmacokinetics, of THC, 
only four blood samples were collected over 120 minutes, which 
is insufficient for complete pharmacokinetic analysis.71 In another 
recent study, a randomized, double-blind, placebo-controlled, 
crossover trial,80 we evaluated the pharmacokinetics of THC in 10 
older subjects with dementia (7 men; mean age= 77.3±5.6 years; 
9 with Alzheimer’s disease). Subjects were randomly assigned to 
receive oral THC or placebo twice daily for three days, separated 
by a four-day washout period. The total treatment period was 12 
weeks. Patients received 0.75 mg THC twice daily in weeks 1–6 and 
1.5 mg THC twice daily in weeks 7–12. The data of one participant 
were excluded because insufficient blood was collected for analysis. 
The median time to reach Cmax (tmax) was one to two hours. THC 
pharmacokinetics increased linearly with increasing dose, but with 
a wide interindividual variation (the coefficient of variation of the 
geometric mean was as high as 140%). The mean Cmax (ng/mL) 
after the first dose (0–6 hours) was 0.41 (0.18–0.90) for the 0.75 
mg dose and 1.01 (0.53–1.92) for the 1.5 mg dose; after the second 
dose (6–24 hours), the Cmax was 0.50 (0.27–0.92) and 0.98 (0.46–
2.06), respectively. To the best of our knowledge, this was the first 
and only study to date to investigate the pharmacokinetics of THC 
in subjects with dementia.75 
Understanding the pharmacokinetics and pharmacodynamics 
of cannabinoid-based drugs will help clinicians to maximize the 
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therapeutic benefits and minimize the toxic effects. Therefore, more 
studies are warranted in this population, especially comparison 
studies with younger and older adults.
CONCLUSION 
Current use and future prospects 
The great burden of LOAD and the lack of adequate therapy explain 
the increasing number of studies (vitro, vivo, human) in this field of 
medicine. Given the complex multifactorial pathogenesis of LOAD, 
the development of a drug targeting a single causal factor will be of 
limited benefit to most patients. The literature consistently reports 
that the endocannabinoid system is associated with LOAD, and a 
number of studies have shown that targeting the endocannabinoid 
system offers a novel pharmacological approach for the treatment 
of LOAD that may be more effective than currently available drugs. 
Cannabinoids can reduce oxidative stress, neuroinflammation, and 
the formation of amyloid plaques and neurofibrillary tangles, the 
hallmarks of LOAD. Moreover, the cannabinoid THC seems to increase 
the availability of acetylcholine and prevent acetylcholinesterase-
induced Aβ aggregation. Cannabinoids are interesting drug 
candidates for the treatment of LOAD in older people for other 
reasons as well. (1) The interactions between the endocannabinoid 
system and other receptors and neurotransmitters in the brain make 
cannabinoids not only a potential drug candidate for LOAD, but also 
for other physical conditions that are common in older people. (2) 
The cannabis plant is easy and cheap to cultivate, which makes 
cannabinoids an attractive drug. (3) Cannabinoid-based drugs (oral 
and mouth spray) have recently been developed and approved for 
use in a fixed dose, which makes drug delivery and dose control 
easier than with the smoking route of drug delivery, especially in 
individuals with cognitive impairment.
In conclusion, currently available studies, both in vitro and in vivo, 
provide an interesting basis for the innovative use of cannabinoids 
as a therapeutic approach to LOAD and other comorbidities in older 
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people. However, the lack of population-based studies justifies further 
research, and especially adequately powered randomized controlled 
trials, in order to assess the safety, efficacy, pharmacokinetics, 
and pharmacodynamics of cannabinoid-based drugs in this frail 
population.
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Abstract
Objectives: Neuropsychiatric symptoms (NPS) are highly prevalent 
in dementia, while effective pharmacotherapy without important 
side-effects is lacking. This study aims to assess the efficacy and 
safety of oral tetrahydrocannabinol (THC) in the treatment of NPS 
in dementia.
Design: Randomized, double-blind, placebo-controlled, repeated 
crossover trial, consisting of six treatment blocks of two weeks each. 
Setting: Two hospital sites in The Netherlands, September 2011 to 
December 2013.
Participants: Patients with dementia and clinically relevant NPS.
Intervention: Within each block THC (0.75 mg twice daily in 
block 1–3 and 1.5 mg twice daily in block 4–6) and placebo were 
administered in random order for three consecutive days, followed 
by four-day washout.
Measurements: Primary outcome was change in Neuropsychiatric 
Inventory score (NPI). Analyses were performed intention-to-treat. 
Data from all subjects were used without imputation. Sample size 
required for a power of 80% was 20 patients, because of repeated 
crossover.
Results: Twenty-two patients [15 men, mean age 76.4 (5.3) years] 
were included, of whom 20 (91%) completed the trial. THC did not 
reduce NPI compared to placebo (block 1–3: 1.8, 97.5% CI -2.1 to 
5.8; block 4–6: -2.8, 97.5% CI -7.4 to 1.8). THC was well tolerated, 
as assessed by adverse event monitoring, vital signs and mobility. 
The incidence of adverse events was similar between treatment 
groups. Four non-related serious adverse events occurred. 
Conclusions: This is the largest randomized controlled trial studying 
the efficacy of THC for NPS, to date. Oral THC did not reduce NPS 
in dementia, but was well tolerated by these vulnerable patients, 
supporting future higher dosing studies.
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Introduction
Nearly all patients with dementia experience behavioral and 
psychological symptoms throughout the course of the disease, 
including agitation, delusions and aberrant motor behavior.1 These 
neuropsychiatric symptoms (NPS) result in a reduction in quality 
of life and cognitive functioning, are distressing to caregivers and 
lead to early institutionalization of patients.2-5 Agitation, on which a 
recent consensus definition has been developed,6 is one of the most 
prevalent dementia-related NPS.7 Agitated behavior and aggression 
are commonly treated with antipsychotic agents. In Dutch nursing 
homes, these are the most frequently prescribed psychotropic drugs 
in dementia patients.8 Unfortunately, benefits of their use are mostly 
limited,9 while adverse effects are harmful, including stroke and 
increased mortality risk.10 Other frequently used psychotropic drugs, 
such as antidepressants, anti-epileptic drugs and benzodiazepines, 
also have limited effects and serious side effects in frail dementia 
patients.11 Citalopram, for example, is often used in clinical dementia 
practice to reduce agitation. High doses have indeed been shown 
effective, yet, the practical application is limited by significant cardiac 
adverse effects, resulting in a clinically significant prolongation of 
the QTc interval, compared to placebo [difference QTc adjusted for 
baseline value: 18.1 ms (6.1 to 30.1), p=0.01].12 This highlights the 
need for alternative pharmacological interventions with an improved 
benefit-to-risk ratio. 
Medical cannabinoids might be such an alternative. Indeed, 
preliminary studies with oral tetrahydrocannabinol (THC) indicated 
improvement in agitated behavior and nocturnal motor activity 
in patients with Alzheimer’s disease.13, 14 Nonetheless, THC may 
also cause relevant side-effects, such as dizziness and sedation,15 
although data on safety in older patients are lacking.16 Therefore, 
in this randomized controlled trial, we aimed to study the efficacy 
and safety of relatively low doses oral THC on NPS, with a focus on 
agitation and aggression, in patients with dementia.
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Methods
Study design
This was a multicenter, phase II, repeated crossover, randomized, 
double-blind, placebo-controlled trial, conducted in accordance with 
the Declaration of Helsinki, Good Clinical Practice, and International 
conference on Harmonisation guidelines and registered at www.
clinicaltrials.org (NCT01302340). The study took place at the 
Alzheimer Centre of the Radboud university medical center 
(Radboudumc, Nijmegen, The Netherlands) and the Vincent van 
Gogh Institute (Venray, The Netherlands), between September 
2011 and December 2013. It was approved by the certified ethics 
committee of Radboudumc. Written informed consent was provided 
before screening by the patient and closest proxy; the first only 
in case the patient was judged capable to consent. Patients were 
assessed at baseline, approximately two weeks before start of study 
medication. Actual study duration was 12 weeks, including two 
treatment periods of three blocks each (Figure 1). In treatment 
period A (block 1–3), low dose THC treatment of 0.75 mg twice daily 
was alternated by placebo. The dosage was increased to 1.5 mg 
THC twice daily in period B (block 4–6). Each block contained two 
drug periods: THC for three consecutive days, followed by placebo 
(or vice versa) and separated by a four-day-washout period. As the 
pharmacodynamic effects of oral THC occurred within 1–2 hours 
after administration in a previous phase I study,17 a study period 
of three days was expected to be sufficient to evaluate the acute 
effects of THC on behavior. The duration of the washout period of 
four days was determined based on the terminal half lives of THC 
(mean 71.9 min) and its active metabolite 11-OH-THC (mean 196 
min) after oral administration of 5 mg THC in the same study.17 
The current crossover study was followed by an optional open 
label extension phase of six months to assess long-term tolerability 
and safety, of which the methods and results are reported in the 
Appendix and Appendix Table 1.
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Changes to study design
Initially, patients were admitted to the hospital during the three 
intervention days of block 1 and 4, for safety evaluation. The burden 
of these admissions was however the main reason that patients 
declined participation. After inclusion of the first 10 patients 
(‘hospital admission group’), the intervention was judged to be safe 
by the researchers. Therefore, the study protocol was amended, 
omitting the hospital admissions, which was approved by the ethical 
committee. In the revised protocol (‘ambulatory group’), admissions 
were replaced by a five-hour day clinic visit (day 1), follow-up phone 
call (day 2) and home visit (day 3), while safety could still be closely 
monitored.
Patient eligibility
Patients diagnosed with dementia type Alzheimer, vascular or 
mixed, according to the NINCDS–ADRA,18 or NINCDS-AIREN,19 
criteria were eligible for participation if they suffered from clinically 
relevant neuropsychiatric symptoms [Neuropsychiatric Inventory 
(NPI) score ≥ 10], with at least agitation or aggression. An informal 
caregiver had to be available. Initially, patients with mild to moderate 
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Figure 1   Schematic overview of study design
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dementia were included [Clinical Dementia Rating Scale (CDR) 0.5–
2]. After inclusion of 10 patients, this criterion was broadened to 
also include patients with severe cognitive disorders (CDR 2–3). 
Exclusion criteria were: major psychiatric disorder, severe or instable 
concomitant illness necessitating treatment changes, frequent 
falling due to orthostatic hypotension, and a history of alcohol or 
drug abuse. Patients using tricyclic antidepressants and opioids were 
excluded. Additionally, as THC is metabolized in the liver through 
the cytochrome P–450 enzymes (CYP): CYP2C9, CYP2C19 and 
CYP3A4, patients using drugs from a predesigned list of inhibitors 
of these enzymes were excluded. Use of concomitant psychotropic 
medication was allowed. 
Intervention and randomization
Active treatment consisted of 0.75 mg and 1.5 mg THC in 
tablet form (Namisol®, Echo Pharmaceuticals B.V., Weesp, the 
Netherlands). These dosages were chosen relatively low, based on 
the positive results of previous preliminary trials using dronabinol,13,14 
in combination with the lack of experience concerning Namisol® in 
a frail patient group, complying to the generally guiding principle 
in  pharmacological interventions in older patients, namely  ‘to 
start low, and go slow’. Placebo tablets were matched to the active 
treatment for weight, taste, color and size. Patients’ caregivers were 
asked to administer the tablets daily (with the exception of hospital 
admissions). Study medication was administered at 10 a.m. and 4 
p.m., because NPS often occur later on the day, when fatigue and 
external signals increasingly interfere. The order of administration 
of THC and placebo was randomized (1:1) per block. Randomization 
was performed by the Radboudumc pharmacy according to a 
computer-generated randomization list. The allocation sequence was 
strictly concealed from participants, caregivers, investigators and all 
other personnel directly involved in the study. Treatment allocations 
were not made available until study completion and database lock.
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Outcomes
Primary outcome measure
The primary outcome was change in NPS, as measured by NPI.20 
This questionnaire is frequently used to assess neuropsychiatric 
psychopathology in interventional studies in dementia and sensitive 
to detect clinical improvement in agitated behavior.21 It evaluates 
12 behavioral domains of which the frequency and severity of NPS 
are scored by a caregiver. This results in a final score ranging from 
0 to 144 (a higher score indicating greater impairment). The 4–
point frequency scale was slightly modified to make it suitable for 
weekly assessment. NPI was assessed at baseline and every third 
treatment day, resulting in two NPI scores per block. 
Secondary outcome measures
Weekly secondary efficacy assessments included Cohen-Mansfield 
Agitation Inventory (CMAI), a 29-item observation instrument for 
assessment of agitated behavior22 and Zarit Burden Interview (ZBI), 
a 22-item questionnaire to assess caregiver burden.23 
Safety assessments
Adverse events
Adverse events (AEs) were solicited from patients and their 
caregivers at all study visits, using open questions and clinical 
observations. All reports of AEs were recorded, whether or not they 
were deemed to be related to study treatment. AEs were coded 
following the classification of Medical Dictionary for Regulatory 
Activities (MedRA). An AE was defined as serious adverse event 
(SAE) if it was fatal or life-threatening, required (prolonged) 
hospitalization, or resulted in persistent or significant disability or 
incapacity. 
Mobility assessments
Influence of study medication on balance and gait was assessed 
using two functional mobility tests for frail older adults: Tinetti 
Performance–Oriented Mobility Assessment (Tinetti POMA)24 and 
Timed Up and Go (TUG).25 More extensive quantitative gait and 
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balance analyses were performed using GAITRiteTM and SwayStarTM.26, 
27 Only patients who were able to walk ten meters and understood 
simple instructions were included in these assessments. 
Other safety assessments
The occurrence and severity of ‘feeling high’ and effects on 
internal and external perception were quantified by using the Bowdle 
Visual Analogue Scale (VAS) rating of 13 symptom scales28 during 
all visits. Other assessments of safety included vital signs, physical 
examination and weight, laboratory tests, electrocardiography and 
Delirium Observation Scale.29 See Appendix Table 2 for a detailed 
overview of all assessments. 
Monitoring
Source document review and verification was performed on a 
regular basis by Clinical Research Centre Nijmegen. Monitoring of 
safety was performed by an independent Data Safety Monitoring 
Board (DSMB), which met regularly during trial conduction to review 
unblinded data. The DSMB recommended continuation of the trial 
without any protocol changes after every review.  
Statistical analysis
The study sample size was estimated based on two-sided testing 
at 0.025 per treatment period, a standard deviation of NPI score 
of eight points at baseline,30 a clinically relevant difference of four 
points31, 32 and a test-retest correlation of 0.65. Sixteen patients 
with complete data would be sufficient to provide a power of 80%, 
due to multiple crossover. As we expected a rather high attrition 
rate (25%) among the vulnerable patients in this study, we aimed 
to enroll at least 20 subjects.
Analyses were based on the intention-to-treat principle, which 
means that data were analyzed according to initial treatment 
assignment, independent of received treatment, compliance or 
attrition. Data of all subjects was used in the analysis without 
imputation. Analyses were performed according to a pre-specified 
statistical analysis plan, which was finalized before unmasking of 
treatment assignment. Differences between THC and placebo on 
399
Chapter 3  |   Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized 
controlled trial
Part III  |   Efficacy of tetrahydrocannabinol in the treatment of neuropsychiatric symptoms 
of dementia
NPI scores were analyzed using Linear Mixed Model with participants 
as random factor and block (six levels) and treatment (three levels: 
placebo, ‘low dose’ THC, ‘high dose’ THC) as fixed factors. 95% 
Confidence intervals (CI) were calculated. Analyses were repeated 
for two dosage regimens versus placebo separately (with 97.5% CI) 
and for hospital-admission group and ambulatory group separately. 
Other efficacy outcome measures were analyzed similarly to the 
primary analysis. Due to a significant effect of type of assessor on 
CMAI scores (mean differencecaregivers vs. research staff +16.5 points, linear 
mixed model analysis with random intercept per subject, type 3 
test of Fixed Effects, num df=1, den df=302, F=188.47, p<0.0001) 
analysis of CMAI scores was repeated with additional correction for 
assessor. The number of AEs was tabulated by system organ class. 
AEs were assigned to THC or placebo when the event started during 
treatment or during the subsequent washout period. Differences in 
AE rates between THC and placebo treatment were compared by 
non-linear mixed model analysis, assuming Poisson distribution of 
AEs. Frequency of SAEs was analyzed using descriptive statistics. 
The correlation between time after THC intake (0–240 min) and 
vital signs was analyzed in a linear mixed model with ‘subject’ as 
random factor and heart rate (HR), systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) as variables. For body sway 
during standing tasks, ranges of angular velocities and angles 
in anteriorposterior direction were calculated. Gait velocity and 
stride length variability were selected as outcome measures for 
quantitative gait analysis. Variability was expressed in coefficients 
of variation (CV) as standard deviation/mean x 100%. Effects of 
1.5 mg THC twice daily versus placebo on body sway and gait were 
analyzed using a dependent t-test or Wilcoxon signed rank test, as 
appropriate. VAS Bowdle scores could not be obtained from persons 
with severe cognitive disorders and were therefore only assessed in 
a part of the study population. Analysis of questionnaires was done 
as reported elsewhere,33 using three clusters: ‘feeling high’, ‘internal 
perception’ and ‘external perception’. Pharmacokinetic data were 
also collected during the crossover study; these will be described 
and published separately. 
100
Chapter 3  |   Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized 
controlled trial
Part III  |   Efficacy of tetrahydrocannabinol in the treatment of neuropsychiatric symptoms 
of dementia
Results
Study participants
In total, 23 patients were assessed for eligibility of whom 
22 fulfilled the entry requirements, who were randomized and 
received study medication (Figure 2). Demographic and baseline 
characteristics are summarized in Table 1 and an overview of co-
morbidities is provided in Appendix Table 3. Baseline NPI scores 
were significantly higher in the ambulatory group compared to 
the hospital admission group (t=-2.56, df=20, p=0.019). Twenty 
patients (91%) completed the 12-week crossover study and two 
patients dropped out because of non-related adverse events. 
Efficacy
Primary outcome
Study results are presented in Table 2. There was no effect of THC 
treatment compared to placebo on NPI. No differences were found 
between low dose THC and placebo and between high dose THC and 
placebo. Analysis per group did also not show significant differences 
between the interventions. A substantial increase in NPI scores over 
the 12-week study duration was found (mean increase per week 0.07 points, 
trend analysis with random intercept per subject, test of Fixed Effects, Num 
df=1, Den df=234, F=12.92, p=0.0004). This increase was observed in both 
THC and placebo treatment periods. Furthermore, for the hospital admission 
group, NPI scores during hospital admissions were significantly lower than 
scores assessed during home visits. In a post hoc analysis, we explored our 
data for clinically relevant effects, defined as a reduction of four points or 
more. Overall, THC versus placebo, induced a clinically relevant decrease in 
NPI scores in 38.9% of treatment blocks (period A, 33.3%; period B, 44.3%; 
χ2=3.19, df=1, p=0.074, ORB versus A 1.58, 95% CI 0.96 to 2.61). An increase in 
NPI scores, indicating a clinically relevant worsening of NPS, was found in 
31.5% (period A, 36.4%; period B, 26.2%; χ2=2.88, df=1, p=0.090, ORB versus A 
0.62, 95% CI 0.36 to 1.08).
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Abbreviations: T = THC; P = Placebo. Period A: 0.75 mg THC twice daily vs. placebo twice 
daily for three consecutive days, separated by a four-day washout period. Period B: 1.5 mg THC 
twice daily vs. placebo twice daily for three consecutive days, separated by a four-day washout 
period. a One patient discontinued in the first block of this period. b One patient discontinued in the 
third block of this period.
Figure 2     CONSORT flow diagram
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Secondary outcomes
No significant differences were found between THC and placebo 
on agitated behavior and caregiver burden, as measured with 
NPI subscale agitation/aggression, CMAI and ZBI (Table 2). 
Furthermore, no differences were found for low dose THC or high 
dose THC versus placebo on these variables. Overall, a substantial 
increase of CMAI and ZBI scores was observed over the 12-week 
study period.
Safety
Adverse events
In total, 184 AEs of mild to moderate severity occurred during the 
crossover study period, similarly distributed over the THC (91 AEs) 
and placebo (93 AEs) conditions (Non Linear Mixed Model Analysis 
assuming Poisson distribution of AEs, random intercept per subject, 
t=-0.29, df=21, p=0.77, incidence rate ratio 0.96, 95% CI 0.7 to 1.3) 
(Table 3). There was no increase in occurrence after administration 
of high dose THC. Four SAEs occurred in three patients, all requiring 
(prolongation of) hospitalization: a gastroenteritis, increase in 
dementia-related NPS symptoms, an exacerbation of a previously 
known vestibular disorder, and symptoms of a malignancy of 
unknown origin. None of these SAEs were judged to be related to 
study medication. Two patients dropped out due to the occurrence 
of symptoms of a malignancy (n=1) and due to extensive use of 
psychotropic rescue medication (n=1).
Treatment compliance and concurrent medication use
Overall treatment compliance to study medication was high; 
98.5% of tablets were administered (THC, 99.5%; placebo, 97.8%). 
Psychotropic rescue medication (mostly benzodiazepines) was 
provided similarly over all conditions: in period A eight times (four 
patients) during THC and 13 times (four patients) during placebo, 
and in period B ten times (four patients) during THC and seven 
times (three patients) during placebo.
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Table 3   Adverse events during crossover study
MedDRA system organ class THC 
Period A
No.
THC 
Period B
No.
Placebo 
Period A
No.
Placebo 
Period B
No.
Severe adverse events (≥grade 3) 0 0 0 0
Mild to moderate adverse events 46 45 48 45
    Administration site 3 0 2 2
    Blood and lymphatic system disorders 0 0 0 1
    Cardiac disorders 1 4 5 1
    Ear and labyrinth disorders 3 1 1 3
    Gastrointestinal disorder 4 3 4 0
    General disorders 6 5 3 6
    Injury and procedural complications 3 1 2 2
    Investigations 0 0 0 2
    Metabolism and nutritional disorders 0 1 2 1
    Musculoskeletal disorder 3 3 0 2
    Nervous system disorders 9 6 13 6
    Psychiatric disorders 9 13 10 15
    Renal and urinary tract infections 1 1 1 1
    Respiratory disorders 2 6 0 1
    Skin and subcutaneous tissue disorders 0 0 2 1
    Vascular disorders 2 1 3 1
Numbers are numbers of events. MedDRA, Medical Dictionary for Regulatory Activities; THC, 
tetrahydrocannabinol. Period A: 0.75mg THC twice daily; period B: 1.5mg THC twice daily.
Other safety outcomes
High dose THC increased SBD by 2.6 mmHg compared to placebo 
within four hours after first tablet intake, while no effects were found 
on HR and DBP. Overall, THC did not have an effect on mobility 
assessed with Tinetti and TUG (Table 4). High dose THC did not affect 
balance when patients were standing on two legs with their eyes 
open. In the eyes closed condition, body sway increased significantly 
after administration of THC, compared to placebo (Cohen’s d for pitch 
velocity, 0.59). No effects were found on velocity or stride length 
variability during walking on preferred speed. Average body weight 
at the end of the study did not differ from screening (dependent 
t-test 0.05, 95% CI -1.1 to 1.0). Feeling high was not reported nor 
observed in any patient. Analyses of questionnaires showed low VAS 
scores (median for feeling high, 0.30; external perception, 0.30; 
internal perception 0.24). THC did not have an effect on VAS scores, 
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with the exclusion of low dose THC on internal perception (mean 
differenceTHC vs placebo 0.025, 95% CI 0.01 to 0.04, Linear Mixed Model 
Analysis, random intercept per subject, type 3 test of Fixed Effects: 
Num df=1, Den df=274, F=10.45, p=0.0014), which was judged 
not to be a clinically relevant increase.
Conclusions
In the present study, we found no benefit of THC treatment (0.75 
mg and 1.5 mg twice daily) on NPS in dementia on either of the 
outcome measures. Although THC failed to improve NPS, intermittent 
treatment demonstrated safety in older dementia patients. Previous 
studies all showed positive effects of THC (2.5 to 7.0 mg daily) 
on behavioral and nighttime disturbances.13, 14, 34, 35 However, two 
of these studies were RCTs with a small number of patients (n=2; 
n=15),14, 34 one study had a retrospective design35 and one was an 
uncontrolled open label study.13 These factors all introduce bias, 
possibly leading to an overestimation of the treatment effect. 
To date, data on safety of medical cannabinoids in older patients 
are scarce,16 while more comprehensive data result from research 
in younger adult patients.15 These latter studies report more 
AEs following THC treatment, compared to placebo (IRR 2.18), 
especially within the first two treatment weeks (IRR 2.91).15 Most 
commonly reported AEs are related to the central nervous system, 
such as dizziness and somnolence. As the patient characteristics 
and route of administration in these studies are diverse and the 
administered dosages significantly higher (5 to 45 mg THC daily), 
no direct comparison can be made with the results provided in 
the current study. Concerning dementia patients, previous studies 
report no adverse events after administration of 2.5 mg THC daily.13, 
34 Nevertheless, administration of higher dosages (5 to 7 mg daily) 
resulted in the occurrence of AEs, such as sedation, euphoria and 
delirium.14, 35
The current study is the first to assess safety by using reports of 
adverse events, as well as vital signs and mobility assessments. The 
lack of relevant side effects suggests that the current dosages are
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well tolerated when administered for a short duration. This suggests 
that it might be worthwhile to conduct higher dosing studies, 
provided that the dose is gradually increased. 
To our knowledge, this is one of the largest randomized controlled 
trial studying the efficacy of THC in dementia patients by using a 
scientifically sound design. Due to the expected acute psycho-active 
effects of THC, we chose a repeated measurements design with 
short intervention periods. This design made it possible to conduct a 
methodologically valid trial, warranting the need of a relatively small 
number of subjects, and is therefore suitable for research in frail, 
dementia patients. The attrition rate in the crossover study was low 
(9%), and treatment compliance high (98.5%). Most participating 
caregivers experienced dementia-related NPS as a serious problem, 
leading to a high internal motivation to complete study participation. 
This study also had limitations. Despite the fact that we have 
included the number of patients needed based on the power analysis 
prior to study conduction, there are several factors that might have 
reduced our ability to detect a treatment effect. First, the administered 
dosages were fixed. We chose our dosages relatively low to minimize 
safety risks for these frail participants, based on the dosages used in 
previous studies in dementia patients,13, 14 and the safety results of 
the phase I study on healthy young volunteers,17 expecting dementia 
patients to be more vulnerable to the psycho-active adverse effects 
of THC. In retrospect, the dosages administered could have been 
higher. Second, the intervention period was relatively short, based 
on the expected acute pharmacodynamic effects of oral THC.17 The 
introduction of longer treatment periods might increase the ability 
to detect an effect, as NPS can vary. Third, the hospital admissions 
led to significantly lower NPI scores compared to scores assessed 
during home stays. This may be caused by the daily structure 
that was offered by the nursing staff and minimal presence of the 
informal caregiver. Fourth, we found a larger standard deviation in 
NPI scores than expected, based on previous studies resulting in 
a lower power.30 Fifth, although the NPI total score at baseline is 
comparable to other intervention studies on dementia-related NPS, 
the severity of agitation is lower, represented by lower baseline NPI 
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agitation/aggression and CMAI scores.12, 36 Sixth, we observed an 
increase in NPI, CMAI and ZBI scores over time. These outcome 
measures were assessed by an informal caregiver, closely involved 
in the care for the participant. Therefore, a high burden of study 
participation or a failure to observe an expected treatment effect, 
are possible explanations for this increase. Last, we did not include 
nursing home patients. This was hampered by legislation on drug 
delivery, despite the fact that these patients probably are the main 
target group for psychoactive interventions in NPS. This study, 
however, is an informative step in the development of new drug 
therapies, specifically targeting this complex patient group.
To conclude, oral THC up to 1.5 mg twice daily did not reduce 
behavioral disturbances in patients with dementia. Yet, assessments 
of safety by using reports of adverse events, vital signs and mobility 
showed that the intervention was well tolerated by this patient 
group. As we studied a relatively low dose, these results suggest 
that it might be worthwhile to conduct future higher dose studies in 
the treatment of dementia-related behavioral disturbances.
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SUPPLEMENTARY MATERIAL
Appendix
Open label extension phase
Methods
At the end of the 12-week study period, patients were asked to 
participate in an optional, open label extension study when study 
treatment was well tolerated and intuitively judged to be profitable 
based on blinded NPI scores. In this extension study, subjects visited 
the research center at 4 weeks, 3 months and 6 months for assessment 
of NPI, CMAI, ZBI, mobility, Mini Mental State Examination (MMSE) 
and safety parameters. All patients who participated in the optional 
open label extension phase were included in the safety analysis, 
as assessment of long term tolerability and safety was the primary 
objective of this study phase. Additionally, patients with three 
completed NPI scores during this extension phase were included in 
the analysis of long term efficacy. Mean differences of the three time 
points were compared using repeated measures ANOVA.
Results
Twelve out of 22 patients (54.5%) entered the open label 
extension study on the patients’ or caregivers’ request, of whom five 
(41.7%) completed this six month treatment period. Reasons for 
premature discontinuation were: lack of efficacy (n=2), lack of study 
drug compliance (n=1), illness of the primary caregiver (n=1), and 
admission to a nursing home (n=3). These latter patients dropped 
out, as the nursing homes were not in the possession of a permit 
for handling THC for research purposes, which is mandatory in the 
Netherlands. Median treatment duration was 140 days (range 15 
to 188 days). Two patients received a daily dose THC of 1.5mg, 
nine patients received 3mg and one patient 4.5 mg THC. In total, 
16 adverse events of mild to moderate severity occurred. The 
most common AEs were ‘agitation’ (n=2), ‘anaemia’ (n=2) and 
‘urinary tract infection’ (n=2). One severe adverse event occurred: 
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a hospitalization in a specialized dementia care unit for further 
observation of cognition and behavior. Adverse events did not lead 
to study discontinuation in any of the patients. THC did not affect 
cognition, mobility or weight. Furthermore, no differences were 
found on the different time points on NPI, CMAI and ZBI (Appendix 
Table 2).
Conclusion
This preliminary open label study phase showed that long term 
treatment with low dose THC was well tolerated by patients with 
dementia and did not affect behavioral disturbances or caregiver 
burden. These results must be interpreted with caution, as the 
attrition rate in this phase was high (58.3%).
Appendix Table 1     Results of the open label extension phase
Week 4
(n=6)
Week 12
(n=6)
Week 24
(n=6)
P-value
Safety assessments
MMSE 18.2 (15.4)a 18.6 (3.6)a 18.4 (6.8)a 0.96
TUG (s) 13.2 (2.7) 15.2 (5.4)b 13.6 (4.0)a 0.38
Tinetti POMA 25.3 (1.9) 24.4 (4.3)a 25.6 (3.2)a 0.44
Weight (kg) 79.0 (10.6) 78.2 (10.9) 76.8 (9.4) 0.14
Efficacy assessments
NPI total 25.3 (11.9) 28.2 (11.1) 23.3 (12.9) 0.70
NPI agitation scale 3.0 (3.3) 3.3 (2.6) 2.2 (3.0) 0.72
CMAI 53.8 (16.1) 53.3 (15.3) 56.6 (22.7)a 0.83
ZBI 38.0 (20.5) 42.5 (17.1) 32.4 (15.1)a 0.51
Values are means (SD) from all patients with three NPI assessments. 
Abbreviations: MMSE, Mini Mental State Examination; TUG, Timed Up and 
Go; Tinetti POMA, Tinetti Performance-Oriented Mobility Assessment; NPI, 
Neuropsychiatric Inventory; CMAI, Cohen-Mansfield Agitation Inventory; ZBI, 
Zarit Burden Interview. a Results based on five patients. b Results based on four 
patients.
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Appendix
Table 3   Relevant medical history and co-morbidity
Number of patients (%) with relevant co-
morbidity or medical history
All 
(n=22)
Hospital 
admission 
group
(n = 10)
Ambulatory
group
(n=12)
Cardiovascular disorders
      Hypertension
      Hypercholesterolemia
      Rhythm disorder
      Vascular disorder
      Ventricular hypertrophia
      Heart failure
      Cardiac ischemia
      Vascular disorder
      Other
17 (77.3)
8 (36.4)
4 (18.2)
6 (27.3)
5 (22.7)
4 (18.2)
1 (4.5)
2 (9.1)
5 (22.7)
1 (4.5)
9 (90.0)
4 (40.0)
0 (0.0)
3 (30.0)
2 (20.0)
3 (30.0)
0 (0.0)
1 (10.0)
2 (20.0)
3 (30.0)
8 (66.7)
4 (33.3)
4 (33.3)
3 (25.0)
3 (25.0)
1 (8.3)
1 (8.3)
1 (8.3)
3 (25.0)
1 (8.3)
Genito-urinary disorders
      Kidney failure
      Urinary difficulty
      Infection
      Surgery
      Other
14 (63.6)
6 (27.3)
3 (13.6)
4 (18.2)
3 (13.6)
6 (27.3)
6 (60.0)
3 (30.0)
1 (10.0)
1 (10.0)
1 (10.0)
3 (30.0)
8 (66.7)
3 (25.0)
2 (16.7)
3 (25.0)
2 (16.7)
3 (25.0)
Gastrointestinal disorders
      Constipation
      Surgery
      Infection
      Other
10 (45.5)
2 (9.1)
5 (22.7)
3 (13.6)
3 (13.6)
3 (30.0)
0 (0.0)
1 (10.0)
2 (20.0)
1 (10.0)
7 (58.3)
2 (16.7)
4 (33.3)
1 (8.3)
2 (16.7)
Musculoskeletal disorders
      Fracture or lesion
      Other
8 (36.4)
6 (27.3)
4 (18.2)
5 (50.0)
5 (50.0)
1 (10.0)
3 (25.0)
1 (8.3)
3 (25.0)
Neurological disorders
      Cerebrovascular disease
      Mobility disorder
      Other
8 (36.4)
4 (18.2)
2 (9.1)
4 (18.2)
4 (40.0)
1 (10.0)
0 (0.0)
3 (30.0)
4 (33.3)
3 (25.0)
2 (16.7)
1 (8.3)
Endocrine disorders
      Diabetes mellitus
      Other
7 (31.8)
6 (27.3)
1 (4.5)
3 (30.0)
2 (20.0)
1 (10.0)
4 (33.3)
4 (33.3)
0 (0.0)
Ear disorders
      Loss of hearing
      Other
6 (27.3)
5 (22.7)
1 (4.5)
3 (30.0)
2 (20.0)
1 (10.0)
3 (25.0)
3 (25.0)
0 (0.0)
Respiratory disorders
      Pneumonia
      Chronic obstructive pulmonary disease
      Other
5 (22.7)
1 (4.5)
1 (4.5)
3 (13.6)
2 (20.0)
1 (10.0)
0 (0.0)
1 (10.0)
3 (25.0)
0 (0.0)
1 (8.3)
2 (16.7)
Psychiatric disorders
      Depression
      Delirium
5 (22.7)
3 (13.6)
2 (9.1)
3 (30.0)
1 (10.0)
1 (10.0)
2 (16.7)
2 (16.7)
1 (8.3)
Dermatological disorders
      Skin malignancy
      Other
4 (18.2)
4 (18.2)
2 (9.1)
1 (10.0)
1 (10.0)
1 (10.0)
3 (25.0)
3 (25.0)
1 (8.3)
Eye disorders 4 (18.2) 1 (10.0) 3 (25.0)
Malignancies 2 (9.1) 0 (0.0) 2 (16.7)
Values are numbers of patients and percentages. The disorders are categorized by Medical 
Dictionary for Regulatory Activities
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Abstract
Objective: To study the efficacy and safety of low-dose oral 
tetrahydrocannabinol (THC) in the treatment of dementia-related 
neuropsychiatric symptoms (NPS).
Methods: This is a randomized, double-blind, placebo-controlled 
study. Patients with dementia and clinically relevant NPS were 
randomly assigned to receive THC 1.5 mg or matched placebo 
(1:1) 3 times daily for 3 weeks. Primary outcome was change in 
Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 
and 21 days. Analyses were based on intention-to-treat.
Results: Twenty-four patients received THC and 26 received 
placebo. NPS were reduced during both treatment conditions. The 
difference in reduction from baseline between THC and placebo was 
not significant [mean difference NPItotal: 3.2, 95% confidence interval 
(CI) -3.6 to 10.0], nor were changes in scores for agitation (Cohen-
Mansfield Agitation Inventory 4.6, 95% CI -3.0 to 12.2), quality of 
life (Quality of Life–Alzheimer’s Disease -0.5, 95% CI -2.6 to 1.6), 
or activities of daily living (Barthel Index 0.6, 95% CI -0.8 to 1.9). 
The number of patients experiencing mild or moderate adverse 
events was similar (THC, n=16; placebo, n=14, p=0.36). No effects 
on vital signs, weight, or episodic memory were observed.
Conclusions: Oral THC of 4.5 mg daily showed no benefit in NPS, 
but was well-tolerated, which adds valuable knowledge to the scarce 
evidence on THC in dementia. The benign adverse event profile of 
this dosage allows study of whether higher doses are efficacious and 
equally well- tolerated.
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Introduction
Most patients with dementia will experience neuropsychiatric 
symptoms (NPS) over the course of their disease.
1 While non-
pharmacologic interventions are preferred, data on their efficacy 
remains limited and the interventions are not easily applicable 
in clinical practice.
2 Pharmacologic treatment is challenging, 
as currently available medications have important drawbacks 
concerning the benefit-to-risk ratio.
3–6 This implicates a serious 
health care problem, as 62% of community-dwelling patients and 
up to 80% of nursing home residents have clinically relevant 
symptoms.
7,8 Structured analgesic treatment has recently been 
demonstrated to be beneficial for dementia-related NPS and in 
particular agitation.
9 D-9-Tetrahydrocannabinol (THC), the main 
constituent of cannabis, has both psychoactive and analgesic 
properties,
10,11 and might therefore serve as an alternative 
pharmacologic treatment. Indeed, some preliminary studies 
suggested improvement in agitation and nocturnal motor activity 
in patients with Alzheimer disease (AD).
12,13 
The effect of THC on the endocannabinoid system is mediated 
by 2 cannabinoid receptors: CB1 receptors are expressed in 
several brain regions, especially the basal ganglia, cerebellum, 
hippocampus, amygdala, and hypothalamus; CB2 receptors 
are primarily found in cells and organs of the immune system. 
Therefore, THC probably has a wide range of CB1-mediated 
receptor interactions with the endocannabinoid system affecting 
emotion, cognition, and behavior. Moreover, psychotropic effects 
are also exerted through interaction with other receptors and 
neurotransmitters, such as acetylcholine, dopamine, serotonin, 
g-aminobutyric acid, glutamate, norepinephrine, prostaglandins, 
and opioid peptides.
14 Interestingly, several animal studies also 
suggest a neuroprotective effect of cannabinoids in the disease 
pathology of AD itself, which is primarily based on a reduction in 
the inflammatory response by microglia cells and the increase 
of amyloid-b clearance.
15,16 Nonetheless, firm evidence of the 
efficacy and safety of THC or other cannabinoids in this vulnerable 
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patient group is lacking and data on older patients in general are 
scarce.
17 
The current article reports the largest study carried out so far 
on evaluating the efficacy and safety of oral THC for behavioral 
disturbances in patients with dementia.
METHODS
Standard protocol approvals, registrations, and 
patient consents
This study was conducted in accordance with the ethical 
principles of the Declaration of Helsinki and Good Clinical Practice, 
approved by a certified ethics committee of the Radboud university 
medical center (Radboudumc) and registered at www.clinicaltrials.
org (NCT01608217). Assessments were done by researchers from 
the Department of Geriatric Medicine of Radboudumc (Nijmegen, 
the Netherlands) and the Department of Elderly of Vincent van 
Gogh Institute (psychiatric hospital, Venray, the Netherlands) from 
November 2012 to June 2014. Participants were recruited from 9 
participating institutes throughout the southeast of the Netherlands, 
including geriatric outpatient clinics (n=2 clinics), psychiatric clinics 
(n=3), nursing homes (n=3, including in total 6 locations), and a 
regional network of integrated care for community-dwelling patients 
with dementia. Written informed consent was provided at screening 
by the patient and closest involved proxy, the first only in case the 
patient was judged capable of consent.
Study design
This was a randomized, double-blind, placebo controlled, 
multicenter, phase II trial. Potential participants were screened 
for eligibility within 4 weeks prior to start of study medication, 
by assessment of somatic and cognitive status and severity of 
behavioral disturbances. Assessments were done at the outpatient 
clinic, nursing home, or at home, depending on patient preference. 
Study intervention was initiated after baseline. Efficacy assessments 
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were scheduled after 14±2 treatment days (phone call) and 21±2 
treatment days (visit). For the purpose of safety assessment and 
compliance, several phone calls were performed by the researchers 
during the intervention period (days 2, 7, and 14). Follow-up 
assessments by telephone were performed 2 weeks after study 
completion.
Participants
Patients diagnosed with AD or vascular or mixed dementia accor-
ding to National Institute of Neurological and Communicative Disorders 
and Stroke–Alzheimer’s Disease and Related Disorders Association18 
or National Institute of Neuro- logical Disorders and Stroke–
Association Internationale pour la Recherche en l’Enseignement en 
Neurosciences19 criteria were eligible for participation if they had 
clinically relevant NPS [minimal Neuropsychiatric Inventory (NPI) 
score ≥ 10], with symptoms reported on agitation, aggression, or 
aberrant motor behavior, existing at least 1 month prior to screening. 
A caregiver  had to be available who was in touch with the patient 
at least twice a week and supervised the patient’s care. 
Exclusion criteria were current major psychiatric disorders and 
any severe or instable concomitant illness, in particular seizures, 
arrhythmias necessitating treatment other than a β-blocker or digoxin, 
severe heart failure, or any concomitant disease necessitating 
treatment changes. Other exclusion criteria were frequent falling 
due to orthostatic hypotension, a history or current alcohol or 
drug abuse, and use of tricyclic antidepressants, fluoxetine, or 
carbamazepine. Use of concurrent psychotropic medication was 
allowed, provided that the dose and frequency were kept stable 
within 2 weeks before and during trial conduction. Analgesic drugs 
had to be stopped prior to baseline assessments, although use of 
analgesic and psychotropic escape medication was allowed.
Changes to study protocol
We initially recruited patients with behavioral disturbances 
as well as persistent pain complaints to secondarily assess the 
efficacy of THC on pain in patients with dementia. However, the 
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number of eligible patients with both symptoms was much lower 
than predicted from the literature.20 After inclusion of the first 8 
patients, the criterion of pain was omitted. In the amended study, 
pain assessments were still included, allowing secondary evaluation 
of the efficacy of THC in reducing pain-related behavior and pain 
intensity in a subgroup of patients, of which the methods and 
results are described in Appendix 1 and Table 1.
Intervention and randomization
Active treatment consisted of 1.5 mg THC in tablet form (Namisol®, 
Echo Pharmaceuticals, Weesp, the Netherlands) 3 times daily for a 
period of 3 weeks. This daily dose was based on preliminary positive 
results of previous trials in patients with severe AD.12,13,21 Control 
treatment consisted of matched placebo tablets. Additionally, 
patients received 1,000 mg acetaminophen 3 times daily in case of 
pain complaints, or of suspected pain in non-communicative patients, 
based on physical examination at screening and information from 
the caregiver or physician. Study medication was administered at 
9 AM, 2 PM, and 8 PM by the primary caregiver or nursing home staff. 
Study medication was packed and distributed by the pharmacy of 
Radboudumc according to Good Manufacturing
Practice. Randomization (allocation ratio 1:1) was performed 
by an independent statistician using a computer-generated 
randomization program, of which the algorithm was stratified per 
center and minimized22 for NPI score, dementia severity, sex, and 
current opioid use. Treatment allocation was strictly concealed 
from participants, caregivers, investigators, and all other personnel 
directly involved in the study and was not made available until study 
completion and database lock.
Outcome measures
Primary outcome measure
The primary outcome was change in NPS, measured with NPI.23 
This questionnaire evaluates 12 behavioral domains, including 
agitation/ aggression and aberrant motor behavior, which were the 
behavioral domains of interest. The frequency and severity of NPS 
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were scored per domain by questioning a caregiver, which resulted 
in a total score ranging from 0 to 144 (a higher score indicating 
greater impairment). NPI was assessed at baseline, day 14 (by 
telephone interview), and day 21 by trained researchers. 
Secondary efficacy outcome measures
Secondary outcomes included assessment of agitated behavior 
and aggression [Cohen- Mansfield  Agitation  Inventory  (CMAI)24], 
activities  of  daily living (Barthel Index25), and quality of life 
[Quality of Life–Alzheimer’s Disease Scale (QoL-AD)26]. These 
were all assessed at baseline and day 21. Overall change was 
assessed by the primary caregiver, using the Caregiver Clinical 
Global Impression of Change (CCGIC), a 7-point scale ranging 
from marked improvement to marked worsening from baseline.
Safety assessments
Adverse events
Adverse events (AEs) were solicited from patients and their 
caregivers at all visits and phone calls up to 2 weeks after study 
drug discontinuation, using clinical observation, open questions, 
and a set of questions on possible THC-related adverse symptoms, 
including the most frequently reported AEs in the phase I study 
with healthy elderly.27 AEs were coded following the classification 
of Medical Dictionary for Regulatory Activities. An AE was defined 
as serious if it was fatal or life-threatening, required or prolonged 
hospitalization, or resulted in persistent or significant disability or 
incapacity.
Other safety assessments
Other safety assessments consisted of evaluation of blood 
pressure, heart rate, and weight, assessed at screening, baseline, 
and day 21, and ECG and biochemistry and hematology blood 
samples, assessed at screening and day 21. The Paired Associate 
Learning Wechsler Memory Scale–Revised (PAL WMS-R)28 was used 
for assessment of possible effects of THC on episodic memory 
function (baseline and day 21).
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Statistical analysis
The study sample size was estimated based on a clinically 
relevant difference of 4 points on NPI29,30 a SD of 12 points31,32 and an 
estimated correlation with baseline of 0.6 and interclass correlation 
coefficient of 0.6. Approximately 130 patients were required for a 
power of 80% (2-sided testing at 0.05). We were not able to enroll 
this number of subjects within the available time period, due to delay 
in getting formal approval for THC use at all sites from the Health Care 
Inspectorate. After trial ending, we performed an analysis to calculate 
the power to yield a statistically significant difference in favor of THC, 
in case we would have been able to extend the study to 130 subjects. 
This analysis is known as the calculation of conditional power. The 
analysis used 10,000 simulated extensions of the outcome data of 
the realized sample to the planned sample size, based on the real 
data that were acquired. Efficacy and safety analyses were based 
on the intention-to-treat principle and performed in accordance with 
a prespecified statistical analysis plan, finalized before unmasking 
of treatment assignment. The primary endpoint, mean difference 
[including 95% confidence interval (CI)] in NPI total score from 
baseline to 14 and 21 treatment days, was evaluated in a linear 
mixed model with participants as random factor and treatment, 
center, baseline NPI, Clinical Dementia Rating score, sex, current 
opioid use, and time as fixed factors. All assumptions for regression 
models were assessed by viewing plots of the residual values to 
check for linearity and homoscedasticity. Analysis was repeated for 
all NPI subdomain scores. In a post hoc analysis, we determined the 
efficacy for 2 subgroups: ambulatory patients and inpatients. Other 
secondary efficacy outcome measures, weight, and vital signs were 
assessed similarly to the primary analysis (without data on day 
14, as these were not collected). Pearson correlation coefficients 
were calculated for change from baseline of NPI and CCGIC scores 
on day 14 and day 21. Due to the limited number of participants 
included in the PAL WMS-R assessments group, these differences 
were compared using Mann-Whitney U test. For analysis of AEs, the 
number of patients with at least 1 unique episode was tabulated per 
treatment group and group difference on incidence (using χ2) and 
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severity of AEs (using Mann-Whitney U) was analyzed. Statistical 
analyses were done using SAS version 9.2 and SPSS version 20 for 
Windows.
Classification of evidence
This interventional study provides Class I evidence that 
oral THC of 4.5 mg daily is not effective in reducing behavioral 
disturbances in patients with dementia (ΔNPI
total
: 3.2, 95% CI 
3.6 to 10.0) and is well-tolerated [occurrence of AEs THC vs 
placebo: 16 (66.7%) vs 14 (523.8%) patients, χ2, p=0.36].
RESULTS
Study participants
In total, 54 patients were assessed for eligibility, of whom 50 
were randomized and received study medication (THC, n=24; 
Placebo, n=26) (Figure 1). Patient characteristics are presented 
in Table 1. Overall, 47 patients (94%) completed the study, while 
three patients discontinued participation due to the occurrence of 
AEs (n=2) and withdrawal of informed consent (n=1).
Treatment compliance and concurrent medication use
Median treatment compliance, based on remaining pill count, was 
98% (67%–100%) in the THC group and 100% (94%–100%) in 
the placebo group. Twenty-nine patients received acetaminophen 
(THC, n=13; placebo, n=16). Four patients (16.7%) in the THC 
group received escape medication, compared to 2 patients (7.7%, 
p=0.33) in the placebo group, which consisted of benzodiazepines 
(oxazepam 5 mg, lorazepam 1 mg) and acetaminophen (500 mg).
Efficacy
Study results are presented in Table 2. NPI total score 
decreased in both treatment conditions after  14  days  (THC, 
p=0.002;  placebo,  p=0.002) and 21 days (THC, p=0.003; 
placebo, p=0.001). There was no difference between THC and 
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Figure 1   CONSORT flowchart of recruitment and selection
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placebo over 21 treatment days (ΔNPI
total
: 3.2, 95% CI -3.6 to 
10.0). Additionally, no differences were observed on agitation 
(ΔNPI
agitation
: -0.1, 95% CI -2.0 to 1.9), aberrant motor behavior 
(ΔNPIaberrant motor behavior: 0.3, 95%  CI  -1.0  to 1.7), or other 
NPI subdomains (see table e-2), except for the domain “eating 
disorders” in favor of placebo (ΔNPI
eating disorders
: 1.0, 95% CI 0.0–
1.92). Analysis per subgroup showed no benefit of THC in 
community-dwelling patients (ΔNPI
total
: 5.0, 95% CI -1.8 to 
11.7) or in inpatients (ΔNPI
total
: 1.5, 95% CI -10.0 to 13.1). 
There were no significant differences between the intervention 
groups on CMAI, QoL-AD, and Barthel  Index.  CCGIC scores after 
3 weeks showed that 8 (36.4%) patients in the THC group had 
minimal to marked improvement from baseline, which was not 
significantly different from 12 patients (50.0%) in the placebo 
group (χ2, p=0.35). A strong correlation was observed between 
NPI and CCGIC scores (day 14: Pearson r=0.65, p<0.001; day 
21: Pearson r=0.73, p<0.01). The conditional power to still 
detect a difference in NPI score of at least 4 points in favor of 
THC treatment, in case we would have been able to extend the 
trial from the actual number of subjects (n=47, 23 on THC and 
24 on placebo) to the initially planned number of subjects (130, 
65 per treatment arm), was 5%.
Safety
Adverse events
The occurrence of AEs was similarly divided along treatment groups 
(Table 3). In the THC group, 16 patients (66.7%) experienced at 
least 1 AE, compared to 14 (53.8%) in the placebo group (χ2, 
p=0.36). Two patients dropped out due to the occurrence of AEs; 
one patient developed pneumonia within 2 days after initiation of 
THC treatment, and one patient experienced persistent nausea 
on placebo. One serious AE occurred during placebo treatment, 
which was not related to study medication. This patient was 
admitted to a specialized dementia care unit due to high caregiver 
burden.
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Table 1   Demographics and patient characteristics
All 
(n=50)
THC
(n=24)
Placebo
(n=26)
Men, n (%) 25 (50.0) 11 (45.8) 14 (53.8)
Age, yr, mean (SD) 78.4 (7.4) 79.0 (8.0) 78.0 (7.0)
Domestic situation, n (%)
Community dwelling
Specialized dementia care unit
Nursing home
24 (48.0)
13 (26.0)
13 (26.0)
13 (54.2)
4 (16.7)
7 (29.2)
11 (42.3)
9 (34.6)
6 (23.1)
BMI, kg/m2, mean (SD)a 25.0 (3.5) 25.0 (3.8) 25.0 (3.4)
Ethnicity, n (%)
Caucasian 50 (100.0) 24 (100.0) 26 (100.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Education, mean (SD)b 3.8 (1.6) 3.8 (1.6) 3.8 (1.6)
Type of dementia, n (%)
Alzheimer 34 (68.0) 16 (66.7) 18 (69.2)
Vascular 7 (14.0) 3 (12.5) 4 (15.4)
Mixed 9 (18.0) 5 (20.8) 4 (15.4)
CDR ratio, n (%)
1
2
3
11 (22.0)
19 (38.0)
20 (40.0)
5 (20.8)
9 (37.5)
10 (41.7)
6 (23.1)
10 (38.5)
10 (38.5)
MMSE score, mean (SD)c 14.8 (6.7) 15.9 (6.7) 14.0 (6.8)
Comorbidities, n (%)
Vascular disorders 21 (42.0) 12 (50.0) 9 (34.6)
Nervous system disorders 19 (38.0) 11 (45.8) 8 (30.8)
Gastrointestinal disorders 18 (36.0) 7 (29.2) 11 (42.3)
Musculoskeletal disorders 17 (34.0) 8 (33.3) 9 (34.6)
Renal and urinary disorders 15 (30.0) 7 (29.2) 8 (30.8)
Psychiatric disorders 14 (28.0) 7 (29.2) 7 (26.9)
Other 24 (48.0) 22 (91.7) 20 (76.9)
Concomitant psychotropic medication, n (%)d
Antipsychotics 10 (20.0) 7 (29.2) 3 (11.5)
Antidepressants 20 (40.0) 9 (37.5) 11 (42.3)
Benzodiazepines 21 (42.0) 8 (33.3) 13 (50.0)
Anticonvulsants 0 (0.0) 0 (0.0)  1 (3.8)
Cholinesterase inhibitors 8 (16.0) 5 (20.8) 3 (11.5)
Memantine 3 (6.0) 2 (8.3) 1 (3.8)
Melatonin 13 (26.0) 5 (20.8) 8 (30.8)
Concomitant analgesic medication, n (%)d
Acetaminophen 15 (30.0) 5 (20.8) 10 (38.5)
NSAIDs 2 (4.0) 1 (4.2) 1 (3.8)
Opioids 2 (4.0) 1 (4.2) 1 (3.8)
Subgroup of patients with pain, n (%)e 23 (46.0) 8 (33.3) 15 (57.7)
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Abbreviations: BMI, Body Mass Index; CDR, Clinical Dementia Rating; MMSE, Mini Mental 
State Examination; NPI, Neuropsychiatric Inventory; CMAI, Cohen-Mansfield Agitation 
Inventory; VRS, Verbal Rating Scale; PACSLAC-D, Pain Assessment Checklist for Seniors with 
Limited Ability to Communicate – Dutch version.
a 3 missings on THC, 4 missings on placebo.
b Education was determined with seven categories where 1 indicates less than six years of 
primary school and 7 indicates a university degree. 6 missings on THC, 8 missings on placebo.
c 11 missings on THC, 10 missings on placebo.
d Concomitant medication used at time of screening. All analgesic medication was stopped 
prior to baseline assessments. When indicated, patients received acetaminophen for the 
duration of the intervention period. 
e patients reporting pain, who are able to reliably assess pain intensity using VRS, or patients 
with a PACSLAC-D score of 4 points or more at baseline.
Other safety outcomes
There were no changes between the groups concerning heart 
rate, blood pressure, and weight (Table 2). Episodic memory 
scores were available for 18 patients with a mild dementia 
severity. PAL WMS-R scores decreased by 1.2 points in the 
THC group and 1.4 points in the placebo group, which was not 
significantly different (p=1.0).
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Table 2    Overview of study results of the application of THC on 
neuropsychiatric symptoms in dementia
No THC No Placebo Mean difference
THC vs placebo
(95% CI)
Primary outcomes
NPI total score
Baseline
Day 14
Day 21
24
19
23
37.4 (13.7)
31.0 (11.3)
27.8 (13.1)
26
23
24
35.6 (13.0)
26.1 (16.9)
23.9 (16.8) +3.2 (-3.6 to 10.0)
NPI agitation/aggression subscale
Baseline
Day 14
Day 21
24
19
23
5.7 (3.8)
4.1 (4.7)
4.5 (4.1)
26
23
24
6.2 (4.3)
5.0 (3.9)
4.4 (4.3) -0.1 (-2.0 to 1.9)
NPI aberrant motor behavior subscale
Baseline
Day 14
Day 21
24
19
23
4.5 (4.6)
4.9 (4.0)
3.6 (3.9)
26
23
24
5.2 (4.1)
4.3 (4.2)
3.7 (4.3) +0.3 (-1.0 to 1.7)
Secondary outcomes
CMAI
Baseline
Day 21
24
23
58.8 (18.5)
56.5 (17.5)
26
24
61.6 (16.4)
53.7 (18.3) +4.6 (-3.0 to 12.2)
Barthel Index
Baseline
Day 21
24
22
13.8 (5.1)
13.3 (5.0)
25
24
13.3 (5.3)
12.0 (5.5) +0.6 (-0.8 to 1.9)
QoL-AD
Baseline
Day 21
24
21
28.3 (4.9)
27.5 (4.6)
24
22
29.6 (5.2)
29.1 (5.0) -0.5 (-2.6 to 1.6)
CCGIC*
Day 14
Day 21
20
22
3.7 (1.0)
3.5 (1.3)
25
24
3.4 (1.2)
3.2 (1.4) +0.2 (-0.5 to 0.9)
Safety assessments
Heart rate, bpm
Baseline
Day 21
23
22
69.8 (11.4)
66.3 (8.6)
24
24
74.5 (12.5)
71.6 (8.0) -3.3 (-7.5 to 0.9)
Systolic Blood Pressure, mmHg
Baseline
Day 21
23
22
138.6 (21.2)
143.7 (16.8)
24
24
143.1 (15.9)
141.3 (20.9) +3.4 (-6.5 to 12.2)
Diastolic Blood Pressure, mmHg
Baseline
Day 21
23
22
77.5 (8.0)
76.9 (7.1)
24
24
82.0 (10.4)
78.2 (9.3) -1.8 (-6.6 to 3.1)
Weight, kg
Baseline
Day 21
22
20
71.0 (14.3)
70.4 (13.8)
22
22
70.9 (13.8)
71.1 (12.9) -0.1 (-0.8 to 0.7)
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Abbreviations: NPI, Neuropsychiatric Inventory; CMAI, Cohen-Mansfield Agitation Inventory; QoL-AD, 
Quality of Life-Alzheimer’s Disease Scale; CCGIC, Caregiver’s Clinical Global Impression of Change.
NOTE. Group numbers are means and standard deviations. Estimates of overall mean differences over 
day 14 and 21are based on linear mixed model analysis for repeated measures with correction for 
(subscale) NPI score at baseline, centre, CDR stage, sex, current opioid use, week and using a random 
intercept. A negative mean difference favors THC for NPI (range 0-144), CMAI (range 29-203) and 
CCGIC (range 1-7). A positive mean difference favors THC for Barthel Index (range 0-20) and QoL-
AD (range 13-52). *7-point scale; 1, marked improvement; 2, moderate improvement; 3, minimal 
improvement; 4, unchanged; 5, minimal worsening; 6, moderate worsening; 7, marked worsening.
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Table 3     Patients experiencing adverse events
MedDRA system organ class and preferred term THC (n=24)
Placebo 
(n=26)
One or more adverse event, n (%) 16 (66.7) 14 (53.8)
Severe adverse events, n (%)  0 (0.0) 0 (0.0)
Nervous system disorders 10 (41.7) 13 (50.0)
Dizziness 4 (16.7) 4 (15.4)
Somnolence 2 (8.3) 4 (15.4)
Aphasia 1 (4.2) 1 (3.8)
Bradykinesia 0 (0.0) 1 (3.8)
Miosis 0 (0.0) 1 (3.8)
Muscle spams 0 (0.0) 1 (3.8)
Sensory loss 0 (0.0) 1 (3.8)
Headache 1 (4.2) 0 (0.0) 
Muscular weakness 1 (4.2) 0 (0.0)
Balance disorder 1 (4.2) 0 (0.0) 
Psychiatric disorders 7 (29.2) 4 (15.4)
Cognitive disorder 3 (12.5) 1 (3.8)
Restlessness 2 (8.3) 1 (3.8)
Agitation 0 (0.0) 1 (3.8)
Euphoric mood 0 (0.0) 1 (3.8)
Apraxia 1 (4.2) 0 (0.0) 
Delirium 1 (4.2) 0 (0.0)
Investigations 1 (4.2) 6 (23.1)
Gamma-glutamyltransferase increased 1 (4.2) 2 (7.7)
Aspartate aminotransferase increased 0 (0.0) 2 (7.7)
Blood alkaline phosphatase increased 0 (0.0) 1 (3.8)
Hepatic enzyme increased 0 (0.0) 1 (3.8)
Gastrointestinal disorders 4 (16.7) 2 (7.7)
Nausea 2 (8.3) 1 (3.8)
Diarrhoea 0 (0.0) 1 (3.8)
Abdominal pain, upper 1 (4.2) 0 (0.0) 
Gastrooesophageal reflux disease 1 (4.2) 0 (0.0) 
General disorders 2 (8.3) 3 (11.5)
Fatigue 2 (8.3) 2 (7.7)
Malaise 0 (0.0) 1 (3.8)
Injury and procedural complications 1 (4.2) 3 (11.5)
Fall 1 (4.2) 3 (11.5)
Respiratory disorders 4 (16.7) 0 (0.0)
Pneumonia 2 (8.3) 0 (0.0) 
Chronic obstructive pulmonary disease 1 (4.2) 0 (0.0) 
Nasopharyngitis 1 (4.2) 0 (0.0) 
Cardiac disorders 1 (4.2) 2 (7.7)
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Chest pain 0 (0.0) 1 (3.8)
Syncope 0 (0.0) 1 (3.8)
Presyncope 1 (4.2) 0 (0.0)
Musculoskeletal disorders 3 (12.5) 0 (0.0)
Back pain 1 (4.2) 0 (0.0)
Neck pain 1 (4.2) 0 (0.0)
Pain in extremity 1 (4.2) 0 (0.0)
Eye disorders 0 (0.0) 2 (7.7)
Drye eyes 0 (0.0) 1 (3.8)
Eye heamorrhage 0 (0.0) 1 (3.8)
Renal and urinary disorders 0 (0.0) 2 (7.7)
Renal impairment 0 (0.0) 1 (3.8)
Urge incontinence 0 (0.0) 1 (3.8)
Skin disorders 2 (8.3) 0 (0.0)
Intertrigo 1 (4.2) 0 (0.0)
Skin disorder, NOS 1 (4.2) 0 (0.0)
Metabolism and nutrition disorders 0 (0.0) 1 (3.8)
Decreased appetite 0 (0.0) 1 (3.8)
Blood and lymphatic system disorders 1 (4.2) 0 (0.0)
Anaemia 1 (4.2) 0 (0.0)
Social circumstances 0 (0.0) 1 (3.8)
Family stress 0 (0.0) 1 (3.8)
Abbreviation: MedDRA = Medical Dictionary for Regulatory Activities; THC = 
tetrahydrocannabinol. Values are numbers of patients (%)
DISCUSSION
We found no benefit of 4.5 mg oral THC daily on behavioral 
disturbances in  patients with dementia after 3 weeks of treatment. 
Additionally, there were no benefits for THC on quality of life, 
activities of daily living, or  pain-related behavior and pain intensity 
(Appendix), while THC was safe and well-tolerated. The number 
of patients experiencing AEs was similar in both groups, while 
known THC-mediated AEs, such as dizziness, somnolence, and 
falls, were more frequently reported during placebo treatment. 
None of the participants reported a feeling “high,” nor was 
behaving “high” observed by caregivers or research staff. 
The current trial is the largest randomized controlled trial 
(RCT) so far studying oral THC in NPS in dementia, with valid 
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and rigorous trial methods. The study sample was representative 
for the overall dementia population, in terms of age, dementia 
severity, and domestic situation. Patients with severe aggressive 
behavior could not be included, as the study’s safety assessments 
cannot be adequately conducted in this group. Taking into account 
this limitation associated with this specific patient population, we 
have included a sample that is representative for the majority of 
the target population with clinically relevant NPS; the level of 
behavioral disturbances, assessed by NPI, was moderate and 
comparable to previous intervention trials.
33–35 We observed an 
improvement in NPS in both groups over the duration of the 
study period, which has been reported before.
34,35 The substantial 
degree of improvement in the placebo group  is  striking (Table 2), 
and may be due to many factors including attention and  support by 
the study team, expectations of patients and caregivers concerning 
THC, and training of nursing home personnel (together called the 
Hawthorne or in- study effect
36
). To correct for this substantial 
placebo response within individual patients, it might be 
worthwhile to implement an individually randomized crossover 
design in future studies. Despite the fact that we studied a 
vulnerable patient population, the attrition level was low (6%) 
and adherence high (98%–100%). This suggests a highly 
motivated group of participants and caregivers, in combination 
with the occurrence of only mild AEs. 
This study has some limitations. Most importantly, we failed 
to enroll the planned number of patients, despite comprehensive 
recruitment efforts throughout various health care settings. 
Rigorous national regulations on medical cannabinoids hindered 
implementation of  the study in the participating clinics. 
Additionally, fewer than expected patients visiting the clinics 
had clinically relevant NPS as well as pain. Omitting the latter 
inclusion criterion significantly stimulated the recruitment. 
Despite this underenrollment, the conditional power of 5% 
emphasizes that it was very unlikely that exposure of more 
participants to the study interventions and assessments would 
have influenced our conclusion. Contrary to the current RCT, 
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previous studies all reported positive effects of oral THC (2.5–7 
mg daily) in patients with dementia.
12,13,21,37 However, important 
methodologic factors significantly limit the robustness of these 
findings: inclusion of small number of patients (n=2 and n=15) 
and uncontrolled or retrospective study designs. In a previous 
randomized trial, we studied dosages up to 3 mg THC daily, and 
did not observe a significant reduction in NPS, nor any relevant AEs 
or effects on vital functions or mobility (unpublished data, 2014). 
Therefore, we used a dosage of 4.5 mg THC daily in this study.
Recent developments regarding the extended legalization of 
marijuana for medical purposes in over 30 US states has stimulated 
the discussion of the therapeutic potential and safety profile of 
cannabinoids for various indications.38,39 Momentarily, effective and 
safe treatments for NPS in patients with dementia are lacking.40 
Several pharmacotherapeutic options have been explored, such as 
acetyl- cholinesterase inhibitors and antidepressants,33,34 but they 
often have a suboptimal benefit-risk profile. For example, while high-
dose citalopram appears to effectively reduce agitation and overall 
behavioral disturbances, significant cardiac AEs limit its usefulness 
in this vulnerable population.34 
Our current trial indicates that 4.5 mg THC daily can be safely 
administered to patients with dementia. The observation that there 
was no biological signal of AEs suggests that the dosage was too 
low, as a psychoactive drug is rarely effective without showing any 
side effects. Therefore, our results warrant further research using 
higher dosages of THC in the treatment of dementia-related NPS.
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Appendix
Efficacy of THC in the treatment of pain in dementia 
patients with neuropsychiatric symptoms
Methods
The efficacy on pain-related behavior and pain intensity was 
evaluated in a subgroup of patients suffering from NPS as well as 
pain. This subgroup was defined as follows: 1) patients with persistent 
pain complaints, who could indicate their own pain intensity reliably, 
as judged by a research physician, or 2) patients with score of 
four points or more at baseline on the Pain Assessment Checklist 
for Seniors with Limited Ability to Communicate, Dutch version 
(PACSLAC-D). The PACSLAC-D1 is an observational assessment scale 
for assessment of pain in non-communicative persons and was used 
in this study to assess pain-related behaviour at baseline and after 
21 days of treatment. Pain intensity was assessed by self-report, 
using the Verbal Rating Scale (VRS).2 This is a six-point scale ranging 
from ‘no pain’ to ‘worst imaginable pain’. VRS assessments were 
done at every visit by means of an interview with the participant, 
and on a daily basis using a diary. Efficacy of THC on pain reduction 
was evaluated in a Linear Mixed Model with participants as random 
factor and baseline scores as fixed factor. VRS diary scores were not 
analyzed, as these assessments did not appear to be feasible in this 
patient group because of their cognitive decline, and resulted in too 
few available and reliable scores. Pearson correlation coefficients 
were calculated for change from baseline for PACSLAC-D and VRS 
interview scores, NPI and PACSLAC-D at day 21, NPI and VRS 
interview at day 21
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Results
In total, 23 patients were included in the subgroup ‘pain’. Within 
this group, more patients received placebo than THC (15 vs. 8 
patients).
PACSLAC-D scores were available for 20 patients (THC, n=7; 
Placebo, n=13), while 13 patients completed the VRS interview 
assessments (THC, n=4; Placebo, n=9). No treatment differences 
between THC and placebo were observed on PACSLAC-D (-1.1, 95% 
CI -6.0 to 3.8) or VRS (-0.03, 95% CI -0.95 to 0.90) (Appendix 
Table 2). Overall, there is an indication that a reduction in PACSLAC-D 
score is positively correlated with VRS interview score (Pearson’s 
r=0.35, p=0.06). No correlation was found between PACSLAC-D 
and NPI total score (Pearson’s r=0.21, p=0.21) nor between VRS 
interview and NPI total score (Pearson’s r=0.16, p=0.36).
Discussion
Low dose of THC did not result in benefit on pain-related 
behavior and pain intensity, compared to placebo. Our ability to 
study the analgesic effects of THC was limited, due to the small 
number of patients included in the pain assessments, because of 
lower prevalence of pain related behavioural disturbances than 
expected  and  the limitations of pain assessment in this patient 
group. These results should therefore be interpreted with caution. 
While self-reporting of pain is often referred to as ‘gold-standard’,3 
VRS assessments are only suitable for patients with mild dementia 
severity as it requires the capability of understanding the task 
and communicating the experienced sensation. Therefore, the 
PACSLAC-D, an observational assessment scale, is developed for 
assessment of pain in non-communicative persons.1 This scale is 
more appropriate for nursing home patients than for community-
dwelling patients, as this first group often express pain and 
discomfort through changes in behaviour. Future studies on the 
efficacy of THC as analgesic treatment, which are still warranted, 
should focus on a more homogeneous patient group, in whom a 
single pain assessment scale is feasible.
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Appendix Table 1      Overview of the results of the application 
of THC on pain assessments in dementia 
patients
n THC n Placebo Mean difference
THC vs placebo
(95% CI)
VRS interview
Baseline
Day 21
5
4
2.6 (1.3)
2.3 (1.0)
11
9
3.1 (1.8)
2.3 (1.0)
-0.03 (-1.0 to 0.9) 
PACSLAC-D
Baseline
Day 21
8
7
8.4 (5.2)
7.4 (8.0)
15
13
7.2 (4.1)
6.2 (5.5)
-0.4 (-3.8 to 3.0) 
Abbreviations: VRS, Verbal Rating Scale; PACSLAC-D, Pain Assessment Checklist 
for Seniors with Limited Ability to Communicate-Dutch version.
NOTE. Group numbers are means and standard deviations. Estimates of mean 
differences are based on linear mixed model analysis for repeated measures with 
participant as random effects for the subgroup of patients with pain. A negative 
mean difference favors THC for VRS and PACSLAC-D. 
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Appendix Table 2      Study results of the application of THC on 
neuropsychiatric symptoms in dementia for 
all subdomains of Neuropsychiatric Inventory
n THC n Placebo THC vs. placebo
(95% CI)
NPI delusions 
Baseline
Day 14
Day 21
24
19
23
1.8 (3.0)
1.9 (3.6)
2.0 (3.5)
26
23
24
1.8 (3.3)
1.3 (2.6)
1.5 (2.7) +0.7 (-0.5 to 1.9)
NPI hallucinations
Baseline
Day 14
Day 21
24
19
23
0.8 (2.6)
0.3 (1.4)
0.0 (0.2)
26
23
24
0.3 (1.2)
0.3 (1.7)
0.3 (1.2) -0.2 (-0.9 to 0.4)
NPI agitation/
aggression 
Baseline
Day 14
Day 21
24
19
23
5.7 (3.8)
4.1 (4.7)
4.5 (4.1)
26
23
24
6.2 (4.3)
5.0 (3.9)
4.4 (4.3) -0.1 (-2.0 to 1.9)
NPI dysphoria
Baseline
Day 14
Day 21
24
19
23
2.9 (4.0)
1.6 (2.4)
2.3 (2.6)
26
23
24
3.4 (3.6)
2.1 (2.7)
1.8 (2.8) 0.0 (-1.0 to 1.1)
NPI anxiety
Baseline
Day 14
Day 21
24
19
23
2.5 (4.0)
2.1 (3.5)
1.5 (2.8)
26
23
24
2.6 (3.7)
1.0 (2.6)
1.3 (2.3) +0.5 (-0.7 to 1.8)
NPI euphoria
Baseline
Day 14
Day 21
24
19
23
(2.5)
0.3 (1.4)
0.5 (1.3)
26
23
24
0.3 (0.9)
0.3 (1.7)
0.0 (0.2) +0.1 (-0.5 to 0.6)
NPI apathy
Baseline
Day 14
Day 21
24
19
23
5.0 (3.7)
5.1 (3.5)
4.1 (3.4)
26
23
24
2.5 (3.1)
2.4 (3.3)
2.3 (3.1) +0.1 (-1.1 to 1.3)
NPI disinhibition
Baseline
Day 14
Day 21
24
19
23
2.5 (3.3)
1.5 (2.6)
2.1 (3.2)
26
23
24
3.1 (3.4)
2.1 (3.0)
2.4 (3.4) -0.1 (-1.6 to 1.4)
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NPI irritability
Baseline
Day 14
Day 21
24
19
23
5.3 (4.3)
5.1 (4.0)
4.3 (4.1)
26
23
24
5.7 (4.8)
4.2 (3.8)
3.9 (4.1) +0.7 (-1.1 to 2.4)
NPI aberrant motor 
behavior
Baseline
Day 14
Day 21
24
19
23
4.5 (4.6)
4.9 (4.0)
3.6 (3.9)
26
23
24
5.2 (4.1)
4.3 (4.2)
3.7 (4.3) +0.3 (-1.0 to 1.7)
NPI nighttime 
behavior disturbances
Baseline
Day 14
Day 21
24
19
23
2.5 (3.6)
1.4 (2.8)
0.8 (2.0)
26
23
24
2.5 (3.1)
2.2 (3.4)
1.8 (2.8) -0.7 (-1.8 to 0.4)
NPI appetite and 
eating abnormalities 
Baseline
Day 14
Day 21
24
19
23
3.1 (4.0)
2.8 (3.8)
2.0 (3.0)
26
23
24
2.1 (3.4)
0.8 (1.9)
0.7 (1.6) +1.0 (0.0 to 1.9)
Abbreviations: NPI, Neuropsychiatric Inventory
NOTE. Group numbers are means and standard deviations. Estimates of overall 
mean differences are based on linear mixed model analysis for repeated measures 
with participant as random effects. A negative mean difference favors THC for NPI 
subdomains.
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Abstract
There is a great concern about the safety of THC-based drugs in 
older people (≥ 65 years), as most of THC-trials did not include such 
group. In this phase 1, randomized, double-blind, double-dummy, 
placebo-controlled, cross-over trial, we evaluated the safety and 
pharmacokinetics of three oral doses of Namisol®, a novel THC 
in tablet form, in older subjects. Twelve healthy older subjects (6 
male; mean age 72±5 years) randomly received a single oral dose 
of 3 mg, 5 mg, or 6.5 mg of THC or matching placebo, in a crossover 
manner, on each intervention day. The data for 11 subjects were 
included in the analysis. The data of 1 subject were excluded due to 
non-compliance to study medication. 
THC was safe and well tolerated. The most frequently reported 
adverse events (AEs) were drowsiness (27%) and dry mouth 
(11%). Subjects reported more AEs with THC 6.5 mg than with 3 
mg (p=0.048), 5 mg (p=0.034) and placebo (p=0.013). There was 
a wide interindividual variability in plasma concentrations of THC. 
Subjects for whom the Cmax fell within the sampling period (over 2 
h), Cmax was 1.42–4.57 ng/mL and tmax was 67–92 min. The AUC0–
2h (n=11) was 1.67–3.51 ng/mL. Overall, the pharmacodynamic 
effects of THC were smaller than effects previously reported in 
young adults.
In conclusion, THC appeared to be safe and well tolerated by 
healthy older individuals. Data on safety and effectiveness of THC 
in frail older persons are urgently required, as this population could 
benefit from the therapeutic applications of THC.
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Introduction
The cannabis plant (Cannabis sativa L.) has been used to treat 
a range of symptoms and diseases for more than 4000 years.1, 2 Its 
broad therapeutic applications reflect the various pharmacological 
and physiological effects of cannabinoids, the bioactive components 
of the cannabis plant.3 The plant contains more than 60 cannabinoids, 
such as delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), 
cannabinol, and cannabichromene.3 While the pharmacological 
effects of most cannabinoids are still not known, THC appears to 
be responsible for most of the physical and psychoactive effects 
of cannabis.3 Cannabinoids exert their effects by binding to two 
cannabinoid receptors, i.e. CB1, which is expressed primarily in the 
central nervous system, and CB2, which is found primarily in the 
immune system and hematopoietic cells.4-6
In recent years, cannabinoid-based drugs and non-smoking routes 
of drug administration have been investigated in clinical trials. To 
date, there are only two oral cannabis-based medicines (dronabinol 
and nabilone) available by prescription in some countries, and one 
available as an oromucosal mouth spray (nabiximols). Dronabinol 
(synthetic THC) and nabilone (THC analog), are approved by the 
United States Food and Drug Administration, and in some European 
countries, for appetite stimulation in AIDS-related anorexia and 
chemotherapy-induced nausea and vomiting. Nabiximols (Sativexs), 
which contains both THC and CBD, is approved in the United Kingdom 
and in some other European countries and Canada, but not in the 
USA, for the management of pain and spasticity in patients with 
multiple sclerosis.
Growing interest in the medical use of cannabis has recently led 
to the development of Namisol®. Namisol® is a novel cannabinoid-
based drug formulation that contains THC (≥ 98%) in tablet form. 
It was developed using a novel drug delivery technology, Alitra™ to 
improve its absorption and bioavailability.7 The results of the first 
trial in humans investigating the optimal route of administration, 
safety, pharmacokinetics, and pharmacodynamics of the drug 
showed that Namisol® (5 mg, 6.5 mg, and 8 mg) might have more 
154
Chapter 5  |   Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: 
A randomized controlled trial.Part IV  |  Safety, pharmacodynamics, and pharmacokinetics of oral tetrahydrocannabinol
favorable pharmacokinetics and pharmacodynamics than currently 
available cannabinoid-based drugs.7 This is because Namisol® 
showed 1) a faster absorption and a shorter time to reach the 
maximal THC concentrations; 2) a smaller variability in tmax (time 
to maximum plasma concentration) and plasma concentrations; 
and 3) faster pharmacodynamic effects, which are important for 
achieving a rapid clinical effect.7 Klumpers et al.7 also reported that 
Namisol® was safe and well tolerated by subjects.7 However, their 
study involved only young adults (mean age 21.4 years, range 18–
27 years), and so findings cannot directly be extrapolated to older 
population (65 years and older). Older people are in general more 
likely to experience adverse drug events, due to a combination of 
age-related physiological changes (such as a decrease in lean body 
mass, diminished renal and hepatic clearance) and a high prevalence 
of comorbidities, which can lead to polypharmacy and drug–drug 
interactions.8-10 
The aims of this trial were first, to assess the safety and tolerability 
of three oral doses of THC (3 mg, 5 mg, and 6.5 mg) in healthy 
older subjects. Second, to evaluate the pharmacokinetics of THC in 
older people and to investigate the relationship between the drug0s 
pharmacodynamic effects and the plasma concentrations of THC 
and its active metabolites 11-hydroxy-delta-9-THC (11-OH-THC) 
and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH).
Experimental procedures
Study design and participants
This phase 1, randomized, double-blind, double-dummy, placebo-
controlled, cross-over trial (ClinicalTrials.gov ID NCT01740960) was 
approved by the local ethics committee (Registration number: NL 
40591.091.12) and carried out at the Radboud University Medical 
Center,  Nijmegen,  The  Netherlands.  The  trial was performed 
according to the International Conference on Harmonization guideline 
for good clinical  practice,  the  ethical  principles  of  the Declaration 
of Helsinki, and the related Dutch laws and regulations. The subjects 
were healthy elderly volunteers who were recruited between August 
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and November 2012 through personal contacts and word of mouth. 
All subjects provided written informed consent before they were 
screened for eligibility. Inclusion criteria were age 65 years or older; 
physically healthy, based on a medical history, physical examination, 
electrocardiography (ECG), results of hematological and biochemical 
blood tests on screening; and body mass index between 18.0 and 
30 kg/m2. Main exclusion criteria were high falls risk (based on body 
sway test); regular cannabis use (defined as smoking one or more 
cannabis cigarettes per week); history of sensitivity/idiosyncrasy to 
cannabis; history of drug or alcohol abuse; smoking more than ten 
cigarettes a day; history of severe comorbidities (e.g. COPD GOLD 
III or IV; heart failure NYHA III or IV) or diabetes mellitus; history 
of psychiatric or cognitive disorders; consumption of more than six 
units of (methyl)xanthine products per day (e.g. coffee, tea, cola, 
chocolate); use of drugs that inhibit CYP2C9, CYP2C19 and CYP3A4, 
and was not possible to discontinue the use of the drugs during the 
study period.
Randomization and masking
Subjects were randomly allocated to receive a single dose of 3 
mg (two 1.5 mg tablets), 5 mg (one tablet), or 6.5 mg (one 5 mg 
and one 1.5 mg tablet) of Namisol® or matching placebo in a double-
blind, double-dummy manner on each intervention day. Subjects 
received three tablets per visit, two of 6-millimeter and one of 
9-millimeter (Namisol® or matching placebo). This double-dummy 
technique was used because of difference of the size of Namisol® 
tablets, 1.5 mg (6 mm) and 5 mg (9 mm). Each subject acted as 
his/her own control and therefore received all study medications 
(single dose per visit) in a crossover design on four occasions (visits 
1–4). The washout period between the visits was 2 weeks. Namisol® 
and placebo tablets were identical in appearance. The randomization 
codes were generated by a computer algorithm for random numbers 
and could only be accessed by the site pharmacist. Study drugs 
were labeled with a unique identification number before delivery 
to the investigators. Sponsor, investigators, site staff, and subjects 
were masked to assignment.
156
Chapter 5  |   Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: 
A randomized controlled trial.Part IV  |  Safety, pharmacodynamics, and pharmacokinetics of oral tetrahydrocannabinol
Interventions
The intervention period (visits 1 to 4) was preceded by a 
screening visit (visit 0) that occurred maximally 2 weeks before 
randomization, during which subjects’ medical history was taken 
and they underwent a physical examination, ECG, hematological 
and bio- chemical blood tests, the Mini Mental State Examination 
(MMSE), the Geriatric Depression Scale (GDS-30) test, and body 
sway test, using the SwayStar™. Subjects who fulfilled the eligibility 
criteria were randomly allocated to receive the trial medications, 
which were administered orally with 100 mL water.
Subjects were asked to abstain from smoking (12 h) and consuming 
alcohol (24 h), grapefruit (48 h) or quinine (24 h) and xanthine-
containing beverages or foods (12 h) before each intervention. 
They were asked not to drive a car for 24 h after ingestion of the 
trial medication or to drink more than 2 glasses of alcohol a day 
or to smoke more than ten cigarettes per day. All subjects were 
instructed to contact the investigator if they developed fever (38°C 
or higher) 3 days before the intervention day and not to start any 
medication without consulting the investigator. Subjects who used 
medication that interacts with THC had to discontinue the medication 
temporarily during the study period (approximately 8 weeks).
Safety assessments
The primary endpoint of the trial was the safety of Namisol®, which 
was assessed by evaluating the incidence and severity of adverse 
events using a standardized THC adverse events checklist and 
spontaneous reporting, vital signs (including systolic and diastolic 
blood pressure, and heart rate), 12-lead ECG, Visual Analog Scales 
(VAS-subtest feeling high), and laboratory safety tests (hematology 
and chemistry). The Test for Attentional Performance (TAP-subtest 
alertness) and SwayStar™ were used to evaluate the effects of 
Namisol® on subjects’ attention and body sway. On each intervention 
day, safety was monitored by research staff for 3.5 h after dosing. 
Moreover, subjects were tele- phoned 24 h after drug (active or 
placebo) ingestion to determine the occurrence of adverse events 
after discharge. All adverse events were recorded with regard to 
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their time of onset, severity, duration, and possible relationship to 
the study drug. The Medical Dictionary for Regulatory Activities was 
used for coding adverse events.
VAS-Feeling high: “Feeling high” was assessed with the 
Bowdle VAS for psychedelic effects.11 Subjects were asked 
to score ‘feeling high’ on a 100-mm horizontal line, with 
‘0’ indicating  not feeling  high and ‘100’ indicating  feeling 
extremely high.
TAP-Alertness: A computerized subtest of the TAP 
was used to measure alertness (reaction time) under two 
conditions. First, a simple reaction time to a visual stimulus, a 
cross “X”, appearing on the monitor screen at randomly varying 
intervals. The subject had to respond as quickly as possible by 
pressing a key when “X” appeared on the screen. Second, the 
visual stimulus “X” was preceded by a cue stimulus presented 
as warning tone. The subject had to respond only when “X” 
appeared on the screen. TAP scores are given in milliseconds.
Body sway: The SwayStar™ (http://www.b2i.info/web/
index.htm), a wireless device attached to the trunk (L3–L5), 
was used to measure body sway over 1 min. The subjects 
were asked to stand quietly and relaxed with feet slightly apart 
on a firm surface, first with eyes open for 30 sec and then 
with eyes closed for 30 sec. The range of pitch velocity scores 
(anterior–posterior movements) was used for analysis. Scores 
are given in degrees per second.
Blood sampling and laboratory analysis
Venous blood samples were collected in EDTA-coated tubes 
(6 mL) before and at 40, 55, and 120 min after dosing, for the 
measurement of plasma concentrations of THC, 11-OH-THC, and 
THC-COOH. The tubes were placed on ice and within 60 min were 
centrifuged for 10 min (2000g, 4 °C). The plasma was pipetted into 
two 1.5 mL cryotubes, which were stored at -80 °C until analysis. 
The plasma concentrations were analyzed at the Analytisch 
Biochemisch Laboratorium b.v. (Assen, The Netherlands), using 
liquid chromatography/ mass spectrometry/mass spectrometry. The 
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lower limit of quantification was 0.1 ng/mL for THC and 11-OH-THC, 
and 0.5 ng/mL for THC-COOH. The analysis was performed using a 
validated assay according to good laboratory practice standards. The 
acceptance criteria for an analytical run was based on bioanalytical 
methods validation for human studies,12, 13 which included accuracy, 
precision, selectivity, post-preparative stability, dilution of samples, 
freeze/thaw stability, refrigerator stability, whole blood stability, and 
long term stability.
Pharmacodynamic  assessments
The VAS-feeling high, TAP-alertness, and body sway were used 
to evaluate the secondary endpoint of this trial, the relationship 
between pharmacodynamic effects of Namisol® and the plasma 
concentrations of THC and its active metabolites. All assessments 
were carried out directly after blood sampling, pre-dosing and at 40, 
55 and 120 min after dosing.
Statistical analysis
Descriptive statistics were used to describe the study population. 
The continuous data are expressed as means ± standard deviation 
(±SD), and categorical data are expressed as frequencies. This study 
is descriptive and explorative. The primary endpoint was the safety 
of THC, based on incidence and severity of reported adverse events. 
To explore the association between administered dose of Namisol® 
(3 mg, 5 mg, and 6.5 mg) and the occurrences of adverse events, 
Generalized Estimating Equations (GEE) were  used to compare the 
proportion of subjects experiencing one or more adverse events, and 
random effects analyses with non-linear mixed models (NLMIXED) 
to compare the number of adverse events per subject per dose, 
assuming that adverse events had a Poisson distribution. The VAS, 
TAP, and body sway scores were analyzed in relation to the Namisol® 
doses, using linear mixed models. The effects of the three Namisol® 
doses on the plasma concentrations of THC, 11-OH-THC, and THC-
COOH, which were measured 40, 55, and 120 minutes after dosing, 
were analyzed with linear mixed models to take into account the 
longitudinal character of the data. Pharmacokinetic parameters 
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including maximum plasma concentration (Cmax), time to maximum 
plasma concentration (tmax), and area under the curve from t = 0 
to 2 h (AUC) were calculated using Phoenix WinNonlin 6.3 (Certara, 
L.P./Pharsight Ltd). For secondary endpoint of the study, the TAP 
and body sway scores were analyzed in relation to THC, 11-OH-
THC, and THC-COOH plasma concentrations, using linear mixed 
models. In all linear mixed models we used “volunteer” as a random 
effect. P values < 0.05 were considered to indicate significance. No 
correction was made for multiple testing because of the explorative 
character of study. All statistical analyses were performed using 
SASMT software (version 9.2).
Results
Baseline characteristics
Twelve healthy elderly subjects (6 male; mean age 72±5 
years, range 65–80 years) were randomized. Their demographic 
characteristics are summarized in Table 1. None of the subjects had 
ever used cannabis and all were in good physical and mental health. 
Only one subject was a cigarette smoker (average 5 cigarettes/
day); 11 subjects used moderate amounts of alcohol. Four subjects 
had no relevant medical history and did not use medications. The 
most common health problems were hypertension (n=3) and 
hypercholesterolemia (n=3). The subjects used an average of 
2±2.1 medications, with cardiovascular drugs such as lipid-lowering 
drugs, aspirin, and beta-blockers being the most commonly used 
medications.
Safety and tolerability
The data for 11 subjects (5 men and 6 women) were included 
in the analysis. The data of 1 subject were excluded due to non-
compliance to study medication. Table 2 lists all reported adverse 
events by dose (40 in total). The first adverse events were observed 
20 min after dosing. All adverse events were mild and most occurred 
between 55 and 120 min after dosing and resolved spontaneously 
before the end of the intervention day (within 3.5 h after dosing). 
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Table 1    Demographics and baseline characteristics of subjects 
randomized in the trial.
Characteristics n = 12
Male, n (%)
Female, n (%)
6 (50)
6 (50)
Age, mean (SD); [range] years 72.1 (5); [65 - 80]
Caucasian race, n (%) 12 (100)
Smokers, n (%) 1 (8)
Cannabis users, n (%) 0 (0)
Alcohol users, n (%)  
     ≤ 2 alcoholic beverage/day, n
     3 - 4 alcoholic beverage/day, n 
11 (91.7)
8
3
aBMI, mean (SD); kg/m-2 26.4 (1.5)
Weight, mean (SD); kg 77.3 (9.8)
Height, mean (SD); meter 170.9 (9.2)
aSBP, mean (SD); mmHg 134.3 (10.6)
aDBP, mean (SD); mmHg 76.7 (6.9)
aHR, mean (SD); beats/minutes 61.3 (10.4)
aMMSE-30, mean (SD) 29.8 (0.6)
aGDS-30, mean (SD) 0,17 (0.4)
Number of medications used by subject, mean (SD) 2 (2.1)
bConcomitant medications, n (%) 
    Lipid lowering 7 (58.3)
    Aspirin 4 (33.3)
    Beta-blockers 3 (25)
    Angiotensin-converting-enzyme inhibitors 2 (16.7)
    Calcium channel blockers 2 (16.7)
    Thiazide diuretics 2 (16.7)
     Proton pump inhibitors 1 (8.3)
     Laxatives 1 (8.3)
     Eye drops 1 (8.3)
Comorbidities, n (%)
     Hypertension 3 (25)
     Hypercholesterolemia 3 (25)
     Cholecystectomy (past) 2 (16.7)
     Valve disease 1 (8.3)
     Stable angina 1 (8.3)
     Myocardial infarction (past) 1 (8.3)
     Colon cancer (past) 1 (8.3)
     Glaucoma 1 (8.3)
aBMI: body mass index; SPB: systolic blood pressure, DBP: diastolic blood pressure; HR: heart 
rate; MMSE: mini mental state examination; GDS: geriatric depression scale.
bNumber of subjects who used one or more medications
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There were no serious adverse events during the trial. More 
subjects reported one or more adverse events with Namisol® 3 mg 
(5 subjects, p=0.036), 5 mg (5 subjects, p=0.036) and 6.5 mg (7 
subjects, p=0.008) than with placebo (1 subject) and overall the 
subjects reported fewer adverse events with placebo (total 1 event, 
p=0.013), Namisol® 3 mg (9 adverse events, p=0.048) and 5 mg (8 
adverse events, p=0.034) than with Namisol® 6.5 mg (22 adverse 
events). Overall, the most frequently reported adverse events were 
drowsiness (27%; including one on placebo), dry mouth (11%), 
coordination disturbance (9%), and headache (9%). There were 
no clinically relevant changes in systolic or diastolic blood pressure 
(difference of 20 mmHg and 15 mmHg at rest, respectively) and 
heart rate (difference of 20 beats/minute) after the administration 
of trial medication. The ECG parameters (e.g. QT and RR intervals) 
were unchanged from screening to the end of trial, and all laboratory 
test results were within the normal range.
VAS-Feeling high scores indicated that four subjects (three 
females and one male) “felt high” after THC. Subject A, a 71-year-
old woman (BMI 28.1 kg/m2) had a VAS score of 8 mm 120 min 
after 3 mg Namisol®, and 13 and 16 mm 55 and 120 min after 
5 mg Namisol®, respectively. Subject B, a 68-year-old man (BMI 
26.1 kg/m2), had VAS scores of 9 and 7 mm 55 and 120 min after 
5 mg Namisol®, respectively. Subject C, a 71-year-old woman 
(BMI 26.5 kg/m2), had a VAS score of 25 mm 120 min after 6.5 
mg Namisol®, and subject D, a 73-year-old women (BMI 23.5 kg/
m2), had a VAS score of 6 mm 120 min after 6.5 mg Namisol®. No 
significant changes were found in subjects’ attentional performance 
(TAP-scores p=0.18) or body sway (eyes open p=0.18; eyes closed 
p=0.16) after the administration of trial medication.
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Pharmacokinetic parameters
The mean THC, 11-OH-THC, and THC-COOH concentration– 
time curves are shown in Figure 1. Plasma concentrations of THC, 
11-OH-THC, and THC-COOH were dose-dependent and significantly 
increased with increasing the dose of Namisol (p< 0.0001). Table 3 
lists the mean pharmacokinetic parameters of THC. There was a wide 
inter-individual variability in plasma concentrations of THC, 11-OH-
THC and THC-COOH. In one subject the THC concentration had not 
reached a maximum by 120 min after 3 mg Namisol®, and in four 
and five subjects after 5 mg and 6.5 mg Namisol®, respectively. For 
subjects for whom Cmax fell within the sampling interval (120 min), 
the geometric mean THC Cmax was 1.42 ng/mL (range 0.53–3.48) 
for 3 mg (n=10), 3.15 ng/mL  (range  1.54–6.95)  for  5 mg  (n=7), 
and  4.57 ng/mL (range 2.11–8.65) for 6.5 mg (n=6).
Table 3    The mean pharmacokinetic parameters of THC after 
administration of single dose Namisol®
Parameters (mean and range) 3 mg (n=11) 5 mg (n=11) 6.5 mg (n=11)
THCa 1.2 (0.13-3.48) 1.9 (0.26-6.95) 2.61 (0.23-8.65)
11‐OH‐THCa 1.69 (0.47-4.34) 2.34 (0.37-8.37) 3.12 (0.37-8.61)
THC-COOHa 13.9 (1.27-27) 19.3 (2.23-48.8) 26.6 (3.51-56.8)
AUC0-2h (h ng/mL) 1.67 (0.80-4.14) 2.61 (0.97-7.55) 3.51 (1.26-11.45)
3 mg (n=10) 5 mg (n=6) 6.5 mg (n=5)
bCmax (ng/mL) 1.42 (0.53-3.48) 3.15 (1.54-6.95) 4.57 (2.11-8.65)
bTmax (h) 0.92 (0.67-0.92) 0.92 (0.67-0.92) 0.67 (0.67-0.92)
aPlasma concentrations 
bReported for subjects who reached the Cmax within 2 hour
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Figure 1    Mean THC, 11-OH-THC and THC-COOH concewntration-
time curve
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Pharmacokinetic/pharmacodynamic effects
Since only 7 of 174 (4%) “feeling high” measurements had scores 
higher than “0”, it was not possible to calculate the association 
between the VAS-feeling high and the plasma concentrations of THC, 
11-OH-THC, and THC-COOH. Body sway-eyes open scores were not 
associated with the plasma concentrations of THC (p=0.14), but 
with the concentrations of its metabolites. An increase of 1 ng/mL in 
11-OH-THC and THC-COOH plasma concentrations was accompanied 
by a mean increase in body sway with eyes open of 0.08 degrees/
second (p=0.006; 95% CI: 0.02–0.14) and 0.008°/s (p=0.024; 95% 
CI: 0.001–0.014), respectively. Furthermore, increases in plasma 
concentrations were associated with increase in body sway with 
eyes closed. An increase of 1 ng/mL in THC, 11-OH-THC, THC-COOH 
plasma concentrations was accompanied by a mean increase in body 
sway with eyes closed of 0.09 degrees/second (p=0.0002; 95% CI: 
0.04–0.13), 0.12°/s (p<0.0001; 95% CI: 0.08–0.16), and 0.007°/s 
(p=0.0087; 95% CI: 0.002–0.012), respectively. However, there 
were no significant differences in the body sway scores  between 
Namisol® and  placebo  and  therefore, observed changes in body 
sway scores associated with the plasma concentrations are clinically 
not  relevant.  TAP- alertness scores were not associated with the 
plasma concentrations of THC (p=0.52), 11-OH-THC (p=0.65), or 
THC-COOH (p=0.84).
Discussion
Safety and tolerability
Owing to the broad therapeutic applications of cannabinoids, older 
individuals are probably the fastest growing population of users, 
with an estimated prevalence between 6.5% and 37% of medicinal 
cannabis users aged between 60 and 93 years.14-17 However, the 
growing interest in the medical applications of cannabinoids should 
be accompanied by discussion of their safety and efficacy in older 
patients.17 Several randomized clinical trials have demonstrated the 
safety and efficacy of cannabinoid-based medicines in the treatment 
of conditions that are common in older individuals.18-21 However, 
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most of these trials either did not include older subjects or, if they 
were included, did not analyze data by age group, which makes it 
difficult to draw firm conclusions about the safety and efficacy of 
cannabinoids in older patients.17
To our knowledge, this is the first phase 1 trial of the safety 
and pharmacokinetics of a cannabis-based medicine that included 
solely older individuals. Single oral doses of Namisol® of 3 mg, 5 mg, 
and 6.5 mg were generally safe and well tolerated by the healthy 
older individuals. The 6.5 mg dose was associated with more 
adverse events than the lower doses, but there was no significant 
difference in the incidence of adverse events between the 3 mg 
and 5 mg doses. The most frequently reported adverse events 
were drowsiness (27%) and dry mouth (11%). All adverse events 
were mild and resolved spontaneously within 3.5 h. There were no 
moderate or serious adverse events. Four of the eleven subjects 
reported “feeling high” after the administration of Namisol®, but 
only 4% of VAS scores were higher than “0”. The sensation was mild 
in intensity (VAS scores ranging between 6 mm and 25 mm, out of 
100 mm) and of short duration. In the previous study of Namisol® in 
young adults (mean age 21 years), 85% and 100% of subjects had 
at least one adverse event after 5 mg and 6.5 mg, respectively, and 
one subject dropped out because of drug- related syncope with the 
5 mg dose; all adverse events were mild to moderate in severity.7 
Our findings, with zero drop-outs and 45% and 64% of subjects 
reporting only mild adverse events with the 5 mg and 6.5 mg doses, 
respectively, suggest that THC is tolerated better by older individuals 
(mean age 72 years) than by younger individuals, a finding which 
we had not anticipated. However, the low rate of unwanted (side) 
effects in older individuals may be correlated with a lower rate of 
wanted (therapeutic) effects. Further studies are required to assess 
the  effectiveness  of  the  three  doses  Namisol® in  the treatment 
of conditions in older individuals.
Pharmacokinetic and pharmacodynamic effects
Our findings showed substantial inter-individual variation in 
plasma concentrations of THC, 11-OH-THC, and THC-COOH, which 
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is in line with previous studies that included individuals of different 
ages, but did not report data for older patients separately.7, 22, 23 
In some subjects, THC concentrations did not reach a maximum 
within the sampling period of 120 min after dosing. This is in 
contrast with previously published data for young adults, where 
maximal concentrations of THC were reached  between  39  and  56 
min  after  oral  Namisol®.7 For subjects for whom Cmax fell within 
the sampling period, the mean Cmax (3.15 ng/mL with the 5 mg 
dose and 4.57 ng/mL with the 6.5 mg dose) was similar to that 
reported for young adults (2.92 ng/mL with 5 mg and 4.43 ng/mL 
with 6.5 mg).7 In this study, the sample schedule was based on 
previously published data for young adults,7 but did not cover a full 
pharmacokinetic curve in older subjects. Therefore, and because of 
the limited number of samples collected, the pharmacokinetic data 
should be handled with caution when extrapolating to other studies. 
Unfortunately, it was not possible to compare our data with those of 
other pharmacokinetic studies involving older subjects, because we 
did not find any pharmacokinetic studies of THC that reported data 
separately for older individuals.
In our trial, the first pharmacodynamic effects of THC occurred 
20 min after dosing and the maximal effects were reported between 
55 and 120 min. These results are quite promising for achieving a 
rapid clinical effect when compared with the action of dronabinol, 
which has an onset of action between 30 min and 1 h, and maximal 
effects between 2 and 4 h.24 We found no significant differences in 
body sway scores (eyes open and closed) after the administration 
of THC. Body sway-eyes open scores were associated with plasma 
concentrations of 11-OH-THC, and THC-COOH, but not THC. This is 
in line with previous studies that showed a larger effect after 11-OH-
THC administration than after THC administration.25-27 Comparison 
of the effects of THC and placebo showed that although higher 
plasma concentrations of THC and its metabolites were associated 
with higher body sway-eyes closed scores in our older subjects, this 
effect was not clinically relevant and would not increase the risk of 
falls.
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Interestingly, the pharmacodynamic effects of THC were smaller 
than we had expected for older people, based on the effects seen 
in young adults.7 A possible explanation for this could be the age-
related physiological changes such as delayed gastric emptying 
time, decreased gastrointestinal motility and absorption surface 
which could affect the absorption and bioavailability of THC. 
Furthermore, cannabinoid receptors (CB1 and CB2) are G protein-
coupled receptors.28 Impairments in intracellular function and levels 
of G-proteins have been observed with aging,29 which may alter the 
pharmacodynamics in older adults. Further comparison studies are 
required to compare the pharmacokinetic and pharmacodynamic 
effects of THC in younger and older adults.
Strengths and limitations of the study
The primary strengths of our study were, first, its design, a 
randomized, double-blind, placebo-controlled trial. Second, it is the 
first randomized, controlled trial of the safety and pharmacokinetics 
of cannabis-based medicine that exclusively included older subjects, 
so that our findings add to the sparse literature on the safety and 
pharmacokinetics of THC in older people. A potential limitation of 
our study is that we could not perform a complete pharmacokinetic 
analysis of THC in older individuals because the study was primarily 
designed to assess the safety and tolerability of THC and therefore, 
only four blood samples were collected (over 120 min). We are 
currently investigating the efficacy of THC in the treatment of pain 
and behavioral disturbances in patients with dementia. In one of 
these studies, we will be collecting a sufficient number of blood 
samples to allow a complete pharmacokinetic analysis of THC and 
its metabolites in older subjects. In conclusion, Namisol®, a novel 
THC in tablet form, appeared to be safe and well tolerated by healthy 
older individuals. Data on safety and effectiveness of cannabinoid-
based medicines in frail older persons with multiple comorbidities 
are urgently required, as this population could benefit from the 
therapeutic applications of cannabinoids.
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Abstract
RATIONALE
Data on safety, pharmacodynamics, and pharmacokinetics of 
tetrahydrocannabinol (THC) are lacking in dementia patients.
METHODS
In this randomized, double-blind, placebo-controlled, 
crossover trial, we evaluated the safety, pharmacodynamics, and 
pharmacokinetics of THC in ten patients with dementia (mean age 
77.3±5.6). For 12 weeks, participants randomly received oral THC 
(weeks 1–6, 0.75 mg; weeks 7–12, 1.5 mg) or placebo twice daily 
for 3 days, separated by a 4-day washout period.
RESULTS
Only 6 of the 98 reported adverse events were related to THC. 
Visual analog scale (VAS) feeling high, VAS external perception, body 
sway-eyes-open, and diastolic blood pressure were not significantly 
different with THC. After the 0.75 mg dose, VAS internal perception 
(0.025 units; 95% CI 0.010–0.040) and heart rate (2 beats/min; 
95% CI 0.4–3.8) increased significantly. Body sway-eyes-closed 
increased only after 1.5 mg (0.59°/s; 95% CI 0.13–1.06). Systolic 
blood pressure changed significantly after both doses of THC (0.75 
mg, -7 mmHg, 95% CI -11.4, -3.0; 1.5 mg, 5 mmHg, 95% CI 
1.0–9.2). The median tmax was 1–2 h, with THC pharmacokinetics 
increasing linearly with increasing dose, with wide interindividual 
variability (CV% up to 140%). The mean Cmax (ng/mL) after the first 
dose (0–6 h) was 0.41 (0.18 - 0.90) for the 0.75-mg dose and 1.01 
(0.53–1.92) for the 1.5 mg dose. After the second dose (6–24 h), 
the Cmax was 0.50 (0.27–0.92) and 0.98 (0.46–2.06), respectively.
CONCLUSIONS
THC was rapidly absorbed and had dose-linear pharmacokinetics 
with considerable interindividual variation. Pharmacodynamic 
effects, including adverse events, were minor. Further studies are 
warranted to evaluate the pharmacodynamics and efficacy of higher 
THC doses in older persons with dementia.
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Introduction
In recent years, there has been increased interest in the medical 
applications of delta-9-tetrahydrocannabinol (THC), the main 
psychoactive cannabinoid of the cannabis plant (Cannabis sativa 
L.). A number of studies have demonstrated its effectiveness in the 
management of clinical conditions that are very common in older 
people, such as neuropsychiatric symptoms (e.g., agitation and 
aggression) in dementia, pain (e.g., neuropathic and spasticity in 
multiple sclerosis), and anorexia.1-4
These therapeutic effects of THC are mediated primarily by 
two cannabinoid receptors: CB1 and CB2.5-7 CB1 receptors are 
mainly expressed in the basal ganglia, cerebellum, hippocampus, 
hypothalamus, and dorsal horn,8 and CB2 receptors are primarily 
found on immune cells and tumor cells.9 THC also interacts with other 
receptors and neurotransmitters in the brain, such as acetylcholine, 
dopamine, serotonin, gamma-aminobutyric acid, glutamate, 
norepinephrine, prostaglandins, and opioid peptides.10 These broad 
and complex interactions underlie the potential pharmacological 
effects of THC as multitarget drug candidate for the management 
of behavior, mood, pain, and anorexia in patients with dementia. 
Oral, fixed-dose THC-based drugs have recently been developed. 
For example, dronabinol (Marinol®) and nabilone (Cesamet®) have 
been approved in North America and some European countries 
for appetite stimulation in AIDS-related anorexia, chemotherapy-
induced nausea/vomiting, and pain. Namisol® is the most recently 
developed THC-based formulation in tablet form but has not yet 
gained marketing approval.11
Unfortunately, preapproval clinical trials of oral THC excluded old 
persons from participation or did not include sufficient numbers, and 
most recent studies that included older participants did not perform 
separate analyses for the older subgroup.12-14 Studies of the potential 
effectiveness of THC in older individuals should include assessment 
of its safety, and especially in individuals with dementia, many of 
whom are frail and vulnerable.12 To date, only four small studies 
have investigated the safety and efficacy of THC as treatment for 
176
Chapter 6  |   Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of 
delta-9-tetrahydrocannabinol in older persons with dementia.Part IV  |  Safety, pharmacodynamics, and pharmacokinetics of oral tetrahydrocannabinol
the neuropsychiatric symptoms of dementia.15-18 All studies found 
THC to be effective and safe in older people with dementia, but as 
the studies were either not randomized or included a limited number 
of patients, it is not possible to draw firm conclusions about the 
safe and effective use of THC in these individuals. Furthermore, 
none of the studies investigated the pharmacokinetics of THC in this 
population. We found only one study in the literature that evaluated 
plasma THC concentrations (peak levels only) in older individuals 
(age 51–78 years), but these individuals were not demented.19 
Drug pharmacokinetics and pharmacodynamics in older people 
may be altered by age-related physiological changes, multiple 
comorbidities, or use of other medications. Aging is accompanied by 
an increase in adipose tissue, a decrease in lean body mass, and a 
decrease in total body water,20 changes which increase the volume 
of distribution of lipophilic drugs such as THC. Moreover, a decrease 
in hepatic blood flow and the slower metabolism of older individuals 
can slow the elimination of lipophilic drugs, thereby potentially 
increasing exposure and side effects.21 In addition, dementia-
related changes in brain volume, number of neurons, and alteration 
in neurotransmitter sensitivity make older patients with dementia 
more sensitive to drugs that act on the central nervous system.20 
Taken together, we hypothesize that the administration of THC to 
older people with dementia may lead to a higher THC concentrations, 
which subsequently lead to an increase in pharmacodynamic effects, 
including adverse effects, compared with previously published data 
for young adults11 or healthy older individuals without dementia.22 
Understanding the pharmacodynamics and pharmacokinetics of 
THC in older, frail, dementia patients will help clinicians to minimize 
side effects and maximize benefit. Therefore, the aim of the 
present study was to evaluate the safety, pharmacodynamics, and 
pharmacokinetics of multiple oral doses of THC in older persons with 
dementia.
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Methods
Study design and participants
This study was part of a multicenter, phase II, repeated 
crossover, randomized, double-blind, placebo-controlled, multiple-
dose escalation trial of the effectiveness of THC in the treatment 
of the neuropsychiatric symptoms of dementia [http:// www.
clinicaltrials.gov, clinical trial identifier number NCT01302340]. The 
study was carried out at the Radboud University Medical Center, 
the Netherlands. Results concerning the effectiveness of THC in the 
management of the neuropsychiatric symptoms of dementia will be 
reported separately.
Figure 1 provides an overview of the study design. The study 
consisted of two treatment periods, A and B. Each period consisted 
of three treatment blocks, resulting in a total of six blocks (period A, 
blocks 1 to 3; period B, blocks 4 to 6). Each block lasted 2 weeks, 
giving a total study duration of 12 weeks. In each block, participants 
received oral Namisol®, a novel THC in tablet form,11 and matching 
placebo (ratio 1:1) in a double-blind crossover manner for 3 days, 
separated by a 4-day washout period. In period A, patients received 
0.75 mg THC twice daily, and in period B, the dose was increased to 
1.5 mg twice daily. Namisol® and placebo were identical in appearance 
and taste, and both were taken under nonfasting conditions with 
water at 10 a.m. and 4 p.m. Study participants stayed overnight at 
the study site on the three intervention days (THC and placebo) of 
blocks 1 and 4 for safety reasons and to facilitate blood sampling, 
resulting in a total of four 3-day admissions. The randomization 
codes were generated by an independent pharmacist, using a 
computer algorithm for random numbers. Sponsor, investigators, 
study staff, and participants were masked to assignment.
Participants had been diagnosed with dementia type Alzheimer, 
vascular dementia, or mixed Alzheimer/vascular dementia, according 
to the National Institute of Neurological and Communicative 
Disorders and Stroke–Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRA)23 or Association Internationale pour la 
Recherché et l’Enseignement en Neurosciences (NINCDS-AIREN)24 
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criteria. All patients had had clinically relevant neuropsychiatric 
symptoms, including at least agitation and/or aggression, in the 
past 30 days (Neuropsychiatric Inventory score ≥ 10),25 and had 
an informal caregiver who looked after the participant at least once 
a week. Main exclusion criteria were major psychiatric disorders 
(e.g., major depression or suicidal ideation, psychosis, mania, or 
current delirium), current history of severe comorbidities, frequent 
falling due to orthostatic hypotension, history of current alcohol 
or drug abuse, and use of tricyclic antidepressants, opioids, or 
drugs from a predesigned list of cytochrome (CYP)2C9, CYP2C19, 
and CYP3A4 inhibitors. Written informed consent was obtained 
from participants (if they were able to consent and to sign) and 
their legal representatives. The study was approved by the local 
ethics committee and was performed according to the International 
Conference on Harmonization guideline for good clinical practice, 
the ethical principles of the Declaration of Helsinki, and relevant 
Dutch laws and regulations.
Safety and tolerability assessments
The safety and tolerability of THC were assessed subjectively and 
objectively, by evaluating the incidence and severity of adverse events, 
carrying out physical examinations, laboratory tests (hematology 
and clinical chemistry), and a 12-lead electrocardiogram, and 
assessing vital signs. The psychedelic effects were assessed with 
visual analogue scales (VAS), and body sway (postural stability) 
was measured using the SwayStar™ (see details below). During the 
study period, adverse events reported by patients and caregivers 
or observed clinically were recorded with regard to their time of 
onset, severity, duration, and causal relationship to study drugs. The 
causality was assessed by a research physician, blinded to treatment 
allocation, using a five-point scale: (1) unrelated, adverse event was 
clearly not related to the intervention; (2) unlikely, adverse event was 
doubtfully related to the intervention; (3) possible, adverse event 
may be related to the intervention; (4) probable, adverse event was 
likely related to the intervention; and (5) definite, adverse event 
was clearly related to the intervention. A serious adverse event 
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was defined as any event that was fatal or life-threatening, that 
required (prolonged) hospitalization, or that resulted in persistent 
or significant disability or incapacity. All adverse events were coded 
using the Medical Dictionary for Regulatory Activities.
Pharmacodynamic effects
The scores for psychedelic effects, body sway, and vital signs 
were used to evaluate the pharmacodynamic effects of THC.
1. Psychedelic effects: The Bowdle VAS for psychedelic effects 
was used to evaluate feeling high, internal perception (inner 
feelings that do not correspond with reality, including mistrustful 
feelings), and external perception (misperception of an 
external stimulus or change in awareness of surroundings).26, 
27 Subjects were asked to score their perceptions on a 100-
mm horizontal line, with “0” indicating no effect and “100” 
indicating extreme effect. The VAS was assessed 1 and 3 h 
after dosing on day 1 of weeks 1, 2, 7, and 8, in patients 
who were able to understand the instructions and perform the 
task. A recent study showed that individuals with dementia 
can use the VAS in a similar way to those without dementia.28
2. Body sway: Body sway was assessed within 2 h of dosing on 
the second day of admission of weeks 1, 2, 7, and 8. Body 
sway was measured (30 s eyes open and 30 s eyes closed) 
with the SwayStar™, a wireless device attached to the trunk 
(http://www.b2i.info/web/index.htm).
3. Vital signs: Systolic and diastolic blood pressure and heart 
rate were measured on day 1 of weeks 1, 2, 7, and 8, before 
and at 15, 30, 45 min, and 1, 2, 3, and 4 h after the first dose.
Blood sampling and laboratory analysis
Venous blood samples were collected during hospital admission 
before and at 11, 30, 45 min, and 1, 1.5, 2, 3, 4, and 6 h after the 
first dose, and before and at 11, 30, 45 min, and 1, 1.5, 2, 3, 4, 6, 
and 18 h after the second dose (in total covering a 24-h period). 
Plasma was separated by centrifugation (2000 × g, 4 °C, 10 min) 
and stored at −80 °C until analysis. After unblinding, blood samples 
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collected in the THC treatment period were analyzed at the Analytisch 
Biochemisch Laboratorium b.v. (Assen, the Netherlands), using 
liquid chromatography with tandem-mass spectrometer detection. 
The lower limit of quantification was 0.1 ng/mL for THC and its 
active metabolite 11-OH-THC. The analysis was performed using a 
validated assay according to good laboratory practice standards.29
Pharmacokinetic analysis
Noncompartmental analysis was performed using Phoenix 
WinNonlin software version 6.3 (Certara, L.P./Pharsight Ltd) to 
determine the pharmacokinetics of THC and 11-OH-THC. The 
following pharmacokinetic parameters were calculated for the 24-h 
period: terminal half-life (t1/2), area under the curve (AUC) from 0 to 
24 h (AUC0–24h), and apparent clearance (CL/F, being the dose/AUC0–
24h). The following parameters were calculated for the two curves 
(curve 1, 0–6 h after the first THC dose; curve 2, 6–24 h after the 
second dose) separately: the maximum plasma concentration (Cmax), 
the time to reach Cmax (tmax), AUC from 0 to 6 h (AUC0–6h), and AUC 
from 6 to 24 h (AUC6–24h), using the linear-up log-down trapezoidal 
rule. Concentration-time graphs were plotted for the two doses. 
Geometric means plus 95 % confidence intervals were calculated for 
each pharmacokinetic parameter for each dose. The coefficients of 
variation (CV%) of the geometric means were calculated to describe 
the interindividual variability in pharmacokinetic parameters. The 
geometric mean ratio (GMR) plus 90% confidence intervals of AUC0–
24h, CL/F, and t1/2 of the 1.5 mg dose versus the 0.75 mg dose were 
also calculated.
Statistical analysis
This study is descriptive and explorative, and therefore, no sample 
size calculation was performed. Descriptive statistics were used 
to describe the study population. Continuous data are expressed 
as means ± standard deviation (±SD), and categorical data are 
expressed as frequencies and percentages. The compliance to study 
medication was calculated for the whole study sample. Differences 
in adverse event rates between THC and placebo were compared by 
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Wilcoxon signed ranks test. The VAS scores were clustered and log-
transformed, and the scores are expressed as units, as described 
previously.11, 27 The 90% range of pitch velocity (anterior–posterior 
movements) scores of the SwayStar™ was used to analyze body 
sway. Scores are given in degrees per second. The VAS, body sway, 
and vital signs scores were analyzed in relation to the THC dose, 
using linear mixed models with participants as a random effect. 
Statistical analyses were performed using SAS™ software, version 
9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Participants
The data of ten patients with dementia were analyzed. Their 
demographic characteristics are summarized in Table 1. The mean 
age of participants was 77.3±5.6 years; their mean body mass 
index was 25.7±2.7 kg/m2; seven participants were men; and nine 
participants had Alzheimer’s disease. Overall, treatment compliance 
to study medication was high, and almost 98% (THC 99%; placebo 
97.5%) of the trial drugs were taken.
Safety and tolerability assessments
All participants completed the study as scheduled. In general, 
THC was safe and well tolerated by these older individuals with 
dementia. In total, 98 adverse events were reported during the 
study period. More adverse events were reported with placebo 
(55 adverse events) than with THC (43 adverse events) (period A, 
0.75 mg THC 21 adverse events and placebo 30 adverse events, 
p=0.290; period B, 1.5 mg THC 22 adverse events and placebo 25 
adverse events, p=0.435).
Thirteen (13 %) of the reported adverse events were considered 
to be possibly (n=12) or probably (n=1) related to study drugs (THC 
and placebo). Of these, only six adverse events (6% of total adverse 
events) were considered to be (possibly) related to THC, two with 
0.75 mg (dizziness and fatigue in one patient each), and four with
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1.5 mg (agitation in three patients and fatigue in one patient). All 
were mild and transitory in nature. There were no THC-related serious 
adverse events. THC treatment was not associated with changes in 
the patients’ physical state, laboratory test results (hematology and 
clinical chemistry), or ECG parameters (e.g., QT and RR intervals).
Pharmacodynamic results
THC did not cause significant changes in scores for VAS feeling 
high, VAS external perception, body sway with eyes open, and 
diastolic blood pressure (Table 2). The 0.75-mg dose, but not 
the 1.5 mg dose, was associated with a statistically significant 
increase in VAS internal The 1.5 mg dose, but not the 0.75-mg 
dose, significantly increased body sway with eyes closed (0.59°/s, 
95% CI 0.13, 1.06). The 0.75 mg dose significantly decreased 
systolic blood pressure (−7.2 mmHg, 95% CI −11.4, −3.0), 
whereas the 1.5 mg dose significantly increased systolic blood 
pressure (5.1 mmHg, 95% CI 1.0, 9.2). Heart rate increased 
significantly after the administration of the 0.75 mg dose only 
(2 beats/min, 95% CI 0.4, 3.8). None of the changes in the 
pharmacodynamic parameters was associated with an adverse event. 
perception scores (0.025 units, 95% CI 0.010, 0.040).
Pharmacokinetic results
Pharmacokinetic parameters are summarized in Tables 3 and 4. 
The data of one person were excluded because no blood samples 
were taken after the first THC dose of 0.75 mg, and only a limited 
amount of blood was taken after the second dose. Although one 
subject was non-Caucasian, his pharmacokinetic data were within 
the range of the others. The median tmax was between 1 and 2 h 
and was not dose dependent. For the 0.75-mg dose, the median 
tmax was reached 1.5 h (range 0.75 – 3.08) after the first dose and 
2 h (range 0.5 – 2.07) after the second dose; for the 1.5-mg dose, 
the median tmax was reached 1h (range 0.5 – 2.2) after the first 
dose and 2 h (range 0.5 – 3.02) after the second dose (Table 3). 
Plasma concentrations of THC and 11-OH-THC increased linearly 
with increasing dose, but there was considerable interindividual
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Table 1   Baseline demographic characteristics
Characteristics n = 10
Male, n (%) 7 (70)
Age, mean (SD) years 77.3 (5.6)
BMI, mean (SD); kg/m-2 25.7 (2.7)
Ethnicity, n
   Caucasian
   Other
9
1
Type of dementia, n
   Alzheimer
   Vascular
   Mixed
9
0
1
MMSE score, mean (SD) 18.5 (6.0)
Smokers, n 0
Comorbidities, n
Cardiac rhythm disorder
Hypertension
Ventricular hypertrophy
Diabetes
Electrolyte disturbances
Kidney function disorder
Vitamins deficiency
Hypercholesterolemia
Liver function disorder
Orthostatic hypotension
5
5
3
2
2
2
2
1
1
1
Medications, n
Anti-dementia drugsa
   Memantine
   Rivastigmine
   Galantamine
Antihypertensivesa
Anticoagulants
Blood glucose lowering drugs
Antidepressants
Antiepileptics
   Antipsychotics
   Proton pump inhibitor
   Other
16
9
5
2
11
4
3
1
1
1
1
12
a Some participants used a combination of drugs within the 
same medication group
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variation in plasma concentrations and hence in pharmacokinetic 
parameters (Figure 2). For THC, Cmax and AUC CV% ranged from 
90 to 140%, and for 11-OH-THC from 38% to 62%. The elimination 
phase of THC was faster than that of 11-OH-THC. The geometric 
mean ratio of the THC AUC0–24h versus the 11-OH-THC AUC0–24h was 
1.7 (95% CI 1.1, 2.9) and 1.9 (95% CI 1.0, 3.6) for the 0.75- 
and 1.5-mg doses, respectively. Individual THC and 11-OH-THC 
AUCs are presented in Figure 3. Two participants had a high THC 
exposure after the 0.75-mg dose. Their AUC0–24h was 8.0 and 8.4 
ng h/mL compared with a value ranging between 0.9 and 2.7 ng h/
mL in the other participants. Three participants had a high exposure 
after the 1.5-mg dose. Their AUC0–24h was 13, 19, and 20 ng h/mL 
compared with a value ranging between 1.2 and 4.1 ng h/mL in 
the other participants. One participant had a greater increase in 
THC AUC after the 1.5-mg dose than the other participants; the 
AUC GMR for this subject was 7 compared with 1.7–2.5 (range) for 
the other participants. The same was seen for 11-OH-THC, but less 
pronounced (Figure 3).
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Figure 2      The mean concentration time profiles of THC and 11-OH-
THC for both the 0.75- and 1.5-mg doses over 24 h
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Figure 3     Individual pharmacokinetic parameter graphs
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Table 4   Geometric mean ratios of THC and 11-OH-THC
.
Parameters THC 11-OH-THC
AUC0-24 (ng/mL
-1h) 2.40 (1.83-3.16) 2.25 (1.82-2.77)
CL/F (L/h) 0.83 (0.63-1.10) 0.89 (0.72-1.10)
t1/2 (h) 1.00 (0.72-1.39) 0.88 (0.58-1.34)
Geometric mean ratio 1.5 mg versus 0.75 mg over one dosing interval 
(90% CI)
Discussion
Safety and tolerability
Older people with dementia and physical comorbidity could greatly 
benefit from the therapeutic application of cannabinoids. Recent 
studies have demonstrated that low doses of THC are effective in 
protecting the brain from neuro-inflammation-induced cognitive 
damage.30-32 Although THC-based drugs have recently been approved 
for clinical use, there are only few data on their safety in older 
individuals with dementia. Our data demonstrate that THC doses 
of 0.75 and 1.5 mg twice daily are safe and well tolerated by older 
individuals with dementia. Only 6 of the 98 reported adverse events 
were related to THC treatment. All adverse events were mild and 
resolved spontaneously without any intervention. Our findings are 
in line with previously published studies showing that THC doses up 
to 5 mg/day are safe to use in older individuals with dementia.15-17 It 
is important to note that the safety data presented in this study are 
based upon short-term use of THC in older subject with dementia. 
Further studies are warranted to evaluate the long-term use of THC 
in this population.
Pharmacodynamics
Overall, THC had fewer pharmacodynamic effects, including 
adverse events, than we had expected for frail older individuals with 
dementia, based on the effects reported by Klumpers et al.11 in young 
adults (mean age 21 years). We found no statistically significant 
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changes in participants’ feeling high, external perception, body 
sway with the eyes open, and diastolic blood pressure after THC. 
The changes in internal perception, body sway with eyes closed, 
systolic blood pressure, and heart rate after THC were not considered 
clinically relevant, as they were small and were not associated 
with adverse events. The current findings are consistent with our 
previous findings from a phase 1 study of Namisol® in healthy older 
individuals without dementia (n=11, mean age 72 years).22
Pharmacokinetics
On the basis of the AUC and Cmax values, THC has linear 
pharmacokinetics in elderly individuals with dementia, showing a 
doubling of the AUC and Cmax with doubling dose from 0.75 to 1.50 mg. 
However, there was considerable interindividual variation in plasma 
concentrations of THC and 11-OH-THC, which is in line with our data 
from a phase 1 study involving healthy older individuals,22 and with 
the results of studies involving individuals of different ages.11, 19, 33 
The median tmax was reached 1–2 h after THC dosing, as has been 
previously reported for healthy older individuals without dementia.22 
In contrast, Klumpers et al.11 reported a shorter tmax between 39 and 
56 min in young adults after Namisol® administration. The AUC0–6h 
for older persons with dementia was two times higher than would 
be expected on the basis of data for young adults administered 
Namisol® (individual concentrations were retrieved and AUC0-6h was 
calculated).11 A possible explanation for the discrepancies in tmax and 
AUC0–6h is that, in the current study, THC was taken in non-fasting 
state, whereas Klumpers et al.11 administered THC to fasting young 
adults. Stott et al.34 in their investigation of the effect of food on the 
absorption and bioavailability of cannabinoids, found that the tmax 
for THC was reached about 2–2.5 h later in the fed state than in the 
fasting state: the mean AUC and Cmax for THC and 11-OH-THC were 
one fold and threefold higher, respectively, in the fed state than in the 
fasting state. Age-related factors, such as delayed gastric emptying 
time, decreased splanchnic blood flow, decreased gastrointestinal 
motility, and decreased absorption surface, could also affect the 
absorption and bioavailability of THC in older individuals. It was not 
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possible to compare our data with data from other pharmacokinetic 
studies involving older individuals with dementia because we did 
not find any relevant studies that reported data separately for this 
group.
The relatively high THC exposure in two participants seems to 
have been due to a diminished metabolism of THC to 11-OH-THC, 
as in both participants the 11-OH-THC/THC ratio of the AUC0–24h was 
less than 1 for both doses, whereas it was almost 2 in the other 
participants. However, the sum of 11-OH-THC plus THC AUC0–24h was 
higher in these two participants than in the other participants, but 
this higher THC exposure was not associated with adverse events.
Strengths and limitations
The main strengths of the current study were, first, its design. 
In this randomized, double-blind, placebo-controlled, repeated 
crossover study, study staff and participants were masked to 
assignment and participants served as their own control. This design 
strengthened the validity of the safety and pharmacodynamic data. 
Second, our study is the first to evaluate the pharmacokinetics and 
pharmacodynamics of THC in older individuals with dementia, a frail 
subgroup of older persons. Therefore, this study can be added to 
the limited literature available on this subject.
The most notable limitation is that we probably used a very low 
THC dose-escalation regimen, 0.75 to 1.5 mg, as only 6 of the 
98 reported adverse events were related to THC treatment and 
the pharmacodynamic effects were in general smaller than we 
had expected for this subgroup of older persons. A future dose-
escalation study is required to determine the maximum tolerable 
dosage. This will help to maximize effectiveness while keeping side 
effects acceptable.
Conclusion
Our findings suggest that low THC doses are safe and well 
tolerated by frail older persons with dementia. Oral THC was rapidly 
absorbed, showing dose-linear pharmacokinetics with maximum 
plasma concentrations being reached between 1 and 2 h after 
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dosing, although there was considerable interindividual variability. 
Overall, THC showed smaller pharmacodynamic effects in frail older 
individuals than expected on the basis of data for young healthy 
adults. These reassuring data warrant further pharmacodynamic 
and efficacy studies with higher THC doses in older patients with 
dementia.
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ABSTRACT
OBJECTIVES: To determine the prevalence and impact of pain in 
dementia patients and the relationship between pain and behavioral 
and psychological symptoms.
DESIGN: Cross-sectional.
SETTING: Community-based.
PARTICIPANTS: Dementia patients and caregivers.
MEASUREMENTS: Pain and its impact on activities of daily living 
(ADL) and sleep at night was assessed by means of questionnaires 
completed by dementia patients and their caregivers. Behavioral and 
psychological symptoms were assessed using the Neuropsychiatric 
Inventory-Questionnaire (NPI-Q), Cohen-Mansfield Agitation 
Inventory (CMAI), and the Cornell Scale for Depression in Dementia 
(CSDD).
RESULTS: Of the questionnaires sent out to 701 patient-caregiver 
dyads, 390 (56%) were returned. The questionnaires of 386 patient-
caregiver dyads were sufficiently complete and included in the 
analysis. Mean patient age was 81.3±7.2 years. The prevalence of 
pain reported by patients and caregivers was 61%. Of those with 
pain, 72% experienced chronic pain, 50% reported pain in multiple 
locations, 29% did not use any pain medications and, 56% and 27% 
reported that pain negatively influenced their ADL and sleep at night, 
respectively. The mean total NPI-Q, CMAI, and CSDD scores were 
significantly higher in patients with pain than in patients without 
pain: 8.2 vs 5.6 (p<0.001), 42.3 vs 38.6 (p=0.012), and 7.1 vs 
4.4 (p<0.001), respectively. Also, the mean total NPI-Q caregiver-
distress score was significantly higher among caregivers of patients 
with pain than among those of patients without pain (10.3 vs 6.7, 
p<0.001).
7203
Chapter 7  |   Prevalence and impact of pain and pain-related behavioral problems in community 
dwelling dementia patients.Part V  |  Pain and pain-related symptoms in dementia
CONCLUSION: Pain is common and often undertreated among 
community-dwelling dementia patients. It is associated with 
decreased ADL, sleep disturbances, behavioral and psychological 
symptoms, and caregiver distress. Our findings underline the 
importance of routinely assessing and treating pain as part of the 
overall management of behavioral problems in dementia patients.
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Introduction
Pain is a significant and growing healthcare problem among older 
people with dementia, because aging is accompanied by an increased 
risk of chronic painful disorders including degenerative disease of 
discs and joints, osteoporotic fractures, fall-related injuries, diabetic 
neuropathy, cardiac pain, and cancer.1, 2 The reported prevalence of 
pain among dementia patients varies from 28% to 90%,3-6 with the 
wide range reflecting methodological differences between studies 
(e.g., setting, pain definition, assessment instrument/scale, pain 
location, and sample size).
The past decade has shown a growing interest in pain and pain-
related behavioral changes among older patients with dementia. 
Several studies have shown that pain management is suboptimal 
in these frail individuals because of their cognitive impairment and 
diminished communication skills, with the result that pain is often 
underreported, unrecognized, and consequently undertreated.7, 
8 Although self-report is generally considered the “gold standard” 
in the assessment of pain,9 patients with dementia, especially 
individuals with moderate and severe dementia, are often less able 
to express their pain and discomfort verbally. Instead, they may 
express their pain via facial expressions, body movements, and 
behavioral disturbances, such as agitation, aggression, aberrant 
motor disturbance, depression, and sleep problems.3 The latter 
symptoms are often not recognized as manifestations of pain, but 
are instead labeled as behavioral and psychological symptoms of 
dementia (BPSD).10, 11 This means that patients with dementia who 
experience pain are more likely to receive psychotropic medications 
than adequate pain treatment.12-14 This again may lead to functional 
decline, falls, reduced quality of life, and increased healthcare 
costs.15-17 In line with these findings, a recent study showed that 
effective treatment of pain with analgesics in patients with dementia 
(n=175) significantly improved agitation and reduced unnecessary 
prescriptions for psychotropic drugs.18 These results emphasize the 
importance of recognizing, assessing, and treating pain effectively as 
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part of the overall treatment and prevention of behavioral problems 
in dementia patients.18 
While the majority of patients with dementia still live at home, 
most studies of pain and pain-related behavioral problems have 
involved residents of long-term care facilities (e.g. residential and 
nursing homes).19 Early recognition and adequate treatment of pain 
in dementia patients living at home may prevent or reduce pain-
related behavioral changes and associated caregiver distress, and 
subsequently may delay nursing home placement.
As there is little known about pain and pain-related behavioral problems in 
patients with dementia living in the community, we aimed: first, to determine 
the prevalence of pain in this population, using information provided by both 
patients and their caregivers; second, to evaluate the impact of pain on 
activities of daily living (ADL) and sleep; third, to investigate the relationship 
between pain and behavioral and psychological symptoms in individuals with 
dementia; and finally, we discuss the potential of oral tetrahydrocannabinol, 
a cannabinoid of the cannabis plant (Cannabis sativa L.), as multi-target 
drug candidate for the management of pain and pain-related behavioral and 
psychological symptoms in patients with dementia.
Methods
The current cross-sectional, community-based, prevalence 
survey was part of the recruitment procedure of a multi-center, 
phase II, randomized, placebo-controlled, double-blind trial of 
the effectiveness and safety of tetrahydrocannabinol (THC) in the 
treatment of behavioral disturbances and pain in patients with 
dementia (ClinicalTrials.gov Identifier: NCT01608217).20 The main 
trial was approved by a certified ethics committee of the Radboud 
university medical center. According to the Dutch law on medical 
research, the current survey did not require additional approval. 
Patients and caregivers were informed about the nature and purpose 
of the survey through their case managers of the dementia-support 
organization.
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Participants and procedure 
Self-administered postal questionnaires were sent to all patients 
with dementia and their informal caregivers (701 patient-caregiver 
dyads), who received support from the local dementia-support 
organization [Help with Dementia; www.hulpbijdementie.nl] in 
North Limburg, a province in the Southeast of the Netherlands. 
To maximize the response rate, all patients and caregivers had 
the opportunity to ask their case managers for assistance with 
completing the questionnaires.
Pain questionnaire
The questionnaire was developed by the research team, with 
input from the case managers of the dementia-support organization 
and patients’ relatives (n=4). The questions were specifically 
designed to be short, understandable, easy to answer, and only 
related to current symptoms without memory dependent reporting 
of past symptoms. We used the questionnaire to collect information 
on demographics, type of dementia, severity of dementia based on 
the Clinical Dementia Rating Scale (if known),21 pain, pain-related 
behavioral and psychological symptoms, and the impact of pain 
on patients and caregivers. The questionnaire was divided into 
two parts. Part one was designed to collect information from the 
patients. The assessment of pain in this part was based on patients’ 
self-report using a single question “Do you have pain right now? 
Yes, No”. Participants who reported pain were asked to provide more 
detailed information on their pain including location(s), duration, 
cause of pain, and use of pain medications. Pain was defined as 
chronic if it lasted for more than three months. The effect of pain 
on patients’ ADL and sleep at night was assessed, based on single 
questions, “Does pain keep you from doing daily activities (e.g., 
housework, bathing, dressing, social activities)? Yes, No”; and “Does 
pain keep you from sleeping at night? Yes, No”, respectively. 
Part two of the questionnaire was designed to collect information 
from informal caregivers. In this part, the caregivers rated patients’ 
pain. The caregivers were asked single questions, which could be 
answered with “Yes” or “No”: 1) Do you think that the patient is 
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in pain?; 2) Do you think that the patients’ behavior has changed 
(since the diagnosis of dementia)?; and 3) Do you think that the 
change in patients’ behavior is related to the pain?. Caregivers were 
also asked to complete the following validated clinical instruments: 
the Neuropsychiatric Inventory-Questionnaire (NPI-Q),22 the Cohen-
Mansfield Agitation Inventory (CMAI),23 and the Cornell Scale for 
Depression in Dementia (CSDD)24, to assess changes in patient 
behavior and symptoms of depression. The impact of pain-related 
behavioral changes on caregivers was evaluated by using the scores 
of the NPI-Q, sub-question “caregiver distress”.
Statistical analysis
Analyses were performed using SPSS, version 20. Descriptive 
statistics were used to present the demographic characteristics. 
The continuous data are expressed as means ± standard deviation 
(±SD), and categorical data are expressed as frequencies and 
percentages. Questionnaires were included in the analysis if both 
patients and caregivers responded. Individuals with dementia were 
categorized as “Patients with pain”, when they or their caregivers 
said that they experienced pain. The variables NPI-Q total score, 
NPI-Q caregiver distress, CMAI and CSDD, violated the assumption 
of a normal distribution and therefore, a non-parametric test (Mann-
Whitney U) was used to compare patients with and without pain. 
In addition, a multiple regression analysis was used to determine 
the influence of presence of pain, age, gender, type of dementia, 
and severity of dementia on the total NPI-Q score. Univariate and 
multivariate analyses were performed to assess the significance of 
all variables.
Results
Patient characteristics 
Of the questionnaires sent out to 701 patient-caregiver dyads, 
390 (56%) were returned to the research office. Of these, 386 
questionnaires (patient-caregiver dyads) were sufficiently complete 
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and included in the analysis. Table 1 provides patients’ charac-
teristics. The mean age of the included patients was 81.3±7.2 years, 
61.4% (n=235) were women and 41% (n=159) were diagnosed with 
Alzheimer’s disease. The prevalence of pain was 60.9% (n=235) 
based on patient self-report and 61.9% (n=239) based on caregiver 
report, as in four questionnaires patients reported no pain whereas 
the caregivers did. Fifty-one percent (n=122) of the patients reported 
pain in one location and 48.9% (n=117) reported pain in two or 
more locations. Most patients (71.5%, n=171) experienced chronic 
pain, with musculoskeletal pain (muscles, neck, shoulders, back, 
and extremities) being the most frequently reported type of pain 
(77.3%, n=180). In total, 28.5% (n=68) of patients who reported 
pain did not use any pain medications. Overall, acetaminophen was 
the most commonly used pain medication (53.6% of the patients 
with pain), followed by non-steroidal anti-inflammatory drugs (5% 
of the patients with pain). Interestingly, 12 patients reported using 
pain medication even though they did not report pain (Table 1).
Impact of pain on ADL and sleep 
More than half of the patients with pain (56%; n=134) reported 
that pain negatively influenced their ADL and 26.8% (n=64) reported 
that pain affected their sleeping at night.
Behavioral and psychological symptoms
There were significant differences in behavioral and psychological 
symptoms between the group of patients with pain and the group 
of patients without pain (Table 2). The mean total NPI-Q, CMAI, 
and CSDD scores were significantly higher in patients with pain 
than in patients without pain (8.22 vs 5.57, p<.001), (42.26 vs 
38.57, p=.012) and (7.08 vs 4.39, p<.001) respectively. Also, 
the mean NPI-Q caregiver distress score was significantly higher 
for the caregivers of patients with pain than for the caregivers of 
patients without pain (10.32 vs 6.69, p<.001) (Table 2). Patients 
with pain had significantly higher scores than patients without pain 
on the following NPI-Q sub-scales: delusions, agitation, depression, 
anxiety, and appetite disturbances (Table 2). Patients who used
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Table 1    Demographic and clinical characteristics of participants 
with dementia
Total Patients with pain
Patients 
without pain
n (%) 386 (100) 239 (61.9) 147 (38.1)
Age, mean (SD) years 81.3 (7.2) 81.6 (7.1) 81 (7.5)
Female, n (%) 235 (60.9) 151 (63.2) 84 (57.1)
Type of dementia, n (%)
   Alzheimer’s disease 159 (41.2) 84 (35.1) 75 (51)
   Vascular dementia 63 (16.3) 44 (18.4) 19 (12.9)
   Mixed dementia* 81 (21) 56 (23.4) 25 (17)
   Other 65 (16.8) 39 (16.3) 26 (17.7)
   Not reported 18 (4.7) 16 (6.7) 2 (1.4)
CDR ratio, n (%)
   1 (mild) 163 (42.2) 93 (38.9) 70 (47.6)
   2 (moderate) 105 (27.2) 65 (27.2) 40 (27.2)
   3 (severe) 27 (7.0) 17 (7.1) 10 (6.8)
   Not reported 91 (23.6) 64 (26.8) 27 (18.4)
Use of pain medication, n (%)
    No 203 (52.6) 68 (28.5) 135 (91.8)
   Yes 183 (47.4) 171 (71.5) 12 (8.2)
   Acetaminophen 137 (35.5) 128 (53.6) 9 (6.1)
   NSAIDs 13 (3.4) 12 (5) 1 (0.7)
   Weak opioids** 8 (2.1) 8 (3.3) 0
   Strong opioids** 11 (2.8) 11 (4.6) 0
   Anti-psychotics 1 (0.3) 1 (0.4) 0
   Anti-depressants 3 (0.8) 2 (0.8) 1 (0.7)
   Anti-migraine 1 (0.3) 1 (0.4) 0
   Unknown 9 (2.3) 8 (3.4) 1 (0.7)
CDR = Clinical Dementia Rating scale; NSAID = non-steroidal anti-inflammatory 
drug.
*Mixed dementia: Alzheimer’s disease / Vascular dementia
**Weak opioids: Tramadol en codeine. Strong opioids: morphine (patch), 
oxycodone, fentanyl (patch) 
     and buprenorphine (patch)
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pain medication had significantly higher scores on both the CMAI 
(p=.021) and CSDD (p=.004) compared to patients who did not 
use any medication for their pain. In the multivariate model, the 
presence of pain and the severity of dementia predicted 9.6% of 
the total NPI-Q score (p<.001), whereas age, gender and type of 
dementia did not contribute significantly to the prediction of the 
total NPI-Q score.
Discussion
This study, with a large sample size, confirms the high prevalence 
and impact of pain in patients with dementia who are still living 
at home. Our data show that over 60% of patients with dementia 
living at home experience pain, using both self-report and caregiver-
report. Pain affected their ADL, sleeping at night, and it is significantly 
related to their behavioral disturbances.
To the best of our knowledge, there are only six studies in the literature 
(PubMed, up to March 01, 2016), that reported the prevalence of pain in 
community-dwelling dementia patients using both self-report and caregiver-
report.25-30 Table 3 summarize these studies. Compared to most studies, our 
study shows a higher pain prevalence, with a higher degree of concordance 
between patient and caregiver reports of patients’ pain (61% and 62%, 
respectively). However, Hunt et al.30 recently reported a similar prevalence 
and concordance rates between patient and caregiver reports (62.7% and 
64.4%, respectively) in a large study of 802 patient-caregiver dyads. It is 
important to mention that our data cannot be directly compared with those 
of the studies of table 3, due to methodological differences in study design, 
sample size, pain assessment tools, and measured pain duration. However, 
all these studies address the high prevalence of pain in dementia patients who 
are still living at home and the importance of assessing and treating pain in this 
population, specifically in the presence of physical frailty. The majority of our 
patients with pain experienced chronic pain (72%), with musculoskeletal pain 
being the most common type of pain (77%), and women (63%) were more 
likely to experience pain than were men (37%). These findings are consistent 
with those of previously published studies.25-31 Another important finding was 
the high prevalence (almost one third) of untreated pain among respondents 
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who experienced pain. Several factors may contribute to this undertreatment. 
For example, many older adults/caregivers may consider pain to be a natural 
part of aging and therefore do not seek medical treatment. Also, pain may 
not be reported by patients or recognized by caregivers/physicians, because 
of patients’ diminished communication skills. Lack of awareness among 
physicians and other health care providers may also contribute to under-
recognition of pain in dementia patients.
Impact of pain on ADL and sleep
Fifty-six percent of our patients with pain reported that pain 
interfered with ADL and one third reported that pain negatively 
influenced their sleep at night. The relationship between daytime 
physical inactivity and pain-related sleep disturbances may be cyclical, 
since sleep disturbances lead to persistent fatigue and excessive 
daytime sleepiness, resulting in decreased daytime functioning.32 
Increased physical activity is recognized as an important factor in 
decreasing behavioral disturbances and improving cognitive function, 
social interaction, and quality of life in people with dementia.33, 34 
Pain limits physical activities, either because activities exacerbate 
pain or because individuals fear pain induced by these activities. 
These two factors, “feeling pain” and “fear of feeling pain”, may 
also reinforce each other, leading to a vicious circle together with 
impaired functioning and dependence.35
Pain and behavioral and psychological symptoms
Currently, most of the available information regarding the 
association between pain and pain-related behavioral disturbances 
in dementia has come from studies conducted in nursing home 
residents,19 with much less information available from studies 
conducted in community-dwelling dementia patients.6, 28, 29 Our 
data show that pain was significantly associated with behavioral 
and psychological symptoms in patients with dementia who are still 
living at home. Previous studies have consistently demonstrated the 
negative impact of behavioral and psychological changes among 
dementia patients on caregivers.6, 15, 36-38 In the literature, depression, 
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agitation, aggression, psychosis, and sleep disturbances were most 
commonly cited as symptoms that caregivers found distressful.39 In 
fact, all these symptoms were common in our dementia patient with 
pain. 
Interestingly, patients who used pain medication had significantly 
higher CMAI (agitated behavior) and CSDD (depressive symptoms) 
scores than patients who did not use any medications for their pain. A 
possible explanation for this finding is that the patients on analgesic 
therapy may have experienced more severe pain, which was not 
well controlled, while the patients without analgesics may have 
experienced milder pain, which did not necessitate pain medications 
so far.
Strengths and limitations
Our findings, which are based on a large sample, contribute to 
the sparse literature on the prevalence and impact of pain and pain-
related behavioral symptoms in patients with dementia who are still 
living at home. However, a number of methodological limitations 
should be considered when interpreting the results. First, while 
our questionnaire included validated measurement scales such as 
NPI-Q, CMAI and CSDD, the questions about pain and their impact 
were newly developed by the research team, though these questions 
bear significant resemblance to other validated scales such as the 
Brief Pain Inventory and the Three-item Scale PEG.40, 41 Second, 
the data collection was based on patient and caregiver report, 
which may have been influenced by the cognitive functions of the 
individuals with dementia. For example, answers may have been 
subject to recall bias. Although self-report is considered the gold 
standard in pain assessment, its validity in people with dementia 
is questionable because these individuals often have disturbed 
perception, thought content, expression, and communication skills. 
Therefore, we strongly recommended that self-report should always 
be accompanied by caregiver observation. Third, pain at a single 
time point, namely “right now”, was the variable being examined to 
determine the prevalence of pain, and not pain over a longer period 
of time (weeks or months). This may have led to underestimation 
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of the prevalence of pain. Fourth, the severity of pain was not 
evaluated in our study. Data regarding pain severity may help to 
improve our understanding of the relationship between pain severity 
and the occurrence of specific behavioral symptoms in dementia 
patients.6 Finally, we did not collect information about whether our 
patients were helped to complete the questionnaires by the case 
managers or caregivers, which may have introduced bias that led 
to a higher degree of concordance between patient and caregiver 
reports of patients’ pain.
Clinical implications and future directions
The management of pain and pain-related behavior disturbances 
in patients with dementia is a complex issue, with numerous 
controversies within the current evidence-base. For example, 
previous studies and clinical guidelines consistently reported the 
importance of enhancing pain assessment in patients with dementia, 
especially in those with diminished communication skills.31, 42-45 
However, currently there are no standardized assessment tool for 
pain in nonverbal older people with dementia, and most available 
tools have poor reliability, validity and clinical utility.42-45 In addition, 
despite the fact that enhancing pain assessment may improve pain 
management, information regarding pharmacological interventions 
for pain in dementia patients is lacking in the literature.43, 44 
Furthermore, currently available analgesics such as acetaminophen, 
non-steroidal anti-inflammatory drugs, opioids, antidepressants, 
anticonvulsants, neuroleptics, and corticosteroids, are often 
ineffective, contraindicated, or cause severe adverse events in 
older people with dementia,11, 43 which contribute to undertreatment 
of pain in this population. There are still significant gaps in the 
evidence-base that limit the accurate assessment and the effective 
management of pain in people with dementia. Further research 
is urgently warranted to develop reliable and valid observational 
instrument for assessing pain in clinical and nonclinical settings, and 
to develop novel therapies for pain in this frail population.
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Tetrahydrocannabinol as a multi-target drug candidate 
for pain and pain-related behavioral and psychological 
symptoms in dementia
As mentioned in section “METHODS”, this study was part of 
the recruitment procedure of a randomized, placebo-controlled, 
double-blind trial of the effectiveness tetrahydrocannabinol (THC) 
in the treatment of behavioral disturbances and pain in patients 
with dementia.20 THC is the main psychoactive cannabinoid of the 
cannabis plant (Cannabis sativa L.), and appeared to be responsible 
for most of its physical effects.46 Several randomized controlled 
trials have demonstrated the potential role of THC in the treatment 
of pain.47 THC exerts some of its multiple therapeutic effects 
through an interaction with the endocannabinoid system. THC acts 
as a partial agonist of the two cannabinoid receptors, CB1, which 
mainly located in the central, and peripheral nervous systems, and 
CB2, which primarily found in cells of the immune system.48-50 Also, 
THC exerts effects by interacting with other cannabinoid and non-
cannabinoid receptors in the brain, such as acetylcholine, dopamine, 
serotonin, gamma-aminobutyric acid, glutamate, norepinephrine, 
prostaglandins, and opioid peptides.51 This broad and complex 
interactions reflect the potential of THC as multi-target drug 
candidate for the treatment of pain and behavioral disturbances 
in dementia patients. However, the data of our recently published 
study,20 showed that THC dose up to 4.5 mg daily did not improve 
pain intensity (assessed with Verbal Rating Scale),52 and pain-related 
behavior [assessed with Pain Assessment Checklist for Seniors with 
Limited Ability to Communicate (PACSLAC-D)],53 in older patients 
with dementia, compared to placebo.  In fact, these results must 
be understood within the context of several major limitations. First, 
the small number of participants in the subgroup of pain (total: 23 
participants: THC 8 and placebo 15); and second, the diminished 
communication skills in dementia patients that influence the ability 
to self-report. In our study, only 13 out of the 23 participants with 
pain were able to respond to the Verbal Rating Scale (self-reporting). 
Moreover, although the observational tool PACSLAC-D has strong 
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psychometric properties and is simple to use,18 the tool contains 
observation items that are not specifically for pain, but overlap 
with those of behavioral and psychological symptoms of dementia. 
Therefore, it is often difficult to distinguish whether the observed 
behaviors are pain-related or dementia-related behaviors. Finally, 
in order to prevent side-effects we probably used too low oral THC 
doses, as the overall results of the pharmacodynamic parameters of 
THC such as effectiveness, side effects, systolic and diastolic blood 
pressure, and heart rate, were small.20
Conclusion
Pain was common and often undertreated among community-
dwelling dementia patients. It was associated with diminished ADL, 
sleep disturbances, behavioral and psychological symptoms, and 
caregiver distress. Overall, our findings support the importance of 
routinely assessing whether individuals with dementia are in pain, in 
order to treat pain and to reduce the burden of pain-related behavioral 
problems in dementia patients and its associated caregiver distress. 
However, the loss of communication ability in dementia patients 
limits self-report of pain. Therefore, a standardized, reliable, and 
valid observational tool is needed for assessing pain in nonverbal 
patients in clinical and nonclinical settings. Facial expressed emotion 
recognition software, if also valid in recognizing mood changes 
in dementia, are an exciting new option for early pain detection. 
In addition, there is a strong need for novel effective and safe 
pharmacological interventions for pain and behavioural disturbances 
in dementia. Although oral THC is a potential multi-target drug 
candidate, more randomized controlled trials are needed to evaluate 
its effectiveness and safety in the treatment of pain and pain-related 
behavioral disturbances in older people with dementia.
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To the Editor: Greater risk of dementia and painful chronic 
conditions or diseases, such as degenerative disc and joint disease, 
diabetic neuropathy, and cancer, accompany aging.1 Thus, many older 
individuals with dementia may be in pain. The reported prevalence 
of pain in elderly adults varies from 28% to 88%,2–4 the wide range 
probably being due to differences in sample sizes, setting, onset and 
type of pain, and methods used to measure pain.
WHAT IS THE PROBLEM?
Pain is difficult to assess and treat in individuals with dementia. 
Although self-report is generally considered the best way to assess 
pain, this is difficult in individuals with dementia, especially those 
with moderate to advanced dementia, because they are less able 
to articulate the pain and discomfort they feel.5 Instead, they 
may express their pain and discomfort behaviorally, as agitation, 
aggression, pacing, wandering, screaming, yelling, and sleep 
disturbances, although these behaviors are often not recognized 
as symptoms of pain but instead as behavioral and psychological 
symptoms of dementia6 so that individuals with dementia are more 
likely to receive psychotropic medication, and not pain medication, 
to treat these manifestations of pain.7 
Over the past decade, a number of observational pain scales have 
been developed for use in nonverbal older persons with dementia,5, 
8 but there is no standardized assessment tool. Moreover, most 
available instruments have poor reliability and validity. A randomized 
controlled trial reported that the use of a stepwise pain protocol 
based on the treatment recommendations of the American Geriatrics 
Society significantly reduced behavioral disturbances and pain in 
individuals with moderate to severe dementia (n=175),9 indicating 
that adequate treatment of pain reduces behavioral disturbances, 
but currently available drugs for the management of pain, such 
as acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, 
antidepressants, and antiepileptic drugs, are often not effective or 
cause serious adverse reactions in older persons.
8
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CANNABINOIDS AS A MULTITARGET DRUG 
CANDIDATE
Recent studies have demonstrated the potential of cannabinoids, 
including delta-9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD), to manage the symptoms of pain and dementia.10 Two 
cannabinoid receptors, CB1 and CB2, mediate the psychoactive, 
behavioral, and analgesic effects of cannabinoids. CB1 receptors 
are highly expressed in the cortex, basal ganglia, cerebellum, and 
hippocampus, whereas CB2 receptors are mainly expressed in the 
immune system.11 Cannabinoids also interact with other receptors 
and neurotransmitters in the brain, such as acetylcholine, dopamine, 
gamma-aminobutyric acid, serotonin, glutamate, norepinephrine, 
prostaglandins, and opioid peptides.11 This wide range of interactions 
reflects the potential pharmacological effects of cannabinoids in the 
management of behavior, mood and pain. 
Cannabinoid-based medicines, such as dronabinol (THC), 
nabilone (THC) and nabiximols (combination of THC and CBD), 
have been recently become available in some countries, and a 
systematic review of randomized trials showed them to be effective 
in the management of pain, being safe and well tolerated,10 but 
none of the 18 trials included in the review recruited participants 
with dementia or provided separate data for older persons (≥ 65), if 
these individuals were included in the study. 
To the best of the knowledge of the authors, there have been 
only two randomized clinical trials of the effect of cannabinoids on 
behavioral disturbances in individuals with dementia. In both trials, 
participants with Alzheimer’s disease were treated using dronabinol. 
The first trial reported that 2.5 mg of THC twice a day was effective 
in the treatment of anorexia and behavioral disturbances, and the 
second reported that 2.5 mg of THC once a day reduced nocturnal 
motor activity and agitation,12,13 although both trials were small, 
involving 12 and two participants, respectively.
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WHAT NEEDS TO HAPPEN
Accurate assessment of pain is crucial for adequate pain 
management. In turn, this requires a reliable and valid observational 
tool for assessing pain in nonverbal individuals with dementia in 
clinical and nonclinical settings. Although cannabinoids are a 
potential multitarget treatment, randomized controlled trials are 
needed to evaluate their safety and efficacy in the treatment of 
pain and pain-related behavioral disturbances in older adults with 
dementia.
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Summary 
The main aim of the studies described in this thesis was to 
evaluate the clinical pharmacology of oral tetrahydrocannabinol 
(THC) in older people with dementia, specifically:
1. To evaluate current evidence in the literature on the medicinal 
use of cannabis and cannabinoids in older people (PART II);
2. To evaluate current evidence in the literature on the potential 
of cannabinoids in the treatment of late-onset Alzheimer’s 
disease and related neuropsychiatric symptoms (PART III);
3. To evaluate the pharmacodynamic (including side effects) 
and pharmacokinetic effects of oral THC in older people and 
individuals with dementia (PART V);
4. To evaluate the effectiveness of THC in the treatment of 
neuropsychiatric symptoms of dementia (PART IV);
5. To evaluate the effectiveness of THC in the treatment of pain 
and pain-related behavioral disturbances in older people with 
dementia (Chapter 4 and PART VI).
PART II    Cannabinoids for older people with 
dementia
In Chapter 1, we performed a systematic review to integrate 
evidence on the indications, efficacy, and safety of medical 
cannabinoids in older people. Despite the large number of studies 
of cannabinoids in the general population (1296 articles), only five 
randomized clinical trials were identified that reported separate data 
for older individuals. On the basis of these studies, cannabinoids 
would appear not to be effective in the treatment of dyskinesia, 
breathlessness, and chemotherapy-induced nausea and vomiting. 
Two studies with small samples (n=2 and n=15) showed that THC 
might be useful in the treatment of anorexia and dementia-related 
behavioral symptoms. The most frequently reported cannabinoid-
related adverse events were sedation-like symptoms (e.g., 
drowsiness, tiredness and somnolence).
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In Chapter 2, based on evidence in the literature (in vitro, in 
vivo and population-based studies), we reviewed the potential of 
cannabinoids in the treatment of late-onset Alzheimer’s disease 
and related neuropsychiatric symptoms. Several in vitro and in 
vivo studies have demonstrated that targeting the endocannabinoid 
system offers a novel pharmacological approach to the treatment 
of late-onset Alzheimer’s disease that may be more effective than 
currently available drugs. A number of studies have shown that 
cannabinoids can reduce oxidative stress, neuroinflammation, 
and the formation of amyloid plaques and neurofibrillary tangles, 
the hallmarks of late-onset Alzheimer’s disease. Moreover, the 
cannabinoid THC seems to increase the availability of acetylcholine 
and prevent acetylcholinesterase-induced Aβ aggregation. 
Unfortunately, our literature search did not identify any population-
based studies of cannabinoids as a potential cure for this type 
of Alzheimer’s disease. We found only four clinical studies of the 
effectiveness of cannabinoids in the treatment of dementia-related 
symptoms (in total 60 subjects treated with the synthetic THC 
dronabinol) and one case report in which the synthetic THC nabilone 
was used. Although the findings from the above-mentioned clinical 
studies and case report suggest that THC is effective and safe to use 
in the treatment of dementia-related symptoms in older people, the 
studies had several important methodological limitations that made 
it impossible to draw firm conclusions about the safe and effective 
use of THC in these patients.
The findings of PART II highlighted three important points: 
first, the under-representation of older people in clinical trials 
of cannabinoid-based drugs, resulting in a lack of evidence on 
their safety and efficacy in this population; second, currently 
available in vitro and in vivo studies provide an interesting basis 
for the innovative use of cannabinoids as a therapeutic approach to 
dementia and dementia-related symptoms; and third, there is an 
urgent need for adequately powered randomized controlled trials to 
assess the evidence for, and the risk–benefit ratio of, cannabinoid-
based drugs in older people with dementia.
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PART III    Efficacy of THC in the treatment of 
neuropsychiatric symptoms of dementia
The proof of concept research question whether THC can 
reduce the neuropsychiatric symptoms of dementia is described in 
Chapter 3 and Chapter 4. The study presented in Chapter 3 was a 
multicenter, phase 2, repeated crossover, randomized, double-blind, 
placebo-controlled trial. For 12 weeks, 22 patients with dementia 
and clinically relevant neuropsychiatric symptoms [15 men, mean 
age 76.4±5.3 years] were randomized to receive oral THC (weeks 
1–6, 0.75 mg; weeks 7–12, 1.5 mg) or placebo twice daily for 3 
days, separated by a 4-day washout period. Although the THC dose 
up to 3 mg daily was safe and well tolerated by the patients, it 
was not more effective than placebo in treating neuropsychiatric 
symptoms. Overall, THC had only minor pharmacodynamic effects, 
including side effects, based on vital signs (systolic and diastolic 
blood pressure, and heart rate), mobility and balance scores, 
body weight, and scores for feeling high, external, and internal 
perceptions. Appendix Chapter 3 provides the data of an open-
label extension phase 2 study that followed the crossover period. 
Of the 12 included participants in this phase (55% of total study 
participants), only 5 (42% of total study participants) completed 
the 6-month treatment period. The reasons for discontinuation were 
not related to adverse events. Long-term treatment with low-dose 
THC had no effect on neuropsychiatric symptoms. Given the small 
number of participants in the open-label study (n=5), the results 
should be interpreted with caution.
In Chapter 4, we describe a multicenter, phase 2, randomized, 
double-blind, placebo-controlled trial. Fifty patients with dementia 
and clinically relevant neuropsychiatric symptoms were randomly 
assigned (ratio 1:1) to receive THC 1.5 mg (n=24) or matched 
placebo (n=26), three times daily for 3 weeks. THC doses up to 
4.5 mg were safe and well tolerated by the older patients with 
dementia. Compared to placebo, THC did not significantly improve 
neuropsychiatric symptoms (Neuropsychiatric Inventory), agitated 
behavior (Cohen-Mansfield Agitation Inventory), quality of life (Quality 
of Life–Alzheimer’s Disease), or activities of daily living (Barthel 
238
SummaryPart VI  |  Summary
Index). In addition, in a subgroup of patients with persistent pain 
(n=23) (Appendix Chapter 4), THC did not reduce pain intensity 
(Verbal Rating Scale) or pain-related behavior (Pain Assessment 
Checklist for Seniors with Limited Ability to Communicate).
In conclusion, THC in doses up to 4.5 mg daily appeared safe and 
well tolerated by older patients with dementia. However, THC was not 
effective in the treatment of neuropsychiatric symptoms, pain, and 
pain-related behavior. The absence of significant pharmacodynamic 
effects, including side effects, suggests that the administered THC 
doses were too low.
PART IV    Safety, pharmacodynamics, 
and pharmacokinetics of oral 
tetrahydrocannabinol in older people with 
dementia
In Chapter 5, we performed a phase 1, randomized, placebo-controlled, 
crossover trial to evaluate the safety, pharmacokinetics, and pharmacodynamics 
of a single oral dose of 3 mg, 5 mg, or 6.5 mg THC in 12 healthy older individuals 
(6 male; mean age 72±5 years). The data for 11 subjects were included in 
the analysis. THC was safe and well tolerated. The most frequently reported 
adverse events were drowsiness (27%) and dry mouth (11%). Participants 
reported more adverse events with THC 6.5 mg than with 3 mg (p=0.048), 5 mg 
(p=0.034), or placebo (p=0.013). Overall, the pharmacodynamic effects of THC 
were smaller than the effects previously reported for young adults. Compared 
to placebo, THC administration was not associated with significant changes 
in systolic and diastolic blood pressure, heart rate, feeling high scores, body 
sway, and subjects’ attentional performance. Plasma concentrations of THC, 
its metabolites 11-hydroxy-delta-9-THC (11‐OH‐THC) and 11-nor-9-carboxy-
delta-9-tetrahydrocannabinol (THC-COOH) increased dose dependently 
with increasing THC dose (p < 0.0001), but there was a wide interindividual 
variability in plasma concentrations. Unfortunately, we could not perform a 
complete pharmacokinetic analysis, because we collected only four blood 
samples (over 120 min) per subject. In contrast to data for young adults, THC 
concentrations did not reach a maximum in some participants during the 120-
min sampling period. In subjects in whom the maximum concentration (Cmax) 
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was reached within the sampling period, Cmax was 1.42–4.57 ng/mL and time 
to reach Cmax (tmax) was 67–92 min. The area under the curve (AUC) from 0 to 
2 h (n=11) was 1.67–3.51 ng/mL.
A complete pharmacokinetic analysis was performed in a 
study involving older individuals with dementia (Chapter 6). This 
pharmacokinetic study was part of the phase 2, randomized, double-
blind, placebo-controlled trial described in Chapter 3. We evaluated 
the safety, pharmacodynamics, and pharmacokinetics of THC in ten 
patients with dementia (mean age 77.3±5.6). Only 6 of the in total 
98 adverse events were considered to be (possibly) related to THC. 
All were mild and transitory in nature. Also, in this study, THC had 
fewer pharmacodynamic effects in older individuals with dementia 
than expected based on the effects reported for young adults. We 
found no statistically or clinically significant changes in participants’ 
feeling high, external perception, body sway with eyes open, and 
diastolic blood pressure after THC. The statistically significant 
changes in internal perception, body sway with eyes closed, systolic 
blood pressure, and heart rate after THC were not considered 
clinically relevant, as they were small and were not associated with 
adverse events. After THC administration, the median tmax was 1–2 
h. THC had dose-linear pharmacokinetics in older individuals with 
dementia, showing a doubling of the AUC and Cmax with doubling of 
the dose from 0.75 to 1.50 mg. However, there was considerable 
interindividual variation in plasma concentrations of THC (coefficient 
of variation up to 140%) and 11-OH-THC (coefficient of variation up 
to 62%), which is in line with our data from a phase 1 study involving 
healthy older individuals (Chapter 5). The mean Cmax (ng/mL) after 
the first dose (0–6 h) was 0.41 (0.18–0.90) for the 0.75-mg dose 
and 1.01 (0.53–1.92) for the 1.5-mg dose. After the second dose 
(6–24 h), the Cmax was 0.50 (0.27–0.92) and 0.98 (0.46–2.06), 
respectively.
On the basis of our data from PART V, THC in doses up to 6.5 
mg and 4.5 mg daily were safe and well tolerated by healthy older 
individuals and older individuals with dementia, respectively. Overall, 
the pharmacodynamic effects of THC in older adults, including 
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those with dementia, were smaller than the effects previously 
reported in young adults. THC was rapidly absorbed and had dose-
linear pharmacokinetics with considerable interindividual variation. 
Further studies are warranted to evaluate the pharmacodynamics 
and pharmacokinetics of higher THC doses in older people with 
dementia.
PART V    Pain and pain-related symptoms in dementia
Chapter 7 reports data on the prevalence and impact of pain 
in patients with dementia and the relationship between pain and 
behavioral and psychological symptoms. This cross-sectional, 
community-based, prevalence survey was part of the recruitment 
procedure of the THC effectiveness trial described in Chapter 4. 
Self-administered postal questionnaires were sent to patients with 
dementia and their informal caregivers (701 patient–caregiver 
dyads). Of these, 390 (56%) were returned. The questionnaires of 
386 patient–caregiver dyads were sufficiently complete for analysis. 
Our data showed that pain is common (over 60% of participants) 
and often undertreated (almost 30%) among community-dwelling 
patients with dementia. It is associated with diminished activities 
of daily living, sleep disturbances, behavioral and psychological 
symptoms, and caregiver distress. Our findings, which are unique 
for being based on a large sample, contribute to the sparse literature 
on the prevalence and impact of pain and pain-related behavioral 
symptoms in patients with dementia who are still living at home.
In the research letter presented in Chapter 8, we discuss the 
challenges in assessing and treating pain in patients with dementia, 
particularly in those with moderate and severe dementia, who 
are less able to articulate the pain and discomfort they feel. We 
concluded that studies, preferably well-designed trials, are needed 
that specifically focus on the effect of cannabinoids on pain and 
pain-related behavioral disturbances in patients with dementia. 
This is warranted, as the study reported in Chapter 7 showed that 
pain is common and has negative effects on dementia patients 
and their caregivers. As mentioned in Chapter 2, the broad 
interactions of cannabinoids with the endocannabinoid system and 
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different neurotransmitters in the brain underscore the potential 
of cannabinoids as multi-target drug candidates for the treatment 
of pain and pain-related behavioral disturbances in older people 
with dementia. However, accurate assessment of pain is crucial for 
adequate pain management, but most available assessment tools 
for nonverbal older individuals with cognitive impairments have a 
poor reliability, validity, and clinical utility.
Overall, the findings of PART VI support the importance of 
routinely assessing pain in patients with dementia, in order to treat 
pain and to reduce the burden of pain-related behavioral problems 
and the associated caregiver distress. Although cannabinoids are a 
potential multi-target treatment, randomized controlled trials are 
needed to evaluate their safety and efficacy in the treatment of 
pain and pain-related behavioral disturbances in older people with 
dementia.
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Samenvatting
Het voornaamste doel van de studies beschreven in dit proefschrift 
was om de klinische farmacologie van tetrahydrocannabinol (THC) in 
tabletvorm te evalueren bij ouderen met dementie, in het bijzonder:
1. Evaluatie van het huidig bewijs uit de literatuur over het 
medicinale gebruik van cannabis en cannabinoïden bij ouderen 
(Deel II);
2. Evaluatie van het huidig bewijs uit de literatuur over de 
mogelijkheden van cannabinoïden bij de behandeling 
van laat beginnende Alzheimer en daaraan gerelateerde 
neuropsychiatrische symptomen (Deel III);
3. Evaluatie van de farmacodynamische (inclusief bijeffecten) 
en farmacokinetische effecten van orale toediening van THC 
bij ouderen en personen met dementie (Deel V).
4. Evaluatie van de effectiviteit van THC bij de behandeling van 
neuropsychiatrische symptomen van dementie (Deel IV);
5. Evaluatie van de effectiviteit van THC bij de behandeling van 
pijn en pijn gerelateerde gedragsstoornissen bij ouderen met 
dementie (Hoofdstuk 4 en Deel VI)
Deel II   Cannabinoïden bij ouderen met dementie
In Hoofdstuk 1 voerden wij een systematische review uit voor 
het integreren van bewijs van indicaties, werking en veiligheid van 
medicinale cannabinoïden bij ouderen. Ondanks het grote aantal 
studies naar cannabinoïden binnen de algemene populatie (1296 
artikelen), werden slechts vijf gerandomiseerde klinische trials 
geïdentificeerd die aparte data rapporteerden voor ouderen. Op basis 
van deze studies bleken cannabinoïden niet effectief te zijn voor de 
behandeling van dyskinesie (bewegingsstoornissen), benauwdheid 
en misselijkheid en braken na chemotherapie. Twee studies met 
kleine groepen (n=2 en n=15) lieten zien dat THC nuttig kan zijn in 
de behandeling van verminderde eetlust en gedragsproblemen bij 
dementie. De meest gerapporteerde bijwerkingen waren sederende 
effecten (zoals duizeligheid, vermoeidheid en slaperigheid).
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In Hoofdstuk 2 herzagen we de mogelijkheden van cannabi-
noïden binnen de behandeling van laat beginnende Alzheimer en 
daaraan gerelateerde neuropsychiatrische symptomen. Verscheidene 
in vitro en in vivo studies hebben laten zien dat het richten van het 
endocannabinoïde systeem een nieuwe farmacologische benadering 
voor de behandeling van laat beginnende Alzheimer biedt welke 
effectiever kan zijn dan momenteel beschikbare medicamenten. 
Een aantal studies hebben laten zien dat cannabinoïden kunnen 
zorgen voor een verlaging in oxidatieve stress, zenuwontsteking 
en de vorming van amyloïde plaatjes en neurofibrillaire knopen, 
de kenmerken van laat beginnende Alzheimer. Bovendien blijkt de 
cannabinoïde THC de beschikbaarheid van acetylcholine te vergroten 
en acetylcholinesterase-geïnduceerde Aβ aggregatie tegen te gaan. 
Helaas heeft onze literaire zoektocht geen populatie-gebaseerde 
studies van cannabinoïden als mogelijke behandeling voor de ziekte 
van Alzheimer aangetroffen. Wij vonden slechts vier klinische 
studies naar de effectiviteit van cannabinoïden bij de behandeling 
van dementie-gerelateerde symptomen (in totaal 60 proefpersonen 
die zijn behandeld met de synthetische THC dronabinol) en één 
case report waarin de synthetische THC nabilone werd gebruikt. 
Hoewel de bevindingen van de bovengenoemde klinische studies 
en het case report suggereren dat THC effectief is en veilig kan 
worden gebruikt bij de behandeling van dementie-gerelateerde 
symptomen bij ouderen, hadden de studies verscheidene belangrijke 
methodologische beperkingen die het onmogelijk maakten om 
eenduidige conclusies te trekken over het veilig en effectief gebruik 
van THC bij deze patiënten.
De bevindingen van Deel II wierpen licht op drie belangrijke 
punten: ten eerste de ondervertegenwoordiging van ouderen 
in klinische trials met cannabinoïde-gebaseerde medicamenten, 
resulterend in een gebrek aan bewijs over hun veiligheid en 
werkzaamheid binnen deze populatie; ten tweede bieden momenteel 
beschikbare in vitro en in vivo studies een interessante basis voor het 
innovatief gebruik van cannabinoïden als therapeutische benadering 
voor dementie en dementie-gerelateerde symptomen; en ten derde 
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is er dringend behoefte aan gerandomiseerde gecontroleerde 
studies met voldoende deelnemers voor het vaststellen van bewijs 
voor, en het risico-voordeel ratio van cannabinoïde-gebaseerde 
medicamenten bij ouderen met dementie.
Deel III    Werkzaamheid van THC bij de behandeling 
van neuropsychiatrische symptomen van 
dementie
Het bewijs van de onderzoeksvraag of THC de neuropsychiatrische 
symptomen van dementie kan verminderen is beschreven in 
Hoofdstuk 3 en Hoofdstuk 4. De studie gepresenteerd in 
Hoofdstuk 3 was een multicenter, fase 2, gerandomiseerde, double-
blind, placebo-gecontroleerde trial. Twee en twintig patiënten 
met dementie en relevante neuropsychiatrische symptomen [15 
mannen, gemiddelde leeftijd 76.4±5.3 jaar] krijgen gedurende 
12 weken THC in tabletvorm voor drie dagen, afgewisseld met 
placebotabletten. Na elke behandelperiode (THC of placebo) kregen 
deelnemers vier dagen geen onderzoeksmedicatie. In de eerste 6 
weken kregen deelnemers 0.75 mg THC tweemaal per dag. In de 
volgende 6 weken werd THC verhoogd naar 1.5 mg tweemaal per 
dag. Hoewel de THC dosis tot 3 mg per dag veilig was en goed werd 
getolereerd door de patiënten, was het niet effectiever dan placebo 
bij de behandeling van neuropsychiatrische symptomen. Over het 
algemeen had THC slechts weinig farmacodynamische effecten, 
waaronder bijeffecten, gebaseerd op vitale kenmerken (systolische- 
en diastolische bloeddruk en hartslag), mobiliteits- en balansscores, 
lichaamsgewicht, en scores voor ‘high’ voelen, externe en interne 
percepties. 
Bijlage Hoofdstuk 3 biedt de data van een open-label 
uittreksel fase 2 studie die de crossover periode volgde. Van de 12 
deelnemers die waren betrokken in deze fase (55% van het totaal 
aantal deelnemers aan de studie), voltooiden slechts 5 (42% van 
het totaal aantal deelnemers aan de studie) de 6-maanden durende 
behandelperiode. De redenen om te stoppen waren niet verbonden 
aan bijeffecten. Langetermijnbehandeling met een lage THC dosis 
had geen effect op neuropsychiatrische symptomen. Gezien het 
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kleine aantal deelnemers in de open-label studie (n=5) dienen de 
resultaten met voorzichtigheid te worden geïnterpreteerd.
In Hoofdstuk 4 beschrijven wij een multicenter fase 2 
gerandomiseerde, double-blind, placebo gecontroleerde trial. 
Vijftig patiënten met dementie en neuropsychiatrische symptomen 
werden willekeurig ingedeeld (ratio 1:1) om 1.5 mg THC (n=24) 
of placebo (n=26), drie maal dagelijks voor 3 weken te gebruiken. 
THC doseringen tot 4.5 mg waren veilig en werden goed getolereerd 
door de oudere patiënten met dementie. Vergeleken met placebo 
was THC niet effectiever in de behandeling van neuropsychiatrische 
symptomen (middels Neuropsychiatric Inventory), geagiteerd 
gedrag (middels Cohen-Mansfield Agitation Inventory), kwaliteit van 
leven (middels Quality of Life–Alzheimer’s Disease), of dagelijkse 
activiteiten (middels Barthel Index). Daarnaast leidde THC niet tot 
een vermindering van pijn (middels Verbale Schaal) of van pijn 
gerelateerd gedrag (middels Pain Assessment Checklist for Seniors 
with Limited Ability to Communicate).
Concluderend bleek THC in doseringen tot 4.5 mg per dag veilig 
voor en goed getolereerd door oudere patiënten met dementie. THC 
was echter niet effectief bij de behandeling van neuropsychiatrische 
symptomen, pijn en aan pijn gerelateerd gedrag. De afwezigheid van 
significante farmacodynamische effecten, waaronder bijeffecten, 
veronderstelt dat de gebruikte THC doseringen te laag waren.
DEEL IV    Veiligheid, farmacodynamiek, en 
farmacokinetiek van orale inname 
tetrahydrocannabinol bij ouderen met 
dementia
In Hoofdstuk 5 voerden we een fase 1 gerandomiseerde, placebo, 
gecontroleerde, crossover trial uit om veiligheid, farmacokinetiek en 
farmacodynamiek van 3 mg, 5 mg, en 6.5 mg THC in tabletvorm 
bij 12 gezonde ouderen te testen (6 mannelijk; gemiddelde leeftijd 
72±5 jaar). De data van 11 deelnemers werd meegenomen in 
de analyse. THC was veilig en werd goed getolereerd. De meest 
gerapporteerde bijwerkingen waren misselijkheid (27%) en droge 
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mond (11%). Deelnemers rapporteerden meer bijwerkingen bij 
6.5 mg THC dan bij 3 mg (p=0.048), 5 mg (p=0.034), of placebo 
(p=0.013). Over het algemeen waren de farmacodynamische 
effecten van THC kleiner dan de eerder vermelde effecten bij 
jongvolwassenen. Vergeleken met placebo werd THC toediening 
niet in verband gebracht met significante veranderingen in 
systolische en diastolische bloeddruk, hartslag, scores van ‘high’ 
voelen, lichaamszwaai, en het concentratievermogen van de 
proefpersoon. Plasmaconcentraties van THC, zijn metabolieten 
11-hydroxy-delta-9-THC (11-OH-THC) en 11-nor-9-carboxy-delta-
9-tetrahydrocannabinol (THC-COOH) namen gelijkmatig toe met de 
THC dosering (p < 0.0001), maar er was een ruime interindividuele 
variabiliteit in plasmaconcentraties. Helaas konden wij geen 
complete farmacokinetische analyse uitvoeren, omdat  slechts vier 
bloedsamples (over 120 min) per proefpersoon waren verzameld. In 
tegenstelling tot de gegevens bij jongvolwassenen, bereikten THC 
concentraties geen maximum in sommige proefpersonen tijdens de 
120 minuten durende bemonsteringsperiode. Bij proefpersonen die 
de maximale concentratie (Cmax) binnen de bemonsteringsperiode 
bereikten, was Cmax 1.42–4.57 ng/mL en de tijd om Cmax te bereiken 
(tmax) bedroeg 67–92 min. Het gebied onder de curve (AUC) van 0 
tot 2 uur (n=11) was 1.67–3.51 ng/mL.
Een complete farmacokinetische analyse is uitgevoerd in een studie 
bij ouderen met dementie (Hoofdstuk 6). Deze farmacologische 
studie was deel van de fase 2, gerandomiseerde, double-blind, 
placebo gecontroleerde trial beschreven in Hoofdstuk 3. Wij 
evalueerden de veiligheid, farmacodynamiek en farmacokinetiek 
van THC bij tien patiënten met dementie (gemiddelde leeftijd 
77.3±5.6). Slechts 6 van de in totaal 98 bijwerkingen werden als 
(mogelijk) gerelateerd aan THC beschouwd. Alle waren mild van 
aard en kortstondig van duur. In deze studie had THC ook minder 
farmacodynamische effecten bij ouderen met dementie dan verwacht 
gebaseerd op de effecten gerapporteerd bij jongvolwassenen. Wij 
vonden geen statistisch of klinisch significante veranderingen in het 
‘high’ voelen, de externa perceptie, lichaamszwaai met open ogen, 
en diastolische bloeddruk van proefpersonen na het gebruik van 
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THC. De statistisch significante veranderingen in interne perceptie, 
lichaamszwaai met gesloten ogen, systolische bloeddruk, en 
hartslag na THC werden niet als klinisch relevant beschouwd, omdat 
deze klein waren en niet in verband konden worden gebracht met 
bijwerkingen. Na THC opname was de mediaan tmax 1-2 uur. THC 
had een dosis-lineaire farmacokinetiek bij ouderen met dementie, 
met een verdubbeling van de AUC en Cmax bij verdubbeling van 
de dosis van 0.75 naar 1.50 mg. Er was echter een aanzienlijke 
interindividuele variatie in plasmaconcentraties van THC (coëfficiënt 
van variatie tot 140%) en 11-OH-THC (variatiecoëfficiënt tot 62%), 
hetgeen correspondeert met onze data van een fase 1 studie bij 
gezonde ouderen (Hoofdstuk 5). De gemiddelde Cmax (ng/mL) na 
de eerste dosis (0–6 uur) was 0,41 (0.18–0.90) voor de 0.75 mg 
dosis en 1.01 (0.53–1.92) voor de 1,5 mg dosis. Na de tweede dosis 
(6–24 uur), was de Cmax respectievelijk 0.50 (0.27–0.92) en 0.98 
(0.46–2.06).
Op basis van onze data uit DEEL V, was THC in dagelijkse 
doseringen tot 6.5 mg en 4.5 mg veilig en werd het goed getolereerd 
door respectievelijk gezonde ouderen en ouderen met dementie. 
Over het algemeen bleken de farmacologische effecten van THC 
bij ouderen, waaronder ook ouderen met dementie, kleiner dan 
de eerder gerapporteerde effecten bij jongvolwassenen. THC werd 
snel geabsorbeerd en had een dosis-lineaire farmacokinetiek met 
aanzienlijke interindividuele variatie. Verder onderzoek is nodig om 
de farmacodynamiek en farmacokinetiek van hogere THC doseringen 
bij ouderen met dementie te bestuderen.
DEEL V    Pijn en aan pijn gerelateerde symptomen bij 
dementie
Hoofdstuk 7 rapporteert data over het voorkomen en de impact 
van pijn bij patiënten met dementie en het verband tussen pijn 
en gedrags- en psychologische symptomen. Dit cross-sectioneel, 
populatie gebaseerd, prevalentie-onderzoek was een deel van 
de rekruteringsprocedure van de THC effectiviteitstrial zoals 
beschreven in Hoofdstuk 4. Vragenlijsten om zelf in te vullen 
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werden verstuurd aan patiënten met dementie en hun informele 
zorgverleners (701 patiënt–mantelzorger koppels). Hiervan werden 
er 390 (56%) teruggestuurd. De vragenlijsten van 386 patiënt–
mantelzorger koppels werden voldoende ingevuld voor analyse. 
Onze data toonden dat pijn veel voorkomt (meer dan 60% van 
de deelnemers) en vaak niet voldoende wordt behandeld (bijna 
30%) bij thuiswonende patiënten met dementie. Het fenomeen pijn 
wordt in verband gebracht met verminderde dagelijkse activiteiten, 
slaapstoornissen, gedrags- en psychologische symptomen, en 
minder spanning voor zorgverleners. Onze bevindingen, welke uniek 
zijn wegens hun basering op een groot aantal deelnemers, dragen 
bij aan de geringe literatuur over het voorkomen en de impact van 
pijn en pijn gerelateerde gedragssymptomen bij thuiswonende 
patiënten met dementie.
In de onderzoeksbrief gepresenteerd in hoofdstuk 8, bespreken 
wij de uitdagingen die optreden bij de beoordeling en de behandeling 
van pijn bij patiënten met dementie, voornamelijk bij patiënten 
met matige en ernstige dementie, die minder goed in staat zijn 
om pijn en de ongemakken die ze ervan ervaren te communiceren. 
Wij concludeerden dat studies, vooral goed ontworpen trials, 
die zich specifiek richten op de effecten van cannabinoïden 
bij pijn en pijn gerelateerde gedragsstoornissen nodig zijn bij 
personen met dementie. Dit is gerechtvaardigd omdat de studie 
beschreven in hoofdstuk 7 aantoont dat pijn gemeenschappelijk 
is en negatieve effecten heeft op personen met dementie en 
hun verzorgers. Zoals vermeld in hoofdstuk 2, duiden de brede 
interacties tussen cannabinoïden, het endocannabinoïdensysteem 
en andere neurotransmitters in de hersenen, op het potentieel van 
cannabinoïden als mogelijke multi-target medicamenten voor de 
behandeling van pijn en aan pijn gerelateerde gedragsstoornissen 
bij ouderen met dementie. Nauwkeurige vaststelling van pijn is 
echter cruciaal voor een adequate omgang met pijn, maar de meeste 
beschikbare beoordelingsinstrumenten voor non-verbale ouderen 
met cognitieve beperkingen hebben een lage betrouwbaarheid, 
validiteit en klinische bruikbaarheid. 
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Over het algemeen ondersteunen de bevindingen van DEEL 
VI het belang van zowel het regelmatig vaststellen van pijn bij 
patiënten met dementie als om pijn te behandelen en de last 
van aan gedrag gerelateerde problemen te verlagen en zodoende 
verlichting te bieden aan de verzorgers. Hoewel cannabinoïden een 
mogelijke multi-target behandeling bieden, zijn gerandomiseerd 
gecontroleerde trials nodig voor het vaststellen van hun veiligheid 
en werkzaamheid bij de behandeling van pijn en pijngerelateerde 
gedragsstoornissen bij ouderen met dementie.
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1.  Introduction
In the past decade, the medicinal use of cannabis and cannabinoids 
has moved to the forefront of public and scientific debate, and the last 
few years have seen a growing interest in the medical use of these 
drugs in older people, for example, in the treatment of dementia, 
dementia-related neuropsychiatric symptoms, and other physical 
conditions that are common in old age.1-5 Tetrahydrocannabinol (THC) 
appears to be responsible for most of the physical and psychoactive 
effects of the cannabis plant6 and has attracted attention as a 
promising drug candidate with broad therapeutic applications. This 
growing interest led to the development of two synthetic THC-based 
drugs in capsule form, namely, dronabinol and nabilone, which are 
currently approved for medicinal use in several countries. However, 
to date, there is a great lack of information in the literature on 
the pharmacodynamics and pharmacokinetics of oral THC in older 
people with dementia. Older people, especially those with dementia 
and multiple comorbidities, may benefit greatly from the broad 
therapeutic applications of THC. This means that there is a need for 
knowledge of the pharmacodynamics and pharmacokinetics of THC-
based drugs in this frail population, in order to maximize therapeutic 
benefit and to minimize side effects.
The studies described in this thesis focused on the clinical 
pharmacology of oral THC in older people with dementia, in particular, 
its pharmacokinetic and pharmacodynamic effects. We used a novel 
THC-based formulation in tablet form, Namisol® (THC ≥ 98%), which 
has not yet gained marketing approval, in our studies.
2.  Past and current state of knowledge of clinical 
pharmacology of oral THC in older people with 
dementia
When preparing for our clinical trials in 2011, we performed a 
pharmacological-oriented literature search for studies of the oral 
use of THC in older people with dementia. At that time (2011), we 
found only two randomized clinical trials7, 8 and one open-label study9 
of the effectiveness of oral THC (dronabinol) in the treatment of 
dementia-related symptoms. The three studies, which included only 
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patients with dementia aged 65 years and older, showed that THC 
was effective and safe to use in older patients with dementia.7-9 There 
were no studies of the pharmacokinetics of THC in older patients with 
dementia. Moreover, we found only one study that reported plasma 
THC plasma concentrations (peak levels only) in subjects aged 51–
78 years, but these individuals did not have dementia.10 Two years 
later, we performed a broad systematic review of the literature 
(up to October 7, 2013) on the medicinal use of cannabinoids in 
older people, including individuals with dementia (Chapter 1). This 
systematic literature search revealed three additional studies that 
included non-demented subjects from different age groups and 
performed analyses for the older group separately. These studies 
showed that cannabinoids were not effective as treatment for 
dyskinesia, breathlessness, and chemotherapy-induced nausea and 
vomiting. A new literature search in February 2015 (Chapter 2) 
revealed an additional retrospective systematic chart review study.11 
The study evaluated the data of 40 geriatric patients with dementia 
who had been treated with oral THC (dronabinol) for behavioral or 
appetite disturbances; however, the age of the patients was not 
reported. The authors concluded that THC was safe and effective to 
use in the treatment of dementia-related symptoms.11
During the writing of this discussion, I updated the literature 
search reported in Chapter 2 to February 4, 2016. I found one new 
open-label prospective study of the safety and efficacy of cannabis 
oil (containing 2.5 mg THC) for the treatment of the behavioral and 
psychological symptoms of dementia [11 patients, mean age 73.2 
years].12 THC doses of 2.5 mg twice/day (n=7) and 7.5 mg twice/
day (n=3) appeared to be safe and effective in the treatment of 
these symptoms. Table 1 summarizes all studies published to date 
on THC-based drugs in patients with dementia. 
Taking the above into account, there is little information in the 
literature about the clinical pharmacology of oral THC in older people 
with dementia. The number of studies available is very limited 
compared with the huge number of publications on cannabis (PubMed 
14,746 papers, February 4, 2016) and cannabinoids (PubMed 13,188 
papers, February 4, 2016). This lack of information about THC in 
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older people, particularly in those with dementia, emphasizes the 
urgent need for more clinical trials because older people may derive 
substantial benefit from the therapeutic use oral THC. The studies 
carried out in this population and presented in this thesis add to the 
sparse literature on the clinical pharmacology of oral THC in older 
people with dementia.
3. Clinical pharmacology of oral THC in 
older people with dementia
3.1. Effectiveness and safety aspects
Although effectiveness and safety are both aspects of the 
pharmacodynamic effects of oral THC, they are discussed separately 
to provide a better overview of findings.
3.1.1.  Is oral THC effective in the treatment of 
dementia-related symptoms?
Dr. Geke van den Elsen has recently discussed our findings on 
the effectiveness of oral THC in dementia patients in her thesis, 
entitled “Tetrahydrocannabinol in the treatment of neuropsychiatric 
symptoms in dementia, 2016” (ISBN: 978-90-9029499-5). In brief, 
our data showed that oral THC in doses up to 4.5 mg/day was not 
of therapeutic benefit in patients with behavioral and psychological 
symptoms of dementia, compared to placebo (Chapters 3 and 4). 
In contrast, all published studies to date (table 1) have shown that 
THC is effective in the treatment of dementia-related symptoms, such 
as behavioral disturbances, loss of appetite, and sleep problems. 
However, the studies were either not randomized controlled trials,8, 
11, 12 or included a very small number of participants.7, 9 Such 
methodological factors may introduce bias, leading to overestimation 
of the therapeutic value of oral THC in older people with dementia. 
However, there are other explanations for the discrepant results. 
1) The short treatment duration with oral THC. In previous studies 
(table 1), THC treatment lasted between 2 and 6 weeks, whereas in 
our crossover study described in Chapter 5 treatment duration was 
shorter (3 days treatment with oral THC followed by a 4-day
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washout period). 2) The THC doses used in our trials were relatively 
low compared with those used in other studies (Chapter 3: up to 
3 mg/day and Chapter 4: up to 4.5 mg/day). And 3) Age-related 
and dementia-related physiological factors, which will be discussed 
below in section 4 “Pharmacodynamics of oral THC”
3.1.2.  Is oral THC safe to use in older people and 
dementia patients?
Despite the rapid increase in the prevalence of older people,13 
including those with dementia, and the possible therapeutic benefits 
of oral THC in the treatment of dementia-related symptoms and 
other physical comorbidities in these individuals, preapproval 
clinical trials of oral THC (dronabinol and nabilone) have excluded 
older individuals, especially those with cognitive impairments, 
from participation or did not include sufficient numbers of older 
participants to allow comparison of their data with those of young 
participants (Chapters 1 and 2). Furthermore, the first (phase 
I) trial involving humans that investigated the optimal route of 
administration, safety, pharmacokinetics, and pharmacodynamics 
of Namisol® included only young participants (mean age 21.4 years, 
range 18–27 years),14 and therefore findings cannot directly be 
extrapolated to older people (Chapters 1 and 2).
In view of this lack of evidence, we conducted the first (to our 
knowledge) phase 1 clinical trial of the safety and pharmacokinetics 
of an oral THC-based medicine in older individuals (Chapter 5). We 
evaluated three oral doses of Namisol® (3, 5, and 6.5 mg) in healthy 
older individuals aged 65 and older. The selection of THC doses was 
based on the data of a phase 1 study of the safety of Namisol® (5, 
6.5, and 8 mg) in young adults (18–27 years).14 All 9 participants 
experienced adverse events with the 8-mg dose, with dizziness 
being the most frequently reported adverse event. Because of the 
high prevalence of adverse events in young adults and the high falls 
risk of older people (because of dizziness), we did not include an 
8-mg dose (Chapter 5). 
We found that a single oral dose of THC up to 6.5 mg/day was safe and 
well tolerated by healthy older individuals (Chapter 5). More subjects reported
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one or more adverse events with 6.5 mg (7/11 subjects) than with 3 mg (5/11 
subjects), 5 mg (5/11 subjects), or placebo (1/11 subject). The most reported 
adverse events in older participants were drowsiness (27% of participants) 
and dry mouth (11% of participants). In contrast, 85% and 100% of young 
adults had at least one adverse event after 5 mg and 6.5 mg THC, respectively, 
and one young participant dropped out because of drug-related syncope with 
the 5-mg dose. The adverse events reported by the young adults were mild to 
moderate in severity,14 whereas none of the older subjects dropped out, and 
45% and 64% reported only mild adverse events with the 5-mg and 6.5-mg 
doses, respectively. This suggests that older individuals (mean age 72 years) 
tolerate THC better than young individuals (mean age 21.4 years). This will 
be discussed in more detail in section 4 “Pharmacodynamics of oral THC”.
The data of phase 2 studies (Chapters 3 and 4) involving older people with 
dementia showed that oral THC in doses up to 4.5 mg daily was well tolerated 
by patients with dementia. There were no serious adverse events related 
to THC treatment, or THC-related dropouts. These findings are consistent 
with those of previously published studies that included older individuals with 
dementia (Table 1). However, in three out of the five studies presented in table 
1, higher doses of THC were used than in our studies: Volicer et al.7 used a 
THC dose of 5 mg/day, Woodward et al.11 used a mean THC dose of 7.03 mg/
day, and Shelef et al.12 used a THC dose up to 15 mg/day. 
It is important to note that the safety data from our studies 
(Chapters 3 to 6) are mainly based on short-term use of oral 
THC. Previous studies suggested that prolonged use of cannabis 
is associated with memory deficits and cognitive impairments.15, 16 
None of the previously published studies (Table 1), including our 
studies, included assessment of memory and cognitive functions 
as outcome measures. Therefore, further studies are warranted to 
evaluate the safety, also in terms of memory and cognitive functions, 
of long-term use of THC in older people with dementia.
4.  Pharmacokinetics of oral THC
Pharmacokinetics refers to the effect of the body on a drug and 
describes the absorption, distribution, metabolism, and elimination 
of a drug. These pharmacokinetic processes can be affected by age-
related physiological changes, physical comorbidities (drug–disease 
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interactions), and polypharmacy (drug–drug interactions). Table 
2 presents the most important pharmacokinetic changes observed 
with aging.17-19
Most of the information available about the pharmacokinetic and 
pharmacodynamic effects of THC comes from studies involving young 
recreational cannabis users. There is much less information available 
from clinical studies of patients using cannabis for medical purposes. 
In general, the route of THC administration and the THC formulation 
determine its rate of absorption. Inhalation and intravenous routes 
of administration provide the most rapid delivery of THC, with peak 
THC plasma concentrations being reported within minutes (3–10 
min),20, 21 whereas oral administration delays absorption (1–4 h).22-23 
Table 2      Pharmacokinetic changes observed with aging.17-19
Parameters Altered physiology Comments
Absorption ↓Gastrointestinal blood flow
↓Gastric acid secretion 
↑Gastric pH
↓Gastric emptying time 
↓Gastrointestinal motility
May diminish the absorption 
of several drugs.
Time of onset of action may 
be delayed.
Distribution ↓Total body water 
↓Lean body mass 
↑Body fat
↓Albumin
Increased volume of 
distribution of lipid-soluble 
drugs, resulting in prolonged 
half-life and duration of 
action.
Increased free fraction of 
drug.
Metabolism ↓Hepatic blood flow 
↓Hepatic mass
↓Enzyme induction 
↓ Activity in mixed function oxidase 
system
Reduced hepatic clearance of 
drugs, leading to toxicity.
Increased potential for drug 
interactions.
For elderly patients, dosage 
should be reduced for 
hepatically cleared drugs.
Elimination ↓Renal blood flow
↓Number of functioning nephrons
↓Kidney mass / size
↓Glomerular filtration rate
Reduced renal clearance 
of drugs, leading to 
accumulation of renally 
cleared drugs.
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In our studies, oral THC (Namisol®) was rapidly absorbed in 
older individuals, with a median time to reach the maximum 
concentration (tmax) of 1–2 h. The plasma concentrations of oral 
THC and its metabolites dose dependently increased with increasing 
THC dose. In both healthy individuals Chapter 5) and individuals 
with dementia (Chapter 6), there was substantial interindividual 
variation in plasma concentrations of THC and its metabolites, which 
is in line with previously published studies that included individuals 
of different ages.14, 25 Older people, especially those with dementia, 
tend to be more sensitive to drugs that act on the central nervous 
system, such as THC.26 For this reason, and because of the wide 
interindividual variation in plasma THC concentrations, it is important 
to tailor THC doses, to minimize side effects. This can be achieved 
by starting at a low dose and gradually increasing the dose until the 
desired therapeutic effect is obtained.
Although our phase 1 study (Chapter 5) was the first randomized, 
controlled trial of the safety and pharmacokinetics of a THC–based 
medicine that exclusively included older subjects, we failed to perform 
a complete pharmacokinetic analysis. This was because the study 
was primarily designed to assess the safety and tolerability of oral 
THC, and so only a limited number of blood samples (4 per subject) 
were collected. In addition, because maximal THC concentrations 
were reached 39–56 min after Namisol® administration in the phase 
1 study involving young adults,14 we considered that blood sampling 
over 120 min would be suitable time span for a pharmacokinetic 
analysis. When the maximum plasma concentration (Cmax) was 
reached within 120 min, the mean Cmax was similar to that reported 
for young adults given Namisol®.14 In our older population, oral 
Namisol® had a Cmax of 1–2 h, shorter than that reported in studies 
of individuals of different ages given dronabinol (1–4 h), nabilone 
(2–4 h), or oral-mucosal THC + cannabidiol (CBD) (Sativex®, 3–4 
h).22-23, 27-29 This difference is probably due to the novel lipophilic 
compound delivery technology, Alitra™, used to increase the 
absorption of Namisol®.14 In contrast, the tmax of THC in older adults 
was longer than the tmax reported for young adults (39–56 min), 
and THC exposure (area under the concentration-time curve 0–6 
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h, AUC0–6h) was two times higher in older adults than in young 
adults administered Namisol®. These discrepancies in tmax and AUC 
could be related to a THC–food interaction, which will be discussed 
below, or due to age-related physiological factors, such as delayed 
gastric emptying time, decreased splanchnic blood flow, decreased 
gastrointestinal motility, and decreased absorption surface, all of 
which could affect the absorption and bioavailability of THC in older 
adults.
Table 3 summarize the pharmacokinetic parameters of THC and 
11-OH-THC after oral administration of Namisol® in young14 and old 
adults (Chapter 5).
4.1.  Effect of food on the pharmacokinetics of THC
Although we did not specifically investigate whether the intake of 
food can alter the pharmacokinetics of THC in older people, such an 
interaction is possible. Below, I discuss THC–food interactions and 
the role of aging, based on information from the literature. 
The mechanism underlying drug–food interactions are complex 
and can be further complicated by age-related physiological 
changes, drug–drug interactions, and drug–disease interactions. 
In fact, the pharmacokinetics of lipophilic compounds such as THC 
can be affected when they are co-administered with food, with both 
the rate [measured as Cmax and tmax values] and extent [measured 
as AUC] of drug absorption from the gastrointestinal tract being 
affected.30 Drug–food interactions may result in increased, delayed, 
or decreased systemic drug bioavailability.30, 31 For example, the 
intake of a high-fat meal or increased secretion of bile salts following 
food intake might improve the solubility and rate of dissolution 
of lipophilic compounds such as THC, thus increasing the rate of 
absorption.31 On the other hand, food can delay drug absorption or 
decrease the rate of absorption as a result of a slow gastric emptying 
and/or increased gastric pH, leading to a decreased Cmax and a longer 
tmax.
30 Delayed gastric emptying and an increase in gastric pH may 
also occur as part of normal aging process (Table 2).26 
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Table 3    Pharmacokinetic parameters of THC and its metabolites 
after oral administration of Namisol® in young and old adults 
(Phase 1 studies).
Parameters 3 mg 5 mg 6.5 mg 8 mg 
                                                  Young adults (mean age 21.4±3.3 years)a
 (n=0) (n=13) (n=9) (n=9)
THC
Cmax (ng/mL) 2.92 (51) 4.43 (42) 4.69 (62)
tmax (min) 56.0 (73) 39.3 (20) 43.6 (26)
t1/2 (min) 71.9 (24) 80.0 (22) 78.8 (21)
11-OH-THC
Cmax (ng/mL) 4.68 (42) 5.94 (44) 6.10 (53)
tmax (min) 74.1 (68) 46.1 (28) 78.4 (63)
t1/2 (min) 196.0 (33) 318.7 (54) 314.1 (58)
                                                   Old adults (mean age 72±5 years)b
(n=11) (n=11) (n=11) (n=0)
THCc 1.2 (0.13–3.48) 1.9 (0.26–6.95) 2.61 (0.23–8.65)
11-OH-THCc 1.69 (0.47–4.34) 2.34 (0.37–8.37) 3.12 (0.37–8.61)
THC-COOHc 13.9 (1.27–27) 19.3 (2.23–48.8) 26.6 (3.51–56.8)
AUC0-2h (h ng/mL) 1.67 (0.80–4.14) 2.61 (0.97–7.55) 3.51 (1.26–11.45)
 (n=10)  (n=6)  (n=5)
Cmax (ng/mL)
d 1.42 (0.53–3.48) 3.15 (1.54–6.95) 4.57 (2.11–8.65)
tmax (h)
d 0.92 (0.67–0.92) 0.92 (0.67–0.92) 0.67 (0.67–0.92)
a Data are presented as means with coefficient of variation (%)
b Data are presented as means and ranges
c Plasma concentrations 
d Reported for subjects who reached the Cmax within 2 hours
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In the study reported in Chapter 6, Namisol® was administered 
to older participants in non-fasting state, which probably led to 
delayed absorption of THC, and prolonged exposure relative to that 
reported for young adults administered Namisol® in fasted state.14 
In practice, it is difficult to establish whether delayed absorption and 
increased exposure are caused by the nutritional state of an older 
individual or by normal aging. We have not found any studies that 
evaluated the effects of food on the pharmacokinetics of oral THC. 
Most available studies on oral THC and food focused on the effects of 
THC on food intake (appetite stimulation). One study assessed the 
effect of food on the single-dose bioavailability of the oromucosal 
spray nabiximols (Sativex®) [THC 10.8 mg / CBD 10 mg], using a 
fed–fasted crossover design (n=12 males, mean age: 28.5 years).32 
The study results showed that food intake can increase the rate 
(Cmax and tmax) and extent (AUC) of exposure to THC and 11-OH-
THC, with the mean AUC and Cmax being 1–3 times higher when 
the oromucosal spray was administered under fed conditions.32 
Moreover, the absorption of THC was also delayed, with the tmax 
for THC increasing from mean 1.5 h (range 0.75–2.00 h) in the 
fasted state to 4 h (range 2.00–4.08 h) in the fed state, giving an 
absorption delay of 2.5 h. For 11-OH-THC, tmax also increased from 
mean 2.13 h (range 1.00–2.50 h) in the fasted state to 4.03 h 
(range 2.53–12.00 h) in the fed state, giving an absorption delay 
of 2 h.32 It is important to note that the study included only young 
adults (mean age 28.5 years), and therefore data cannot be directly 
translated to older adults. 
The development of a novel drug formulation, such as THC-
based drugs, should include an assessment of the effect of food 
on the pharmacokinetics of the drug, especially in older people. 
This knowledge is needed in order to provide patients with 
specific instructions regarding drug use (e.g., dosage, appropriate 
administration time). It might also be useful when trying to interpret 
drug failure or side effects.
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5.  Pharmacodynamics of oral THC
Pharmacodynamics refers to the physiological effects of drugs 
on the human body. All drugs have specific mechanisms of action, 
both for their therapeutic effects and their side effects. The aging 
process may increase or decrease the sensitivity to particular drugs, 
especially drugs that affect the central nervous system.26 This is 
because advancing age may be accompanied by changes in the 
affinity of drugs at specific receptor sites or in the number of receptor 
sites. In practice, sometimes it is difficult to determine whether the 
differences in the effect or response to a drug in an individual older 
person are due to pure age-related pharmacodynamic changes 
(e.g., reduced number of receptors) or age-related pharmacokinetic 
changes (e.g., concentration of drug that reaches the target). In 
general, THC can affect most organ systems, as summarized in 
Table 4.6, 33-35 The intensity, type, and duration of these effects in 
general depend on the plasma THC concentration.
5.1.  THC mechanisms of action
In our clinical trials (Chapters 3 to 6), we investigated a 
wide range of THC pharmacodynamic parameters, including 
the effect of THC on dementia-related behavioral disturbances, 
adverse events, systolic and diastolic blood pressure, heart rate, 
electrocardiographic parameters, clinical chemistry parameters, 
psychedelic effects (feeling high, internal and external perceptions), 
attentional performance, and mobility (body sway and gait). The 
first pharmacodynamic effect (a side effect) of THC occurred 20 min 
after dosing. This is quite promising for achieving a rapid therapeutic 
effect, for example, when treating pain. However, overall, oral THC 
showed smaller pharmacodynamic effects, including side effects, 
than we had expected for older people with dementia, based on 
the effects reported in young adults.14 There are several possible 
explanations for these discrepancies. First, we used a very low THC 
dose in our clinical trials; however, we found oral THC not to be
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Table 4    Pharmacodynamic effects of tetrahydrocannabinol.6, 33-35 
Body system Effects
Central Nervous System
Psychological Euphoria “feeling high”, dysphoria, anxiety/panic, 
reduction of anxiety, hallucinations, depersonalization, 
precipitation or aggravation of psychosis.
Perception internal perception (inner feelings that do not 
correspond with reality, including mistrustful feelings), 
external perception (misperception of an external 
stimulus or change in awareness of surroundings), 
hallucinations, distortion of time perception.
Sedative Sleepiness, somnolence,  drowsiness.
Cognitive and 
psychomotor 
performance
slowing of reaction time, difficulty in concentration and 
performance of complex tasks, memory impairment, 
decreased learning ability, enhanced creativity and 
skilled activities. 
Motor function Increased or decreased motor activity, ataxia, 
dysarthria, tremulousness.
Appetite Increased appetite 
Analgesic pain relief.
Anti-emetic Anti-emetic effect with acute doses, but tolerance may 
occur with chronic use . Hyperemesis may occur with 
high doses or chronic use.
Body temperature Decrease of body temperature.
Cardiovascular System 
Heart rate/rhythm Tachycardia with acute dosage due to vagal inhibition by 
inhibited release of acetylcholine; bradycardia with long-
term use due to the development of tolerance.
Premature ventricular contractions, atrial fibrillation, 
ventricular arrhythmia also seen with acute doses.
Peripheral circulation Vasodilatation, orthostatic hypotension, hypertension (in 
horizontal position), conjunctival redness.
Cardiac output Increased cardiac output and myocardial oxygen 
demand. 
Cerebrovascular System
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Cerebral blood flow Increased with acute dose and decreased with long-term 
use.
Respiratory System 
Bronchi Bronchodilation.
Pulmonary function 
(FEV1; FVC) 
Improve with acute dose.
Gastrointestinal System 
Motility Reduced gastrointestinal motility and decreased gastric/
colonic emptying.
Liver Increased risk of hepatic steatosis/fibrosis, especially in 
patients with Hepatitis C.
Pancreas High risk of pancreatitis long-term use of high dose.
Musculoskeletal system 
Muscles Increased muscles relaxation and reduced muscles 
spasticity.
Bon May negatively impact bone healing. 
Immune System 
General effect Immunomodulatory effects with suppressive and/or 
stimulatory effects; anti-inflammatory and anti-allergic 
effects.
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of therapeutic benefit in the treatment of behavioral disturbances 
in patients with dementia (Chapters 3 and 4). The combination 
of a low rate of unwanted (side) effects and a low rate of wanted 
(therapeutic) effects raises the question whether THC doses were 
high enough for appropriate pharmacodynamic responses. Second, 
age- and dementia-related changes in the body and brain influence 
how the body handles a drug, relative to how drugs are handled in 
young subjects, and these changes may be further complicated by 
multiple comorbidities and related polypharmacy, which all can lead 
to drug–drug and drug–disease interactions.26 For example, age-
related physiological changes, such as delayed gastric emptying 
time, decreased gastrointestinal motility, and absorption surface, 
could affect the absorption and bioavailability of THC. Furthermore, 
dementia-related changes in the brain, such as degeneration of 
neurons, loss of neural circuits, decreased number of receptors and 
neurotransmitters (e.g., dopamine, and serotonin), may alter the 
pharmacodynamics of THC. Moreover, cannabinoid receptors (CB1 
and CB2) are G protein-coupled receptors,40 and impairments in the 
intracellular function and levels of G-proteins have been observed 
with normal aging,41 which may also alter the pharmacodynamics of 
THC in older adults. Third, food may also affect the pharmacokinetics 
of THC (see above, Effect of food on the pharmacokinetics of THC). 
In our clinical trials, oral THC was administered to older participants 
in a fed state, which probably delayed absorption and increased THC 
exposure, relative to absorption and exposure measured in young 
adults administered THC in a fasted state.
In conclusion, the pharmacodynamic effects of oral THC in 
older adults, including patients with dementia, were smaller than 
expected based on its effects previously reported in young adults. 
The combination of low rate of unwanted (side) effects and low rate 
of wanted (therapeutic) effects suggests that the THC doses used 
in our trials were too low. Further efficacy and safety studies are 
warranted to evaluate the pharmacodynamics and pharmacokinetics 
of higher THC doses in younger and older adults, including those 
with dementia.
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6.  THC for pain in dementia
Pain is a significant and growing healthcare problem among older 
people with dementia, because aging is accompanied by an increased 
risk of chronic painful conditions, such as degenerative disease 
of discs and joints, osteoporotic fractures, fall-related injuries, 
diabetic neuropathy, angina, and cancer.42, 43 In the cross-sectional 
prevalence survey described in Chapter 7, we found that pain was 
highly prevalent among community–dwelling patients with dementia. 
In over 60% of participants, pain was reported by both patients 
and caregivers. Moreover, pain was associated with behavioral and 
psychological symptoms, decreased activities of daily living, sleep 
disturbances, and caregiver distress. Symptoms such as delusions, 
agitation, depression, anxiety, and appetite disturbances were 
significantly more common in patients with pain than those without 
pain. Our findings underline the importance of routinely assessing 
and treating pain as part of the overall management of behavioral 
problems in patients with dementia. Adequate treatment of pain 
in patients with dementia living at home may prevent or reduce 
pain-related behavioral changes and associated caregiver distress, 
and subsequently may delay nursing home placement. However, 
currently available pain medications, such as acetaminophen, 
nonsteroidal anti–inflammatory drugs, opioids, antidepressants, and 
antiepileptic drugs, are often not effective, contraindicated, or cause 
serious adverse events in older people. Given these limitations of 
currently available medications, finding an effective and safe therapy 
for pain in older people should be given priority. 
Previous randomized control trials have demonstrated the 
potential of cannabinoids, including oral THC, in the management 
of pain,44 but none of these trials included participants with 
dementia or provided separate data for older persons (≥ 65), if 
these individuals were included in the study. In contrast, our data 
from a phase 2, randomized, double-blind, placebo-controlled trial 
(Chapter 4, Appendix) showed that, compared with placebo, 
THC in doses up to 4.5 mg daily did not diminish pain intensity 
(assessed with Verbal Rating Scale) or improve pain-related 
behavior (assessed with Pain Assessment Checklist for Seniors with 
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Limited Ability to Communicate) in older patients with dementia. 
However, these results should be interpreted with caution because 
of important potential limitations. First, few patients were treated 
with THC. Of the 23 patients included in the subgroup ‘pain’, 8 were 
randomized to receive THC and 15 to receive placebo. Moreover, 
the study was initially designed to include patients with dementia, 
behavioral disturbances and persistent pain, to secondarily evaluate 
the effectiveness of THC in relieving pain. Although pain is common 
and associated with behavioral disturbances in patients with 
dementia (Chapter 7), it was very difficult to recruit patients with 
both symptoms. Therefore, after we had succeeded in recruiting 8 
patients, we amended the study protocol to omit pain as a strict 
inclusion criterion. In the amended protocol, pain assessments were 
still included, to allow secondary evaluation of THC effectiveness in 
pain. Second, it is a challenge to assess pain in cognitively impaired 
older people, particularly in those with moderate or severe dementia, 
because they are less able to articulate the pain and discomfort they 
feel. This point has been addressed and discussed in Chapter 8. A 
number of observational pain tools have been developed for use in 
nonverbal older people with cognitive impairments, but as yet there 
is no standardized assessment tool.45 Moreover, most available 
assessment tools have poor reliability, validity, and clinical utility.45 
In our study described in Chapter 4, we used two tools to assess 
pain in our patients: 1) the Pain Assessment Checklist for Seniors 
with Severe Dementia (PACSLAC–D),46 an observational checklist; 
and 2) the Verbal Rating Scale (VRS), a self-report scale.47 Although 
PACSLAC–D has strong psychometric properties and is simple to 
use,48 the checklist contains observation items that are not specific 
for pain, but overlap with those for the behavioral and psychological 
symptoms of dementia. This makes it difficult to determine whether 
the observed behaviors are related to pain or dementia. In addition, 
only 13 of the 23 participants with pain were able to understand 
and to use the VRS (self-reporting). Changes in a patient’s ability 
to articulate pain verbally represent an important challenge in the 
assessment and treatment of pain, since self-report is considered 
the gold standard of pain assessment.49 In our phase 1 trial involving 
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healthy older people (Chapter 5), the first pharmacodynamic effects 
of THC (Namisol®) occurred 20 min after dosing and the maximal 
effects occurred between 55 and 120 min. This suggest that the 
drug has a rapid pain-relieving effect compared with dronabinol, 
which has an onset of action between 30 min and 1 h, and a maximal 
effect between 2 and 4 h.20
In summary, the accurate assessment of pain in patients with 
dementia is crucial for adequate pain management. In turn, this 
requires a reliable and valid observational tool for assessing pain 
in nonverbal individuals with dementia in clinical and nonclinical 
settings. Although oral THC is a potential multi-target drug candidate 
with a promising pharmacodynamic profile, more randomized 
controlled trials are needed to evaluate its effectiveness in the 
treatment of pain and pain-related behavioral disturbances in older 
people with dementia.
7.  Conclusions and recommendations 
The main aim of the studies described in this thesis was to 
evaluate the clinical pharmacology of oral THC in older people with 
dementia, specifically its pharmacokinetics, pharmacodynamics, 
safety, and efficacy.
7.1.  Conclusions
1.  Despite the large number of publications on cannabinoids, 
including THC, there is still a significant lack of information on 
its clinical pharmacology in older people with dementia.
2.  The results of in vitro and in vivo studies provide an interesting 
basis for the innovative use of cannabinoids as therapeutic 
approach to dementia and dementia-related symptoms.
3.  THC in doses up to 6.5 mg daily and 4.5 mg daily is safe and 
well tolerated by healthy older people and by older people with 
dementia, respectively. THC has a very low rate of adverse 
effects in both groups.
4.  Overall, the pharmacodynamic effects of THC in older 
people, including those with dementia, are smaller than the 
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pharmacodynamic effects previously reported in younger 
people.
5.  THC in doses up to 4.5 mg daily is not effective in the treatment 
of the neuropsychiatric symptoms of dementia, pain, and 
pain-related behavior.
6.  The combination of a low rate of unwanted (adverse) effects 
and a low rate of wanted (therapeutic) effects suggests that 
the THC doses used in our trials were too low.
7.  THC is rapidly absorbed in older people and has dose-linear 
pharmacokinetics with considerable interindividual variation.
8.  Pain is common among community-dwelling patients with 
dementia. It is associated with diminished activities of daily 
living, sleep disturbances, behavioral and psychological 
symptoms, and caregiver distress. Our findings underline the 
importance of routinely assessing and treating pain as part of 
the overall management of behavioral problems in dementia 
patients.
7.2 Recommendations
Despite the large number of publications on THC-based drugs, 
many aspects of their clinical pharmacology remain unclear in older 
people with dementia. Older people with dementia and multiple 
comorbidities might benefit from the use of THC as a multi-target 
drug candidate, a drug for several conditions (e.g., behavioral 
disturbances, pain, and loss of appetite). The work presented in this 
thesis may fill some of the gaps that exist in our current knowledge 
of the pharmacodynamics and pharmacokinetics of oral THC in older 
people with dementia. On the basis of our findings, future studies of 
the pharmacodynamics and pharmacokinetics of THC that may be 
relevant to older patients with dementia are suggested below.
7.2.1.  Evaluation of higher THC doses
The main challenge for the near future is to find the right THC 
dose for older people with dementia. The choice of dose to manage 
behavioral disturbances and pain in patients with dementia should 
be based on achieving maximum therapeutic benefit with minimum 
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toxic effects. However, the fear of potential psychoactive adverse 
effects in patients with dementia often interferes with population-
based studies. Our clinical trials data showed that this fear, which is 
probably unfounded, may lead to under-dosing of THC-based drugs. 
Future studies of oral THC should evaluate higher THC doses. On 
the basis of our findings (Chapters 3 to 6) and the findings of others 
(Table 1), we believe that THC doses up to 5 mg twice daily can 
be given safely to older patients with dementia, but this should be 
tested in a randomized, double-blind, placebo-controlled trial with a 
crossover design. The crossover design is the best way to evaluate 
brief drug exposures with immediate and transient effects.
7.2.2.  Population pharmacokinetic/pharmacodynamic 
modeling 
There is little information in the literature on the pharmacokinetic/ 
pharmacodynamic relationship of oral THC in older people. Given 
the substantial interindividual variation in the pharmacokinetics and 
pharmacodynamics of oral THC, and the importance of ensuring 
adequate dosing in frail older patients with dementia, it would be 
helpful if there were a population pharmacokinetic/pharmacodynamic 
model to guide the search for an optimal THC dose. Such a simulation 
model, which takes into account the variability component, would 
make it possible to match a particular therapeutic target with a 
target dose.
7.2.3.  Pharmacodynamics and pharmacokinetics evaluation: 
Older versus younger adults
It is important to determine whether age affects the 
pharmacodynamics and pharmacokinetics of THC in older adults, and 
whether this effect is of therapeutic relevance. Although in the studies 
described in this thesis data for older patients were compared with 
published data for young adults, there were important differences 
between studies in terms of given doses, dose schedule, number of 
blood samples, sampling time, fasting versus fed states, and type 
of tests used for pharmacodynamic evaluation. It would be better to 
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directly compare young and old subjects in the same study, in order 
to allow better evaluation of parameters and to minimize bias.
7.2.4.  Evaluation of food intake on THC 
pharmacokinetics
The development of a novel drug formulation, such as oral 
THC, should include the assessment of the effects of food on the 
pharmacokinetics of the drug, especially in older people. The 
discrepancies between tmax and AUC values measured in our older 
participants (Chapter 5) and those reported for young adults could 
be related to a THC–food interaction or age-related physiological 
changes. Therefore, it is of great interest to evaluate the effect of 
food on the pharmacokinetics of oral THC. This would help us to 
better understand whether the altered pharmacokinetics in young 
and old individuals are food- or age-related.
7.3.  Take-home message
The lack of information about the pharmacokinetic and pharmacodynamic 
effects of THC in older people with dementia warrants further research. Until 
then, careful evaluation of the risk–benefit ratio is needed before oral THC can 
be recommended and prescribed to frail older dementia patients.
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geneeskunde heeft gestudeerd. Zijn artsexamen heeft hij in 2004 
behaald aan de Universiteit Leiden. Hierna is hij 10 maanden 
werkzaam geweest als arts-assistent cardiologie in het Rijnmond-
Zuid ziekenhuis te Rotterdam. 
Van mei 2005 tot en met mei 2010 volgde hij de opleiding Klinisch 
Geriatrie en van januari 2010 tot en met juni 2011 de opleiding 
Klinische Farmacologie aan het Radboud Universitair Medisch 
Centrum, Nijmegen. Tussen 2010 en 2016 werkte Amir Ahmed als 
klinisch geriater/hoofdbehandelaar afdeling Psychogeriatrie in het 
Vincent van Gogh te Venray. Daar was hij tussen 2013 en 2016 de 
voorzitter van de medische staf. Amir Ahmed is verbonden aan de 
afdeling Geriatrie/Alzheimer Centrum en de afdeling Farmacologie 
en Toxicologie van het Radboud Universitair Medisch Centrum als 
onderzoeker. In 2011 startte hij met zijn promotieonderzoek wat 
geresulteerd heeft in dit proefschrift. Hij is docent en gastspreker bij 
verschillende onderwijscentra. 
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In mei 2016 richtte Amir Ahmed GerCare Consulting op, een 
medisch bedrijf dat medische consultaties en adviezen biedt 
aan Geestelijke Gezondheidszorg instellingen, verpleeghuizen, 
(geriatrische) revalidatiecentra en huisartsen. Tevens biedt het 
bedrijf ondersteuning aan zorginstellingen bij medicatieveiligheid 
en het ontwikkelen van (psycho)geriatrie afdelingen en geriatrische 
revalidatie units. In oktober 2016 zal Amir Ahmed starten met zijn 
nieuwe opleiding “Master of Business Administration in International 
Healthcare Management” aan de Frankfurt School of Finance & 
Management, Frankfurt (Duitsland).
Amir Ahmed is getrouwd met Youlia Ahmed (Internist-nefroloog) 
en vader van drie kinderen: Dina, Maryam en Sami.
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